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ABSTRACT 
PART 1. DESIGN AND SYNTHESIS OF CYSTEINE / CYSTINE PRODRUGS AND 
BIOISOSTERES INCLUDING SYMMETRICAL AND UNSYMMETRICAL 
DISULFIDES DESIGNED TO INCREASE CYSTINE LEVELS IN THE CNS IN 
ORDER TO DRIVE THE CYSTINE / GLUTAMATE ANTIPORTER: A NOVEL 
TREATMENT FOR SCHIZOPHRENIA AND DRUG ADDICTION  
by 
 
Edward Merle Johnson II 
 
 
The University of Wisconsin-Milwaukee, 2012 
Under the Supervision of Professor James M Cook 
 
 
Schizophrenia is a debilitating disorder that affects almost 1% of the world's 
population; pharmacotherapy expenditures for this disorder exceed $10 billion dollars 
even though existing medications exhibit a poor safety/efficacy profile. It is estimated 
that 75% of patients discontinue drug treatment, in part due to poor safety/efficacy. The 
current data set demonstrates that cysteine prodrug NAC reverse the behavioral and 
neurochemical effects of PCP used to model schizophrenia.   
 
As a result cysteine prodrugs represent a highly novel approach to treating 
schizophrenia; indeed, these compounds may ultimately be more effective than existing 
medications because these drugs target the pathology underlying schizophrenia and 
reverse behaviors used to model negative symptoms and diminished cognition produced 
by PCP, which are behaviors and symptoms that are not treated with current first line 
medications. Specifically, therapeutic endpoints produced by cysteine prodrugs include 
increasing stimulation of group II metabotropic glutamate receptors and restoring levels 
of glutathione. The latter effect has the potential to reverse several specific abnormalities 
that have been observed in schizophrenia including increased oxidative stress, decreased 
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NMDA receptor function, altered gene expression, and abnormal cell proliferation / 
synaptic connectivity.  
 
Throughout this study, multiple series of compounds have been presented and 
explored, specifically 2 series of cysteine/cystine prodrugs, 2 series of cysteine/cystine 
bioisosteres and 1 series involving the coupling of two different series of compounds, 
namely, unsymmetrical disulfides ( mixed dimers).   Also in this study, it will be shown 
through the use of in vivo and in vitro screening methods, diketopiperazine cystine 
prodrug monomers and dialkylated versions show high promise as novel antipsychotic 
agents.  Furthermore, the diketopiperazine cystine prodrug dimers and dialkylated dimers 
also have shown promise in becoming novel antipsychotic agents by overcoming the 
detrimental effects of PCP-induced deficits in sensorimotor gating by restoring pre-pulse 
inhibition in multiple screenings.   
 
Bioisosteres of cysteine and cystine have shown vast improvements over N-
Acetylcysteine by competing with C14 uptake and increasing glutamate levels by driving 
the cystine/glutamate antiporter.   It has also been shown that simple modifications to the 
cysteine/cystine moiety also improve outcomes far greater then N-Acetylcysteine alone. 
Once the most effective compounds are determined by screening methods, the research 
strategy benefits by combining the two such compounds as an unsymmetrical disulfide in 
order to enhance their effects and help eliminate their disadvantages.  As an early 
example to this approach two mixed dimers were synthesized and have shown extremely 
positive results in screening methods described here.   
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ABSTRACT 
PART 2. DESIGN AND SYNTHESIS OF SUBTYPE SELECTIVE ESTER 
BIOISOSTERES OF BZR LIGANDS FOR GABAA / BENZODIAZEPINE 
RECEPTORS TO ENHANCE METABOLIC STABILITY 
 
by 
 
Edward Merle Johnson II 
 
 
The University of Wisconsin-Milwaukee, 2012 
Under the Supervision of Professor James M Cook 
 
 A series of 1,4-benzodiazepines and imidazobenzodiazepines including 
bioisosteric ligands was synthesized in search of subtype selective ligands for 
GABAA/benzodiazepine receptor subtypes.  In this study, it was clear that the improved 
method for synthesizing benzodiazepines was successful. This is based on the number 
and quantities of numerous compounds synthesized utilizing the improved method.   
Although the efficacy of XHe-II-053 (4) was decreased in Phase I because of the 
metabolism of the C-3 ester to the acid, the bioisostere EMJ-I-026 (5) has been shown to 
exhibit non-sedating anxiolytic activity in mice as well as a binding/oocyte profile in 
vitro consistent with a non-sedating anxiolytic.  Seven bioisosteric analogues were 
designed in order to circumvent any potential metabolic liability in humans of the 
previously described ligand. In fact, the bioisosteric analogues were much more stable in 
human liver microsomes than XHe-II-053 (4) again indicating these bioisosteres are 
potential nonsedating anxiolytics as well as useful for treatment of anxiety disorders in 
human populations. These ligands were also stable on human blood, brain and kidney. 
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Gratifyingly, ligand 5 was clearly an α3 Bz/GABAergic receptor subtype 
selective ligand at pharmacologically relevant doses (approximately 100 to 200 nM) and, 
presumably, provides an agent to study physiologically processes mediated by α3 
subtypes including anxiety and, in addition, was much more stable on human liver 
microsomes. In this regard α3 subtype selective ligand, oxadiazole 5 (EMJ-I-026), has 
been evaluated in the light dark paradigm and clearly is a nonsedating anxiolytic, wherein 
this ligand was anxiolytic with no sedative properties, in vivo, as compared to diazepam. 
This study indicated that the ester function in these molecules can be replaced with a 
metabolically more stable ester bioisostere and still retain anxiolytic activity. The indepth 
study of these ligands in animal models and other receptor systems are underway by 
collaborators. 
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PART 1. DESIGN AND SYNTHESIS OF CYSTEINE / CYSTINE PRODRUGS AND 
BIOISOSTERES INCLUDING SYMMETRICAL AND UNSYMMETRICAL 
DISULFIDES DESIGNED TO INCREASE CYSTINE LEVELS IN THE CNS IN 
ORDER TO DRIVE THE CYSTINE / GLUTAMATE ANTIPORTER: A NOVEL 
TREATMENT FOR SCHIZOPHRENIA AND DRUG ADDICTION  
 
by  
 
Edward Merle Johnson II 
 
  
2 
 
I. Background and Introduction 
1. General Background to Schizophrenia, Drug Addiction and Current 
Treatments. 
 
Schizophrenia is a debilitating disorder afflicting 1% of the world's population. 
The development of effective medications to treat schizophrenia is reliant on advances in 
characterizing the underlying pathophysiology.  Chlorpromazine and other 
phenothiazines are considered first generation antipsychotics (termed "typical 
antipsychotics") useful in the treatment of schizophrenia.1,2  However, the antipsychotic 
efficacy of phenothiazines was, in fact, serendipitously discovered. These drugs were 
initially used for their antihistaminergic properties and later for their potential anesthetic 
effects during surgery.1  Hamon and colleagues extended the use of phenothiazines to 
psychiatric patients and quickly uncovered the antipsychotic properties of these 
compounds; shortly thereafter, the pharmacologic characteristics of dopamine receptor 
blockade were linked to the antipsychotic action of chlorpromazine (Thorazine).1 This led 
to the development of additional dopamine receptor antagonists, including haloperidol 
(Haldol).  For nearly fifty years dopamine antagonists were the standard treatment for 
schizophrenia even though these drugs induce severe side effects ranging from 
Parkinson's disease-like motor impairments to sexual dysfunction and are only effective 
in treating the positive symptoms of schizophrenia.2 
 
In the 1970’s, clozapine became the first atypical or 2nd generation antipsychotic 
agent introduced.2 Clinical trials have shown that clozapine produces fewer motor side 
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effects and exhibits improved efficacy against positive and negative symptoms relative to 
1st generation compounds. 2,3 However, clozapine was briefly withdrawn from the 
market because of the potential to produce severe agranulocytosis, a potentially fatal side 
effect requiring patients to undergo routine costly hematological monitoring.  As a result, 
clozapine is only approved for treatment-resistant schizophrenia; this did not occur in the 
U.S. until 1990.  Although also a dopamine receptor antagonist, the therapeutic site of 
action for clozapine is thought to involve blockade of serotonin receptors.  This led to the 
generation of other serotonin receptor antagonists in the 1990’s with the goal of 
improving the safety profile of clozapine. 
 
The growth potential for novel antipsychotics was revealed following the 
introduction of risperidone in 1994; within two years risperidone overtook haloperidol in 
the number of prescriptions written by physicians. While it was generally assumed that 
the newer 2nd generation antipsychotics also exhibited the favorable efficacy profile 
produced by clozapine, the clinical data was ambiguous.  As a result, NIH recently 
funded the largest (1,493 participants), longest (18 months), most expensive ($42.6 
million), and most thorough (1 typical and 4 atypical drugs were included) clinical trial to 
examine this assumption. The results of the Clinical Antipsychotic Trials of Intervention 
Effectiveness (CATIE), released in September 2005 indicated there was no benefit to the 
newer 2nd generation compounds (clozapine was not tested); specifically 1st and 2nd 
generation drugs did not differ in the incidence of severe motor side-effects nor were 2nd 
generation agents found to be more effective than 1st generation antipsychotics.4  
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In the CATIE trial, 74% of the patients discontinued treatment prior to completing 
the 18 month trial in part due to a lack of efficacy and intolerability of the treatment 
regimen.  As a result, current expenditures on antipsychotic agents may underestimate the 
full market potential. Regardless, atypicals currently have over 90% of the $10 billion 
antipsychotic market. Collectively, these data indicate there is a pressing need for novel 
antipsychotic agents.  It is important to note that the efficacy of the prototypical 1st and 
2nd generation (chlorpromazine, clozapine) antipsychotics were serendipitously 
discovered; the development of effective antipsychotic agents will be facilitated by 
understanding and targeting the pathophysiology underlying schizophrenia, as mentioned 
above. 
 
Evidence indicates that the pathophysiology of schizophrenia involves a 
dysregulation in cortical functioning. Altered cortical functioning in schizophrenia 
involves, in part, altered glutamate signaling NMDA Receptor antagonists, including 
phencyclidine (PCP), produce a broad range of schizophrenia-like symptoms in healthy 
individuals5,6,7,8 and exacerbate symptoms in schizophrenic patients.9,10 PCP or the 
related compound ketamine also produces parallel cognitive and behavioral alterations in 
rodents that are used as a preclinical model of schizophrenia, including pronounced 
deficits in working memory and social withdrawal.11,12,13  Altered cortical functioning in 
schizophrenia has also been attributed to diminished glutathione which can account for a 
number of specific abnormalities associated with schizophrenia including increased 
oxidative stress, altered gene expression, and abnormal cell proliferation and 
connectivity.14,15  Cystine-glutamate antiporters, which exchange extracellular cystine for 
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intracellular glutamate may underlie cortical dysfunction in schizophrenia.  Recent 
laboratory data illustrates that glutamate released from these antiporters provides 
endogenous tonic stimulation to group II mGluRs and thereby regulates synaptic 
glutamate and dopamine release.16,17  Thus, altered glutamate signaling could arise as a 
consequence of decreased cystine-glutamate exchange.  
 
Furthermore, cystine transport via cystine-glutamate exchange is the rate-limiting 
step in the synthesis of glutathione; therefore, the depletion of glutathione in 
schizophrenics indicates diminished cystine-glutamate exchange. Drs. J. Meador-
Woodruff and V. Haroutunian at the University of Michigan and Mount Sinai School of 
Medicine, respectively, have recently discovered that the expression of cystine-glutamate 
antiporters is reduced in post mortem tissue obtained from schizophrenics.17 Collectively, 
these data indicate that altered cystine-glutamate exchange may contribute to the 
pathology of schizophrenia. Increasing the activity of cystine-glutamate exchange 
reverses the behavioral and neurochemical effects of PCP that are used to model 
schizophrenia. Specifically, it has been recently determined that the cysteine prodrug N-
Acetylcysteine (NAC), used to increase the activity of cystine-glutamate antiporters, 
reverses the PCP-induced alterations in glutamate signaling in the prefrontal cortex, as 
well as PCP-induced deficits in cognitive function and social withdrawal.  Accordingly, 
the main goal of the present research is to determine the antipsychotic properties of 
cysteine/cystine prodrugs. 
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Addiction to psychomotor stimulants is marked by a transition in drug 
consumption from a casual, recreational style of use to a more compulsive, excessive 
pattern.18,19,20  Acute cocaine use is associated with numerous effects, including feelings 
of euphoria and increased energy, which likely contribute to repeated recreational 
consumption.  Chronic use results in plasticity that is thought to underlie the emergence 
of persistent craving and paranoia that contributes to compulsive drug seeking 
behavior.21,22,23  Unfortunately, cocaine addiction still is lacking an effective 
pharmacotherapy, which will likely require compounds targeting plasticity pathogenesis 
for the transition in use patterns.  
 
Uncontrolled drug use and heightened susceptibility to relapse are defining 
features of addiction that contribute to the transition in drug consumption from a 
recreational to a compulsive pattern.18,19  Identification of drug-induced neuroplasticity 
underlying this transition should facilitate the development of effective 
pharmacotherapies.  Long-term plasticity which results in augmented excitatory 
neurotransmission within corticostriatal pathways has been implicated in addiction.  
Human cocaine abusers exposed to craving-inducing stimuli exhibit increased activation 
of excitatory circuits originating in cortical regions, including orbital and prefrontal 
cortex and projecting to the ventral striatum.24,25  Preclinical data also indicate the 
existence of drug-induced plasticity leading to activation of corticostriatal pathways.  
Activation of these circuits results in heightened extracellular glutamate in the nucleus 
accumbens26,27 and stimulation of ionotropic glutamate receptors, both of which are 
necessary for cocaine primed reinstatement.28,29  Furthermore, the dorsomedial prefrontal 
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cortex has been shown to be necessary for reinstatement produced by exposure to drug-
paired cues using the contextual reinstatement paradigm and in response to electrical foot 
shock.30   As a result, identification of cellular mechanisms capable of regulating synaptic 
glutamate may represent targets in the treatment of addiction.31   
 
Recent data illustrates that glutamate released from these cystine-glutamate 
antiporters provides endogenous tonic stimulation to group II metabotropic glutamate 
receptors (mGluRs) and thereby regulate synaptic glutamate and dopamine release.32  
Thus, altered glutamate signaling could arise as a consequence of decreased cystine-
glutamate exchange.  Repeated cocaine administration has been shown to blunt the 
activity of cystine-glutamate exchange32, which likely contributes to a sequence of events 
including diminished group II mGluR autoregulation33 and increased excitatory 
neurotransmission in the nucleus accumbens.  Cysteine prodrugs, such as N-
Acetylcysteine (NAC), are used to drive cystine-glutamate exchange by elevating 
extracellular cystine levels, thereby creating a steep cystine concentration gradient.   
 
Preclinical studies have shown N-Acetylcysteine is effective in blocking 
compulsive drug-seeking in rodents.  Further, extant clinical data also show a reduction 
in cocaine use and craving in cocaine abusers receiving NAC.  Unfortunately, the full 
clinical efficacy of targeting cystine-glutamate exchange may be unrealized when 
utilizing NAC due to extensive first-pass metabolism and limited passive transport of this 
drug across the blood-brain barrier.  As a result, here we propose to synthesize novel 
cysteine or cystine prodrugs.  Note, cysteine is the reduced form of cystine and is 
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readily oxidized in vivo to cystine thus elevating either cysteine or cystine levels 
would increase cystine-glutamate exchange.  We will then utilize in vitro and in vivo 
screens to select the most promising novel compounds.  Potential for therapeutic 
efficacy of the novel compounds will be determined in animal models involving 
drug-seeking behavior produced by stress, drug-paired cues, and a cocaine priming 
injection. 
 
Addiction to cocaine and other illicit drugs is estimated to cost our society $181 
billion which equates to $603 per U.S. citizen. The cost of addiction can be dramatically 
lowered through the use of treatments; unfortunately, many drugs of abuse, including 
cocaine, lack a single approved pharmacotherapy. Addiction to psychomotor stimulants, 
such as cocaine, is marked by a transition in drug consumption from a casual, recreational 
style of use to a more compulsive, excessive pattern that arises as a result of drug-induced 
changes in brain functioning. In order to develop effective treatments, it will likely be 
necessary to identify and target the altered brain functioning underlying addiction. 
Towards this end, drug-induced changes in glutamate release from cystine-glutamate 
antiporters have been linked to pathological alterations in neural transmission and 
normalizing cystine-glutamate function blocks compulsive drug-seeking in preclinical 
models. Furthermore, small-scale clinical studies using N-Acetylcysteine to target 
cystine-glutamate exchange have shown modest efficacy including reduced drug craving 
and cocaine use. The efficacy of N-Acetylcysteine is limited due to extensive metabolism 
in the liver and poor passive transport into the brain.  Large does are required for efficacy 
which can result in liver toxicity.18,19,22 
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As a result in the present research one seeks to develop novel ligands that are 
more potent and effective in targeting cystine-glutamate exchange in the brain. They 
necessarily need to be of longer duration in vivo than N-Acetylcysteine and more 
readily pass through the blood brain barrier. This will involve the design of 
compounds and the synthesis of the most promising ones in order to utilize them in 
vitro and in vivo screening techniques to determine which compounds are most 
effective and potent in targeting cystine-glutamate exchange. Specifically, mixed 
cortical cell cultures will be employed to compare the capacity of brain cells to 
utilize the novel ligands to target cystine-glutamate antiporters.   
 
Later the potency and efficacy of these novel compounds in blocking cocaine-
primed, stress-primed and cocaine-paired use primed reinstatement in preclinical 
models of compulsive drug seeking will be assessed.  Collectively, this research has 
the potential to identify cystine-glutamate antiporters as a novel target in the 
treatment of addiction and to generate a series of compounds that may ultimately be 
effective in treating cocaine addiction as well as schizophrenia.17,20,29  
 
2. Release of extracellular glutamate: Identification of a novel source.  
 
Unlike traditional neurotransmitters, glutamate release is from both vesicular and 
nonvesicular stores. While synaptically released vesicular glutamate has been studied in 
great detail, basal extracellular glutamate sampled in vivo is present in micromolar 
concentrations in the extracellular space outside of the synaptic cleft.  This pool of 
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glutamate is primarily maintained by nonvesicular release since levels are relatively 
insensitive to blockade of voltage-dependent Na+ and Ca++ channels.34,35,36  Nonvesicular 
glutamate release has also been detected in hippocampal and prefrontal cortical tissue 
slices37 indicating that nonvesicular release is not unique to the nucleus accumbens nor is 
it an artifact of microdialysis.  The origin of nonvesicular glutamate has recently been 
demonstrated to arise, in part, from cystine-glutamate exchange.32  Data indicate that 
unlike Na+ or Ca++ channels, blockade of cystine-glutamate antiporters produces a >50% 
decrease in extracellular glutamate levels in the nucleus accumbens.32  As stated above, 
this pool of glutamate contributes to synaptic neurotransmission by supplying 
endogenous tone to extrasynaptic group II mGluRs.  Therefore, cystine-glutamate 
antiporters represent a novel cellular mechanism capable of modulating synaptic 
glutamate release into the nucleus accumbens following activation of corticostriatal 
pathways. In light of the importance of glutamate signaling for brain functioning in the 
normal and diseased states, it is important to characterize the role of cystine-glutamate 
antiporters to schizophrenia. 
 
 
  
Figure 1.  Regulation of glutamate signaling 
by cystine-glutamate antiporters. 
Nonvesicular release of glutamate (G) 
stimulates group II metabotropic glutamate 
receptors (mGluRs). Stimulation of these 
receptors decreases the release of vesicular 
glutamate (G) into the synapse, decreasing 
glutamate receptor signaling. C, cystine; G, 
glutamate; II, group II mGluRs. 
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3. Cystine-Glutamate Antiporter. 
 
Cystine-glutamate antiporters function by transporting extracellular cystine 
(oxidized form of cysteine) into cells coupled with the export of intracellular 
glutamate.38,39 The antiporter exists as two separate proteins, the light chain xCT unique 
to cystine-glutamate antiporters and the heavy chain 4F2 that is common to many amino 
acid transporters.40,41 The antiporter is ubiquitously distributed throughout the body and 
brain.39,42,43 The  regulation of cystine-glutamate antiporter activity is poorly understood, 
however, previous studies have indicated that extracellular cystine concentration and 
intracellular glutathione levels44 can regulate the activity of these antiporters.  
 
Cysteine prodrugs, including N-Acetylcysteine, are commonly used to elevate 
extracellular levels of cystine or cysteine, as well as intracellular glutathione levels, 
because these compounds are safer, more stable, and more likely to penetrate the blood 
brain barrier.45,46,47 In essence, cysteine prodrugs appear to penetrate the blood brain 
barrier, are rapidly degraded first into cysteine. Cysteine is subsequently oxidized into 
cystine because of the oxygen rich milieu of the extracellular space. The elevation in 
cystine increases the substrate concentration gradient, thereby increasing the activity of 
cystine-glutamate antiporters. The net effect is an increase in glutamate release and an 
increase in the synthesis of glutathione. 
  
4. Glutathione and Cystine
 
Once transported into the cell, cystine is rapidly reduced to cysteine
Intracellular cysteine represents the rate
glutathione.37 Excess glutathione is released into the extracellular space, where it is 
degraded by γ-glutamyltranspeptidase into cysteine. Cysteine is subsequently oxidized 
into cystine because of the oxygen rich milieu of the extracellular space. This cycle 
appears to be the major source of extracellular cystine in the brain
glutathione levels can impact the activity of cystine
decrease in glutathione following oxidative stress results in an increase in the expression 
Figure 2.  Schematic illustrating the uptake and recycling of cystine.  Schematic 
of three uptake mechanisms for cyst(e)ine, including cystine
antiporters (xc-; 1), Na
glutamyltranspeptidase (3), which only occurs  if cystine serves as the acceptor 
for the γ-Glu moiety (e.g., amino acid x).   Glu (glutamate),  Cyss (cystine), Cys 
(cysteine), γ-Glu-Cys (
-Glutamate Antiporter Activity.
-limiting step in the synthesis of the antioxidant 
.
49
 Alterations in 
-glutamate exchange. Specifically, a 
-glutamate 
+
-dependent glutamate transporters (XAG-; 2), and 
γ-glutamylcysteine), Gly (glycine), GSH, glutathione.
Figure 2 
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of xCT, the active subunit of cystine-glutamate exchange. This will serve to increase 
cystine-glutamate exchange assuming that the substrates (e.g., extracellular cystine) are 
available. 
 
5. Cystine-Glutamate Antiporters and Schizophrenia. 
 
Extant data indicate that diminished cystine-glutamate exchange may contribute 
to the pathophysiology of schizophrenia. First, schizophrenia is associated with a 
profound reduction in prefrontal cortical glutathione levels.50 A reduction in glutathione 
indicates decreased cystine-glutamate exchange because a) cystine-glutamate exchange is 
the rate-limiting step in glutathione synthesis; b) metabolism of glutathione is the primary 
source of extracellular cystine needed to maintain the activity of cystine-glutamate 
antiporters. Secondly, diminished cystine-glutamate exchange may also contribute to a 
decrease in the levels of xCT, the active subunit for cystine-glutamate exchange, which 
has recently been observed. This would be an expected compensatory change following 
diminished cystine uptake in an attempt to maintain glutathione levels. Thirdly, a recent 
study indicates an increase in the levels of group II mGluRs in post mortem tissue from 
schizophrenics.51 This would be an expected compensatory change following a reduction 
in the stimulation of this receptor. These studies are consistent with the hypothesis that 
diminished activity of cystine-glutamate antiporters contributes to the pathophysiology of 
schizophrenia. 
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As a result, cysteine prodrugs may be effective antipsychotic agents, in part, by 
directly targeting the pathology underlying schizophrenia. Moreover, cysteine prodrugs 
will likely achieve a number of therapeutic endpoints including: a) increased group II 
mGluR stimulation; b) decreased synaptic glutamate; c) increased NMDA receptor 
stimulation; and d) increase glutathione levels. 
 
6. Clinical Applications of N-Acetylcysteine and Pharmacokinetics. 
  
N-Acetylcysteine (NAC) is the only cysteine prodrug used clinically; for these 
purposes it has been proposed as a mechanism to restore glutathione, which is or has been 
proposed as a therapeutic endpoint for a number of conditions including respiratory 
disorders52, acetaminophen-induced hepatotoxicity53,54,55, HIV56,57,58,59, influenza60, 
malaria61, cancer62,63,64, Alzheimer’s65, and heart disease.66,67,68 There are a number of 
advantages to NAC, including a favorable safety profile even following long-term 
administration of high doses (e.g., 1-4 g/day); a dose range that has IRB approval to 
administer to cocaine addicts.18,19  However, pro-oxidant effects of NAC in this dose 
range have been observed in healthy individuals.69 High doses are needed because of the 
poor oral bioavailability of NAC, which has been estimated at four and ten percent.70,71,72 
Disulfide linking to proteins and deacetylation of NAC in the intestinal mucosa and 
lumen are probably the greatest factors in this apparent low oral bioavailability of NAC.  
 
Brain tissue levels are considerably lower and have been estimated to be in the 
range of 0.4% of plasma levels (or ~ 0.016-0.04% of orally administered NAC). This is 
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due, in part, to poor passive penetration of the blood brain barrier, which is not surprising 
given a partition coefficient of -0.99 as opposed to 2-4 generally associated with 
reasonable passive diffusion.70,72  As a result, these studies indicate a need to generate 
novel cysteine prodrugs that exhibit less first pass metabolism and a higher 
partition coefficient.  If developed, these compounds could result in increased 
potency and efficacy as well as a diminished pro-oxidant effects associated with high 
dose NAC administration.  It is important to note that NAC administration in cocaine 
abusers is well tolerated, but the longest period monitored was 28 weeks in a small 
patient population.73  It is possible that pro-oxidant effects of high dose NAC 
administration may produce toxicity when administered in larger populations for a longer 
period of time. Furthermore, higher doses of NAC may yield even greater efficacy than 
what is being tested. 
 
7. Possible Approaches to increase CNS Cysteine/Cystine Levels. 
 
 As previously stated above, the overall goal of the research is to increase 
cysteine/cystine levels in the central nervous system (CNS).  Even though the main 
pathway to accomplish this goal is to synthesize various analogues of cysteine/cystine in 
order to bypass metabolism, penetrate the blood brain barrier and deliver cysteine/cystine 
to the CNS, other pathways were considered and explored.  The first of such other 
pathways included pharmaceutical formulation techniques.   Currently, cystine/cysteine 
and analogues (NAC) are either commercially available as an oral solution or an 
immediate release tablet/capsule formulation.  This, of course, causes the compound to be 
16 
 
quickly released and either absorbed by the body or eliminated due to GI overload; 
bioavailability is around 5-6%.  This immediate release type of formulation also must be 
taken multiple times a day at high quantities to maintain desired serum concentrations.  
The idea is to design either a slow release (sustained release) formulation that will slowly 
release a large amount of the desired compound (cystine/cysteine) over 8 to 12, or 12 to 
24 hrs.  
 
 This, of course, could be done by a number of methods:  a) using time released 
micro-encapsulated pellets compressed into a tablet or loaded into a capsule; b) partition 
tablet design that would allow for the immediate release of some drug, followed by the 
slow release of the remaining drug in either 1 to 4 slow dissolving partitions; c)  osmotic 
pump type capsule that will slowly release a steady stream of the desired compound into 
the GI system; d) matrix type tablets which will slowly erode and release the desired 
compound.   All methods described above have been and are currently used in the 
pharmaceutical field to provide a vehicle for once or twice a day dosing.    
 
 Of course, this formulation approach is not novel, except for the case of it here for 
cystine/cysteine and analogues (NAC).  This approach does have a few drawbacks 
associated with it, as found in other drugs on the market that employs a similar approach 
such as a) dose dumping (where all of the drug is prematurely released); b) time and 
resources in order to design and formulation of the release vehicle and product (should be 
able to incorporate current technology to assist with this method).   
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 Some possible advantages include a) once or twice daily dosing of the drug; b) 
provide a constant stream of drug to the GI system which may result in greater 
absorption, which in turn would outpace the metabolism of the drug, permitting for 
higher serum levels and higher CNS levels; c) be a relatively quick and easy method in 
addressing cystine/cysteine rapid metabolism and poor bioavailability; d) relatively 
cheaper and faster than designing and synthesizing many series of new cystine/cysteine 
analogues.    
 
 Another idea for formulation is to design and implement an oil/water type vehicle 
in which the desired compound, cystine/cysteine or analogues, is encapsulated in many 
micro lipid bilayer cells and stored in a gel capsule.  This method could be accomplished 
by a study and discovery of the correct commercially available lipid used in micro bilayer 
creation.  Once the appropriate lipid is found, the size of the micro lipid bilayer cells 
would have to be addressed.  Currently, micro lipid bilayers are created by rapidly 
stirring the mixture of water, drug and lipid then pressing it through a predefined pore 
size filter.  The pore size will determine the micro lipid bilayer cell size.  This cell size 
would have to be studied and experimented with to obtain the desired outcome in the 
body.  The cells cannot be too large because they will not be absorbed correctly and may 
even be digested by the GI system before absorption. Too small of a cell size will not 
carry enough of the desired drug and my end up tied up and carried by the plasma 
proteins and other transporter systems in the blood.   
 
18 
 
 Some disadvantages may include: a) the time and potential cost in developing the 
correct vehicle; however, using current literature and other resources may help reduce 
this problem; b) The potential biological effect of overloading the body with lipids 
(weight gain, fatty liver, high triglycerides, ect.); c) the need for multiple daily doses to 
maintain levels; d) digestion of the micro lipid bilayer cells and dose dumping.    
 
 Some possible advantages would include: a) a method to get cystine/cysteine or 
analogues (NAC) rapidly absorbed and past the liver in first pass metabolism; b) potential 
slower metabolism of the drug due to the drug being hidden in the micro cells; c) constant 
stream of free drug into the blood, as the micro lipid bilayer cells slowly breakdown, they 
will release the drug into the blood similar to a slow release formulation; d) potential 
higher CNS levels due to the ability of the micro lipid bilayer cells to move readily and 
passively transverse the Blood, Brain Barrier (BBB).   
 
 The second, and more chemistry chemically-based approach to increase the 
cysteine/cystine levels in the CNS in order to drive the cystine/glutamate antiporter 
would be to make series of cysteine/cystine analogues.  This was the method that was 
studied here and will be described from this point on. The thought was to drive the 
cystine/glutamate antiporter by providing cysteine/cystine at high enough concentrations 
in the CNS to facilitate the antiporter action.  However, this method was different from 
current pharma perspectives because this study focused only on one desired outcome 
(product), cystine.  All compounds currently designed or studied here should have no 
biological activity in their original form but require conversion into cystine/cysteine, in 
19 
 
vivo. This approach limits the testing of such compounds because in order for the 
compounds to show activity, they must be metabolized or transformed into the active 
compound (cystine/cysteine).  For the many different series, all compounds were 
designed to be given orally in order to be converted into cystine/cysteine.  Any method of 
testing that bypasses metabolism will result in a possible negative result.    
 
The ideal approach would be to design better ligands to drive the 
cystine/glutamate antiporter that can be given either orally or tested in vitro and have 
similar outcomes.   The process would involve analyzing cystine and determining the key 
structures that are responsible for receptor binding and activation of the antiporter 
(Structure Activity Relationships).  After which, one could start designing new ligands 
that should bind to the receptor and activate the antiporter.  In the process of design, 
certain issues will be addressed and incorporated into the ligands.   
 
 Metabolism is a major issue to be addressed.  When new ligands are designed, 
care will be taken to ensure that the final ligands will not be sensitive to rapid metabolism 
by the body.  This will be accomplished by incorporation of certain functional groups and 
likewise, elimination of certain functional groups.  Along with metabolism, solubility is 
also a key issue to address.   As with metabolism, great care will be taken to ensure the 
final ligands possess the appropriate solubility profile by including certain functional 
groups.  Solubility is better expressed as the LogP of a compound.  This is an important 
issue to address because a ligand must have the ability to cross the BBB and enter the 
CNS. Once again, in the design of the final ligands, care will be taken to ensure the 
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appropriate LogP (between 2-5), although some ligands may be outside of this range for 
practical reasons or as negative controls.   
 
 This approach does have certain drawbacks that must be realized which include: 
a) since the antiporter will be driven by ligands and not cystine, the ligand will enter the 
nerve cell and won’t be converted into glutathione, which has been shown to be 
beneficial further down the line; b) the potential amount of time and cost associated with 
the design and synthesis of a new series of ligands that may or may not even bind to the 
receptor and activate the antiporter, which is, of course, a usual problem associated with 
medicinal chemistry. 
 
 Some advantages of the ligand approach include: a) the use of high throughput 
screening techniques.  Since the ligands will be designed and synthesized in the active 
form, in vitro testing will be easier and more reliable; b) the lack of the metabolism 
requirement to convert the ligand into the active compound; c) all of which would lead to 
shorter down time in the design of future ligands and improving outcomes.      
 
8. Approach to be studied: cysteine/cystine analogues. 
 
This research relates generally to the treatment of schizophrenia and drug 
addiction by increasing cysteine/cystine levels in the CNS.  More particularly, the 
present research is directed to the design and synthesis of cysteine and cystine 
prodrugs designed to be metabolized into cysteine and cystine, therefore, increasing 
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cysteine and cystine levels in the CNS.  This research also involves the design and 
synthesis of cysteine and cystine mimics known as bioisosteres, used to drive the 
cystine-glutamate antiporter.  Together, all of these analogues will be studied for 
their usefulness as antipsychotic medications in the treatment of schizophrenia.  As 
well, the respective compounds are applicable for the potential reduction of drug 
cravings in drug addicted individuals.  This approach will also be useful in 
determining some structure active relationships of the cystine/glutamate antiporter. 
 
 The cystine-glutamate antiporter is a highly novel cellular process that likely 
contributes to the pathology underlying schizophrenia and drug addiction. Unlike 
existing medications, cysteine prodrugs appear to exert antipsychotic properties, in part, 
by reversing pathology underlying the disease. While no one theory or mechanism of 
pharmacological effect is adopted herein, cysteine prodrugs appear to restore diminished 
signaling to glutamate receptors and diminished glutathione levels observed in 
schizophrenics.  A depleted glutathione level can lead to a number of effects which are 
observed in schizophrenia such as: increased oxidative stress, and impaired cystine-
glutamate antiporter activity, glutamate neurotransmission, synaptic connection, and gene 
expression.  
 
 Increased excitatory neurotransmission in the nucleus accumbens may arise, in 
part, by diminished activity of cystine-glutamate antiporters.  The recent data collected in  
the present research illustrates that glutamate released from these antiporters provides 
endogenous tonic stimulation to group II or 2/3 metabotropic glutamate receptors 
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(mGluRs) and thereby regulates synaptic glutamate and dopamine release. Thus, 
altered glutamate signaling could arise as a consequence of decreased cystine-glutamate 
exchange.  Repeated cocaine administration has been shown to blunt the activity of 
cystine-glutamate exchange, as mentioned, which likely contributes to a sequence of 
events including diminished group II mGluR autoregulation and increased excitatory 
neurotransmission in the nucleus accumbens.  
 
 Impaired cystine-glutamate antiporter activity and faulty glutamate 
neurotransmission bear on the issue of uncontrolled drug use, i.e., drug addiction, as 
described above.  Cysteine prodrugs, such as N-Acetylcysteine (NAC), are used to drive 
cystine-glutamate exchange by apparently elevating extracellular cystine levels, thereby 
creating a steep cystine concentration gradient. Preclinical studies have shown N-
Acetylcysteine to be effective in blocking compulsive drug-seeking in rodents. 
Furthermore, extant clinical data also shows a reduction in cocaine use and craving in 
cocaine abusers receiving NAC. Unfortunately, the full clinical efficacy of targeting 
cystine-glutamate exchange may be unrealized when utilizing NAC due to extensive 
first-pass metabolism and limited passive transport of this drug across the blood-brain 
barrier. The prodrugs described in this research should not significantly be eliminated by 
liver metabolism and should readily pass through the blood-brain barrier.  Cysteine is the 
reduced form of cystine and is readily oxidized in vivo to cystine; therefore, elevating 
either cysteine or cystine is believed to increase cystine-glutamate exchange, as described 
earlier.  
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 The cysteine prodrug NAC has been previously shown to have a favorable 
safety/tolerability profile in human subjects.70,71  In fact, NAC has been used for decades 
in humans for other indications (e.g., as a mucolytic, acetaminophen 
toxicity)53,54,55,63 and as an experimental treatment (HIV, cancer)56,57,58,59,62,63,64 
without producing severe adverse effects.70,72  However, NAC undergoes extensive first 
pass metabolism requiring the usage of high doses that limit the utility of the drug and, 
potentially, increase the chances of side effects due to the buildup of metabolized by-
products, as discussed.70,72  The prodrugs presently described in this research are 
designed to substantially avoid the problem of first pass metabolism and poor blood brain 
barrier permeability, and therefore exhibit increased efficacy as compared to prior 
cysteine prodrugs as illustrated by improved potency and/or efficacy.  
 
 Repeated cocaine alters glutamate neurotransmission even following protracted 
withdrawal and this likely contributes to addiction since abnormal activation of 
corticostriatal pathways correlates with craving in humans and is necessary for cocaine 
seeking in rodents.  Revealing cellular mechanisms underlying altered corticostriatal 
activation should advance our understanding of the neurobiological basis of addiction and 
identify novel therapeutic targets. 
 
 Models of pathological glutamate signaling proposed to underlie addiction need to 
account for the existence of multiple pools of extracellular glutamate.  Aside from 
synaptic glutamate maintained by vesicular release, extrasynaptic glutamate is sustained 
primarily by nonvesicular release.  In support, basal extrasynaptic glutamate sampled by 
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microdialysis is largely independent of vesicular glutamate.  Glutamate transporters may 
partition the two pools by limiting glutamate overflow from the synapse into 
extrasynaptic compartments, and restricting entry of nonvesicular glutamate into 
synapses.  Although confined to the extrasynaptic compartment, nonvesicular glutamate 
regulates neurotransmission by stimulating group II metabotropic glutamate receptors 
(mGluRs) which are extrasynaptic receptors capable of inhibiting vesicular release.  
Therefore, extrasynaptic receptors permit crosstalk between the two pools and indicate 
that altered nonvesicular glutamate release may contribute to pathological glutamate 
signaling linked to addiction. 
 
 Cystine-glutamate exchange via the cystine/glutamate transporter system may be 
critical in the capacity of extrasynaptic glutamate to regulate corticostriatal signaling in 
the normal and pathological states.  First, nonvesicular release from cystine-glutamate 
exchange maintains basal extracellular glutamate in the nucleus accumbens, and thereby 
regulates the extent of endogenous group II mGluR stimulation.  Repeated cocaine blunts 
transporter activity which leads to reduced basal and increased cocaine-evoked glutamate 
in the nucleus accumbens that persists for at least three weeks after the last cocaine 
treatment.27,28  These changes are relevant for drug seeking since N-Acetylcysteine, a 
cysteine prodrug used to drive the transporter system, blocks cocaine-evoked glutamate 
in the nucleus accumbens and subsequent cocaine-induced reinstatement.27,28 
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9. Potential Pitfalls in Novel Approaches to Treat CNS Disorders.  
  
Since the approach here relies heavily on the design and synthesis of cyclic 
peptide analogues of cysteine and cystine, the concerns in regard to novel medicinal 
chemistry follow here. There is no guarantee that these cyclic peptides will by efficiently 
hydrolyzed by amidases or metabolized to liberate cystine, although many amidases and 
nonselective peptidase hydrolyases exist in the brain tissue.70,72 Substitutions on these 
cyclic diketopiperazine rings can potentially further complicate the liberation of cystine 
since hydrolysis of amides can be hindered due to steric crowding. Hence, without any 
direct evidence of whether such hydrolysis will take place, different types of analogues 
will be prepared. 
 
Based primarily on data from the first lead compound (1), as shown in Figure 3 
and Figure 4, this approach definitely shows promise.  According to what is known about 
the mechanism of the transporter and the mechanism of cystine in the transporter, the first 
lead compound (1) most likely remained intact longer in the blood and passed through the 
blood brain barrier after which it was hydrolyzed by enzymes or decomposed into the 
desired product, cystine.   
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Sensorimotor gating, a process compromised in schizophrenic patients, is often 
measured using pre-pulse inhibition whereby a mild auditory stimulus (pre-pulse, 2-15 db 
above background) precedes (100 ms) a startle-eliciting auditory stimulus (50 dB above 
background).  Intact sensorimotor gating will result in suppression of the startle reflex 
when preceded by the pre-pulse. Since improvement in pre-pulse inhibition tracks 
improvement in symptoms that are largely insensitive to current treatments, this paradigm 
has become one of the most commonly used screening paradigms. Figure 4 illustrates the 
capacity of PCP to disrupt pre-pulse inhibition, rendering the pre-pulse ineffective in 
suppressing the startle reflex.  PCP is commonly used to disrupt pre-pulse inhibition 
because this abnormality, in addition to negative and cognitive symptoms, is insensitive 
to 1st generation antipsychotics, thereby providing predictive validity.  Also illustrated in 
Figure 4 is the impact of N-Acetylcysteine (NAC) and NCE on sensorimotor gating 
deficits produced by phencyclidine administered orally (right). * indicates a significant 
difference from rats receiving PCP only (e.g., 0 N-Acetylcysteine or NCE), Fisher LSD, 
p < 0.05. 
Figure 4 
Preliminary studies in rats using oral N-acetyl cysteine 
(NAC) and compound 1 (NCE) in the PCP model. 
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One concern early on in the design plan was that substitutions on diketopiperazine 
rings can potentially further complicate the liberation of cystine for hydrolysis of amides 
can be further retarded due to steric crowding.  Fortunately, it was shown very early  by 
Abderhalden,74 in 1932, that “cleavage experiments in which the action of 0.1 N NaOH, 5 
N HCl, trypsin-kinase and erepsin on amino-acid-(2,5-diketopiperazine)s was determined 
and showed that the substitution of an amino acid radically greatly diminished the 
stability of the diketopiperazine ring which readily opened up to form the tripeptide.”74  
 
Furthermore, it was also shown earlier by Kawai,75 in 1928, that “glycine-DL-
phenylalanine as well as II (the diketopiperazine) was hydrolyzed asymmetrically by 
crepsin and the digestion mixture showed distinct L-rotation after a certain time.”75 
However, it was also shown by the same author that “III (another diketopiperazine) was 
not hydrolyzed by erepsin, trypsin, ect..”75 which indicates one can manipulate stability 
by substituent patterns.  
 
Other authors later reported that certain diketopiperazines were not hydrolyzed by 
enzymes. In 1936, Greenstein76 reported “the diketopiperazine, anhydro-l-lysyl-glutamic 
amide, was completely resistant to pepsin, trypsin and papain-HCN.”76  The author does 
caution the reader that “while these results are not sufficient in themselves to discredit the 
diketopiperazine hypothesis, they do imply that considerable caution should be exercised 
in applying the anhydride structure to proteins.”76  
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After further studies by Abderhalden77, it was reported in 1940 that based on 
another author’s work (Sibata) “pepsin should be able to split basic peptide anhydrides 
while the splitting of the acid anhydrides by trypsin, papain and cathepsin should also be 
possible.”77 Abderhalden used numerous enzymes in his studies including dipeptidases, 
polypeptidases, trypsinkinases, and pepsin.  “Although the experimental conditions 
varied widely, negative (non-hydrolysis) results were obtained with all substrates and all 
enzymes.”77 However, the author continues to report “upon repeating some of the 
experiments, it was found that glycyl-l-glutamic acid anhydride was split up by 
trypsinkinases.”77     
 
Based on these authors, it was apparent that the debate on whether 
diketopiperazines were readily metabolized by enzymes was a complicated matter. While 
it was possible to find cases where diketopiperazines were metabolized, it is also just as 
easy to find cases where they were not.  It is important to note, that based on a majority 
of the cases, the more stericaly hindered diketopiperazine was either more rapidly 
metabolized or decomposed to the hydrolysis product which would be hydrolyzed readily 
in the CNS by amidases, peptidases and non-specific hydrolyases.74,76,77 
 
Due to these discrepancies, further reading and research into the subject was 
required.  Martins and Carvalho published a mini-review in 2007 in regard to the use of 
diketopiperazines as drugs, their biological activity and synthesis.78 As pointed out in the 
article, “their peculiar heterocyclic system (diketopiperazine) found in several natural 
products constitutes a rich source of new biologically active compounds.”78 The authors 
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established their importance by providing a list of the most common biological uses for 
diketopiperazines. “Some of the most important biological activities of diketopiperazines 
are related to the inhibition of plaminogen activator inhibitor-1 (PAI-1) and alteration of 
cardiovascular and blood clotting functions. They also express activity as antitumour, 
antiviral, antifungal, antibacterial, and antihyperglycaemic agents as well as affinity for 
calcium channels and opioid receptors, GABAergic receptors, serotoninergic 5-HT1 and 
oxytocin receptors”78. “Diketopiperazines are privileged structures for the discovery of 
new lead compounds by combinatorial chemistry and are considered ideal for the rational 
development of new therapeutic agents” as described by Martins.78 The metabolism of 
diketopiperazines is referenced as “diketopiperazines are considered as constrained 
amino acid and protein β-turn mimetics.  An additional example of the recognition and 
metabolism of cyclic dipetides by enzymes was demonstrated with tyrosine hydroxlyase, 
which catalyses the limiting step in catecholamine biosynthesis.”78 
 
 As one concluded, the issue concerning the fate of diketopiperazines in the 
mammalian body is complex and multifaceted.  However, it is certain that 
diketopiperazines hold a very important part in the drug discovery process as is 
demonstrated by the current drugs in clinical trials and the ones being marketed.78  Listed 
below in Figure 5 are a list of relevant hydrolytic enzymes found in the CNS.  Theses 
enzymes should play a major role in the metabolism of the cysteine/cystine prodrugs, 
bioisosteres and analogues synthesized in order to release the desire compound 
cysteine/cystine.  
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Figure 5: List of Relevant Hydrolytic Enzymes Found in the CNS 
1) Peptidases – hydrolyzes amide (peptide) bonds into an amine and a 
carboxylic acid 
a. General Peptidases – nonspecifically hydrolyzes amide bonds on a 
wide range of compounds  
b. Aminopeptidases – specific to protein metabolism and amino acid 
peptide bonds 
c. Cysteinylglycinase – hydrolyzes the peptide bond between cysteine 
and glycine 
d. Cysteine proteases – specific to peptide bonds that contain the 
amino acid cysteine 
e. Serine proteases – specific to peptide bonds that contain the amino 
acid serine 
2) Esterases – hydrolyzes esters into an acid and an alcohol  
a. General Esterases – nonspecifically  hydrolyzes ester bonds on a 
wide range of compounds 
b. Acetylesterases – hydrolyzes off acetyl groups (acetic acid) 
c. Thiosesterases – hydrolyzes  thioesters to form thiols and carboxylic 
acid 
3) Hydrolases – nonspecifically catalyzes the hydrolysis of chemical bonds 
a. Hydrolyzes the following bonds:  amide bonds, esters bonds, 
anhydride bonds, sulfur-sulfur bonds, carbon-sulfur bonds, 
carbon-carbon bonds, ether bonds, along with a wide range of 
other functional groups   
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II. Design and Synthesis of Cysteine and Cystine Prodrugs 
1. Initial Approach to the Synthesis of Cysteine and Cystine Prodrugs 
 
The initial approach was to design cysteine and cystine prodrugs that will be 
either metabolized or chemical converted, in vivo, into the desired product, cystine.  
Since cysteine is known to be oxidized into cystine in the extracelluar region of the brain, 
either end-point was desirable.  Using chemistry previously described by Schölkopf79  
and scaled up in our laboratory, a synthetic route was outlined that followed the classic 
Schölkopf chiral auxiliary pathway, Scheme 1.79 Cysteine or the dimer cystine were 
suspended (individually) in THF and treated with triphosgene and heated to 45oC.  The 
unstable anhydride intermediates, 2 and 6 respectively, which resulted were treated with 
glycine ethyl ester HCl salt under basic conditions at -70 oC.  This should have resulted in 
the more stable esters 3 and 7, respectively.  Heating esters 3 and 7 (individually) to 
reflux in toluene would normally promote intramolecular cyclization to form the first 
diketopiperazine targets, 4 and 1, respectively, after which, the final desired 
diketopiperazines could be obtained through simple alkylation (see 5 and 8).  
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Certain problems became apparent during the large scale synthesis of the desired 
diketopiperazine targets 5 and 8.  Cysteine, unlike many other amino acids used in the 
past,79 has a reactive side chain and free thiol, which can undergo addition cyclization 
reactions when treated with triphosgene, as shown in Scheme 2.  Although this problem 
was discussed and ways to overcome this problem were previously devised, such as 
protecting the thiol group, it was decided to proceed with the original synthetic pathway.  
The secondary product turned out to be more difficult to remove and made up a 
significant amount of the yield (~65%) compared to the initial estimates.  Continuation of 
this synthetic route proved to cause additional problems with solubility and unidentifiable 
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byproducts, which was thought to be formed by the polymerization of the cysteine with 
itself or glycine.  Because of these problems and the need to synthesize analogues quickly 
for in vitro and in vivo testing, the cysteine pathway was temporarily held to pursue the 
cystine pathway. 
 
 
Since cystine is the disulfide of cysteine, there was no free thiol group to react and 
cyclize during the anhydride formation or the intramolecular cyclization reaction.  
However, there was another problem not confronted when the monomer of the amino 
acid had been employed.  Since, cystine was a dimer, there are twice as many amino acid 
functional groups that must be considered when carrying out reactions.  Also, these 
functional groups are in close proximity to each other and may undergo intramolecular 
reactions or intermolecular reactions to form polymers.  In order to prevent 
intermolecular reactions, all reactions were carried out under conditions of high dilution; 
4-5 times that of normal.  Also, each reaction was cooled and heated only when needed to 
prevent any unintentional intramolecular reactions from taking place.   
 
Although certain precautions were taken to prevent side reactions and prevent 
problems, it became apparent in the beginning that the disulfide amino acid cystine will 
be difficult to work with as a starting material.  The solubility of the disulfide was much 
34 
 
lower than the monomer, which was to be expected, but to the extent that the reactions 
took 3-4 times longer, even after adjusting the equivalents and concentrations of the other 
reagents to closely match past procedures due to the larger volume of solvent required for 
solubility and to prevent intermolecular reactions with the disulfide amino acids.   
Confirmation that each reaction went to completion was also difficult due to the 
solubility of the starting material and product along with the presences of multiple 
functional groups in a symmetric compound.  After each reaction was complete, workup 
(filtering and washing) and recrystallization of the product from water/methanol resulted 
in very low yields (~15-25% of 1) compared to the initial parent compounds and 
pathways previously executed in this laboratory (90-98%), in other work.79   
  
In the initial synthetic route to the diketopiperazine targets, the cysteine pathway 
did not work in a practical sense and will need to be revised for future exploration.  
Although the cystine pathway did offer some benefits to the cysteine pathway, it also had 
some problems and will also be revised for future exploration.  Of the initial compounds 
proposed, only compound 1 was synthesized in any measurable quantity (30 grams) and 
has been tested in vivo on rats to determine if this line of compounds will be 
advantageous to pursue.  In the preliminary studies shown before, it is clear that 
compared to the current standard, N-acetyl cysteine, diketopiperazine 1 (NCE) was more 
active (see Figure 4) and analogues pursued further. 
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2. Improved Synthesis of Cysteine and Cystine Prodrugs. 
 
Based on the knowledge from the previous chemistry and the problems 
confronted, the synthesis of the diketopiperazine targets was revised to provide an 
improved pathway which would result in fewer side products and yet provide an 
opportunity for drug development.  As shown in Scheme 3, the lead diketopiperazine 
targets 12 and 13 are outlined.79,80,81,82 The chemistry employed is analogous to the 
Schölkopf chiral auxiliary currently being used in Milwaukee for alkaloid total synthesis 
and was scaled up to kilogram scale.79  Protection of the thiol (-SH group) in cysteine 
using tert-butyl alcohol in the presence of hydrochloric acid or phenylsulfenyl chloride or 
triphenyl methyl chloride was required to insure the formation of the Schölkopf chiral 
auxiliary and prevent other cyclization reactions, as previously depicted above in Scheme 
2.  The S-protected-cysteines (9a-9c) were treated with triphosgene (individually) to form 
the unstable anhydride intermediates (10a-10c).  This step was followed by condensation 
with any number of the desired amino acid ethyl or methyl esters, followed by heating to 
reflux in toluene to effect the intramolecular cyclization to targets (11a-11c), 
respectively.  
 
Outlined in Figure 6 are the possible compounds that can be made from using 
naturally occurring amino acids.  However, unnatural amino acids and designer amino 
acids can also be prepared and will be incorporated into the list of test compounds.  The 
initial choices for monomer and dimers are boldfaced and underlined in Figure 6.  
Diketopiperazine compounds containing amino acids cysteine, glycine, phenylalanine, 
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proline, and valine (12a, 12b, 12c, 12d, 12e) were considered the most important target 
compounds.  These compounds were chosen for reasons of either partition coefficients 
(valine, proline), active transport (phenylalanine, proline), or the breakdown products are 
important for glutamate/cystine antiporter function (cysteine, glycine).  
 
Thiol deprotection of diketopiperazine 11 using the appropriate reagents will lead 
to the free thiol targets (see 12).  Alkylation of amide 12 will produce another desired 
prodrug diimidate 13. During the design of this synthetic route, it was discovered that 
simple hydrolysis of diimidate 13 with trace amounts of hydrochloric acid and water 
resulted in the production of monoimidates 14 and 15, which are patented. Upon further 
treatment with acidic water, monoimidates 14 and 15 were completely converted back 
into the dealkylated diketopiperazine (see 12), which would occur in the stomach, as 
planned.   
 
The treatment of target compounds (11b-11c, 12) with either a) 2-
mercaptoethanol, b) iodine and pyridine in dichloromethane, or c) catalytic amounts of 
iodine in ethanol, produced the symmetrical disulfide dimer 16, as shown in Scheme 4.  
 
This revised synthetic route, Scheme 3, had many advantages over the initial 
route outlined above in Scheme 1. a) To date this is the only practical synthetic route that 
leads to both monomers and dimers (cysteine and cystine prodrugs), b) protection of the 
thiol group prevents side cyclization reactions and facilitates chromatographic 
purification, c) initial monomer synthesis eliminates the problems of multiple functional 
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groups reacting with reagents or each other simultaneously, d) the occurrence of 
undesired intramolecular and intermolecular side reactions is decreased, e) this work can 
be easily expanded to incorporate additional amino acid reagents.  
 
Listed in Table 1 is a list of compounds prepared following Scheme 3 and 
Scheme 4 by members of the Cook group, under the direction of myself and/or 
synthesized by myself, the primary project researcher. Compounds that are “boxed” in 
each general scheme were actually synthesized as shown in the general scheme. After 
which is a detailed listing of some key reactions and target prodrugs.  The complete 
experimental details are located in Chapter IX – Experimental Section, and includes 
weights, molar quantities, volumes, temperatures, and spectral data.  
 
The rational of the prodrug approach is that upon oral administration in a subject, 
chemical entities are readily converted in vivo to the pharmaceutically active compounds 
in either the stomach (pH=2) or the gut (pH=10).  According to the previous literature78 
and preliminary studies, the diketopiperazine targets should pass largely intact through 
first pass metabolism and then should be hydrolyzed (cleaved) into the corresponding 
amino acids by peptidases or hydrolyases in cells contained within the CNS depicted 
before in Figure 5.    
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Table 1. Cysteine and Cystine Prodrugs from Scheme 3 and Scheme 4 
Compound Number: 1 
Cook Code: WYME-ST-GG 
Promentis Code: Pro-052 
Chemical Formula: C10H14N4O4S2 
Molecular Weight: 318.37 
Log P: -3.2 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Dimer 
 
 
HN
NHO
O
S
NH
HN O
O
S
 
Compound Number: 9a 
Cook Code: ME-StBu 
Promentis Code: Pro-048 
Chemical Formula: C7H15NO2S 
Molecular Weight: 177.26 
Log P:0.21 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
 
S
NH2
OH
O
(H3C)3C
 
Compound Number: 9b 
Cook Code: WYME-SSPh 
Promentis Code: Pro-044 
Chemical Formula: C9H11NO2S2 
Molecular Weight: 229.32 
Log P: 1.76 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
 
SPh
S
H2N
OH
O
 
Compound Number: 9c 
Cook Code: WYME-STrt 
Promentis Code: Pro-058 
Chemical Formula: C22H21NO2S 
Molecular Weight: 363.47 
Log P: 4.39 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
 
CPh3
S
H2N
OH
O
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Compound Number: 10b 
Cook Code: WYME-SSPh-5 
Promentis Code: Pro-045 
Chemical Formula: C10H9NO3S2 
Molecular Weight: 255.31 
Log P: 2.29 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
 
HN
O
S
SPh
O
O
 
Compound Number: 10c 
Cook Code: N/A 
Promentis Code: N/A 
Chemical Formula: C23H19NO3S 
Molecular Weight: 389.47 
Log P: 4.93 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
 
 
Compound Number: 11b 
Cook Code: N/A 
Promentis Code: N/A 
Chemical Formula: C11H12N2O2S2 
Molecular Weight: 268.36 
Log P: 0.85 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
 
 
Compound Number: 12a 
Cook Code: WYME-SBGH 
Promentis Code: Pro-013 
Chemical Formula: C5H8N2O2S 
Molecular Weight: 160.19 
Log P: -1.83 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
 
HN
NHO
O
SH
 
Compound Number: 12c 
Cook Code: WYME-SBPh 
Promentis Code: Pro-015 
Chemical Formula: C12H14N2O2S 
Molecular Weight: 250.32 
Log P: 0.34 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
HN
NHO
O
SH
Ph
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Compound Number: 12d 
Cook Code: WYME-SBPr 
Promentis Code: Pro-068 
Chemical Formula: C8H12N2O2S 
Molecular Weight: 200.26 
Log P: -1.13 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
 
HN
NO
O
SH
 
Compound Number: 12e 
Cook Code: WYME-SBVa 
Promentis Code: Pro-018 
Chemical Formula: C8H14N2O2S 
Molecular Weight: 202.27 
Log P: -0.45 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
 
HN
NHO
O
SH
 
Compound Number: 17 
Cook Code: WYME-051407-SM 
Promentis Code: Pro-024 
Chemical Formula: C4H9NO2S 
Molecular Weight: 135.18 
Log P: -0.66 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
 
 
Compound Number: 18 
Cook Code: WYME-051707-SE 
Promentis Code: Pro-021 
Chemical Formula: C5H11NO2S 
Molecular Weight: 149.21 
Log P: -0.32 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
 
HS
NH2
OCH2CH3
O
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Compound Number: 19 
Cook Code: ME-SEt 
Promentis Code: Pro-023 
Chemical Formula: C5H11NO2S 
Molecular Weight: 149.21 
Log P: -0.33 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
 
S
NH2
OH
O
H3C
 
Compound Number: 20 
Cook Code: ME-SPh 
Promentis Code: Pro-027 
Chemical Formula: C9H11NO2S 
Molecular Weight: 197.25 
Log P: 1.0 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
 
S
NH2
OH
O
Ph
 
Compound Number: 21 
Cook Code: ME-SBZY 
Promentis Code: Pro-020 
Chemical Formula: C10H13NO2S 
Molecular Weight: 211.28 
Log P: 1.07 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
 
S
NH2
OH
O
Ph
 
Compound Number: 22 
Cook Code: WYME-SPhCO 
Promentis Code: Pro-029 
Chemical Formula: 
Molecular Weight: 225.26 
Log P: 0.94 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
 
S
NH2
OH
O
Ph
O
 
  
45 
 
Compound Number: 23 
Cook Code: WYME-SS-am 
Promentis Code: Pro-032 
Chemical Formula: C6H14N4O2S2 
Molecular Weight: 238.33 
Log P:-2.69 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Dimer 
 
 
NH2
S S
NH2
NH2H2N
O O
 
Compound Number: 24 
Cook Code: WYME-ST-tBu 
Promentis Code: Pro-061 
Chemical Formula: C26H29NO2S 
Molecular Weight: 419.58 
Log P: 5.53 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
 
CPh3
S
H2N
O
O
C(CH3)3
 
Compound Number: 25 
Cook Code: WYME-SBPr6 
Promentis Code: Pro-016 
Chemical Formula: C14H16N2O2S2 
Molecular Weight: 308.42 
Log P: 1.55 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
 
HN
NO
O
S SPh
 
Compound Number: 26 
Cook Code: ME-StBu-6 
Promentis Code: Pro-049 
Chemical Formula: C9H16N2O2S 
Molecular Weight: 216.3 
Log P: -0.7 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
 
HN
NHO
O
S C(CH3)3
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Compound Number: 27 
Cook Code: WYME-ST-G6 
Promentis Code: Pro-051 
Chemical Formula: C24H22N2O2S 
Molecular Weight: 402.51 
Log P: 3.48 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
 
 
Compound Number: 28 
Cook Code: WyME-SB-P6 
Promentis Code: Pro-014 
Chemical Formula: C18H18N2O2S2 
Molecular Weight: 358.48 
Log P: 3.01 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
HN
NHO
O
S
Ph
SPh
 
Compound Number: 29 
Cook Code: WyME-ST-P6 
Promentis Code: Pro-055 
Chemical Formula: C31H28N2O2S 
Molecular Weight: 492.63 
Log P: 5.65 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
HN
NHO
O
S
Ph
CPh3
 
Compound Number: 30 
Cook Code: WYME-ST-Pr 
Promentis Code: Pro-057 
Chemical Formula: C27H26N2O2S 
Molecular Weight: 442.57 
Log P: 4.19 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
 
HN
NO
O
S CPh3
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Compound Number: 31 
Cook Code: WYME-ST-V6 
Promentis Code: Pro-062 
Chemical Formula: C27H28N2O2S 
Molecular Weight: 444.59 
Log P: 4.86 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
HN
NHO
O
S CPh3
 
Compound Number: 32 
Cook Code: WYME-SBSS 
Promentis Code: Pro-017 
Chemical Formula: C10H18N2O2S2 
Molecular Weight: 262.39 
Log P: -0.24 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
HN
NHO
O
SH
S(H3C)3C
 
Compound Number: 33 
Cook Code: WYME-ST-S6  
Promentis Code: Pro-059 
Chemical Formula: C29H32N2O2S2 
Molecular Weight: 504.71 
Log P: 5.08 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
HN
NHO
O
S
S
CPh3
(H3C)3C
 
Compound Number: 34 
Cook Code: N/A  
Promentis Code: Pro-1036 
Chemical Formula: C10H18N2O3S 
Molecular Weight: 246.33 
Log P: -1.07 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
 
HN
NH
O
OStBu
OH
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Compound Number: 35 
Cook Code: N/A 
Promentis Code: Pro-1038 
Chemical Formula: C16H22N2O2S 
Molecular Weight: 306.42 
Log P: 1.46 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
 
HN
NH
O
OStBu
 
Compound Number: 36 
Cook Code: WyME-ST-PP 
Promentis Code: Pro-056 
Chemical Formula: C24H26N4O4S2 
Molecular Weight: 498.62 
Log P: 1.13 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Dimer 
 
 
Compound Number: 37 
Cook Code: WYME-ST-SS 
Promentis Code: Pro-060 
Chemical Formula: C20H34N4O4S4 
Molecular Weight: 522.77 
Log P: -0.01 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Dimer 
 
 
Compound Number: 38 
Cook Code: WYME-ST-VV 
Promentis Code: Pro-064 
Chemical Formula: C16H26N4O4S2 
Molecular Weight: 402.53 
Log P: -0.45 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Dimer 
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Compound Number: 39 
Cook Code: N/A 
Promentis Code: Pro-1016 
Chemical Formula: C12H18N4O6S2 
Molecular Weight: 378.42 
Log P: -3.93 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Dimer 
 
 
HN
NH
O
OS
OHNH
HN
O
O S
HO
 
Compound Number: 40 
Cook Code: N/A  
Promentis Code: Pro-1022 
Chemical Formula: C12H18N4O4S2 
Molecular Weight: 346.43 
Log P: -2.22 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Dimer 
 
 
HN
NH
O
OS
NH
HN
O
O S
H3C CH3
 
Compound Number: 41 
Cook Code: N/A 
Promentis Code: Pro-1024 
Chemical Formula: C18H30N4O4S2 
Molecular Weight: 430.59 
Log P: 0.39 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Dimer 
 
 
HN
NH
O
OS
CH3
NH
HN
O
O S
H3C
H3C CH3
 
Compound Number: 42 
Cook Code: N/A 
Promentis Code: Pro-1025 
Chemical Formula: C18H30N4O4S2 
Molecular Weight: 430.59 
Log P: 0.25 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Dimer 
 
 
HN
NH
O
OS
H3C CH3
NH
HN
O
O S
CH3H3C
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Compound Number: 43 
Cook Code: WYME-BFVa 
Promentis Code: Pro-005 
Chemical Formula: C12H33N2O2S 
Molecular Weight: 258.38 
Log P: 2.49 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
 
N
NEtO
OEt
SH
 
Compound Number: 44 
Cook Code: WYME-0625-SBBFGE 
Promentis Code: Pro-011 
Chemical Formula: C9H16N2O2S 
Molecular Weight: 216.3 
Log P: 1.12 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
 
N
NEtO
OEt
SH
 
Compound Number: 45 
Cook Code: WYME-BFPh 
Promentis Code: Pro-004 
Chemical Formula: C16H22N2O2S 
Molecular Weight: 306.42 
Log P: 3.28 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
 
N
NEtO
OEt
SH
Ph
 
Compound Number: 46 
Cook Code: WYME-SBB-FGL 
Promentis Code: Pro-012 
Chemical Formula: C18H30N4O4S2 
Molecular Weight: 430.59 
Log P: 2.69 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Dimer 
 
 
N
NO
O
S
Et
Et
N
N O
O
S
Et
Et
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Compound Number: 47 
Cook Code: WYME-SSB-FVV  
Promentis Code: Pro-065 
Chemical Formula: C24H42N4O4S2 
Molecular Weight: 514.74 
Log P: 5.44 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Dimer 
 
 
N
NEtO
OEt
S
N
N OEt
EtO
S
 
Compound Number: 48 
Cook Code: WYME-SSB-FPP 
Promentis Code: Pro-066 
Chemical Formula: C32H42N4O4S2 
Molecular Weight: 610.83 
Log P: 7.02 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Dimer 
 
 
N
N
EtO
OEt
S
Ph
N
N
OEt
EtO
S
Ph
 
Compound Number: 49 
Cook Code: WYME-STBF-PhM 
Promentis Code: Pro-047 
Chemical Formula: C16H22N2O2S 
Molecular Weight: 306.42 
Log P: 2.4 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
 
N
NHEtO
O
S
Ph
CH2CH3
 
Compound Number: 50 
Cook Code: WYME-SH-NPh6  
Promentis Code: Pro-080 
Chemical Formula: C12H14N2O2S 
Molecular Weight: 250.32 
Log P: 0.14 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
N
NH
SH
O
O
Ph
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Compound Number: 51 
Cook Code: WYME-ST-N6 
Promentis Code: Pro-071 
Chemical Formula: C16H22N2O2S 
Molecular Weight:306.4 
Log P: 1.27 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
N
NH
S
O
O
Ph
 
Compound Number: 52 
Cook Code: WYME-SB-GH6NPh 
Promentis Code: Pro-084 
Chemical Formula: C19H20N2O2S 
Molecular Weight: 340.4 
Log P: 2.11 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
 
N
NO
O
SH
Ph
Ph
 
Compound Number: 53 
Cook Code: WYME-ST-N2Ph 
Promentis Code: Pro-092 
Chemical Formula: C23H28N2O2S 
Molecular Weight: 396.5 
Log P: 3.23 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
 
N
N
O
O
Ph
Ph
S
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2.1. Preparation of 4-Methylbenzenesulfenyl Chloride.78  
 
 4-Methylbenzenesulfenyl chloride is not commercially available and, therefore, 
must be synthesized.  Under a nitrogen atmosphere, N-chlorosuccinimide was slurried in 
methylene chloride. While stirring at rt, 4-methylbenzenethiol was added to the mixture. 
The clear solution which resulted was then allowed to stir at rt. A small amount of 
precipitate which formed was removed by filtration. The filtrate, assumed to contain the 
theoretical quantity of 4-methylbenzenesulfenyl chloride was used immediately and 
directly in many of the following synthetic transformations.   
    
2.2. Representative Procedure for Synthesis of Bis-Dipiperazinedione 
(Symmeterical Dimers): Bis-[2,5-Piperazinedione, 3-(mercaptomethyl)-] 
(1). 
 
 
As shown in Scheme 5, the trityl protected diketo-piperazine 27 was dissolved in 
a solution of methylene chloride and methanol with stirring.  Pyridine was then added to 
the mixture which resulted, followed by a solution of iodine in methanol.  The mixture 
was allowed to stir at rt. The reaction progress was followed by TLC until all the starting 
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material was consumed. The solution was stirred for a total of 26 h and the precipitate 
was filtered off. The solid was washed with cold methanol and then decolorized by 
shaking with 10% aqueous sodium bisulfate. The precipitate was filtered and dried to 
yield dimer 1 as white solid.  
 
2.3. Synthesis of (R)-2-Amino-3-(phenyldisulfanyl)propanoic acid (9b). 
 
 
 
As shown in Scheme 6, powdered sodium bicarbonate was added to a solution of 
L-cysteine hydrochloride mono-hydrate in absolute ethanol at 0 °C in one portion. 
Phenylsulfenyl chloride was then added dropwise with stirring to the mixture. After the 
complete addition of the reagent, the reaction mixture was allowed to stand at rt and the 
sodium chloride, which was produced during the reaction, was removed by filtration. 
After bringing the pH of the solution to alkaline by the addition of pyridine into the 
filtrate, the fine precipitate which formed, was allowed to stand for a couple of hours, 
after which it was filtrated and washed well with ethanol.  It was dried to provide the 
crude acid as a white solid. After recrystallization from aq HCl (1.0 N), the final product 
S-thiol-phenyl-L-cysteine (9b) was obtained as colorless plates.  
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2.4. Synthesis of 2-Amino-3-tritylsulfanyl-propionic acid (S-trityl-L-
cysteine) (9c). 
 
H3N
OH
O
SH
H2N
OH
O
S
Ph3CCl/DMF, 2 d
NaOAc, 89% yield
CPh3
9c
Scheme 7
Cl
 
As shown in Scheme 7, L-Cysteine hydrochloride and trityl chloride were stirred 
in DMF for 2 days at rt. A 10% sodium acetate solution was then added dropwise and the 
white precipitate (9c) which formed was filtered and washed with distilled water. 
Afterward, the residue was stirred in acetone at 50 °C for 30 min, after which it was 
cooled to 0 °C and filtered. The precipitate (9c) was washed with a little acetone and 
diethyl ether and dried in vacuo. S-Trityl-L-cysteine 9c was obtained as a white powder.   
    
2.5. Synthesis of (R)-4-((Phenyldisulfanyl)methyl)oxazolidine-2,5-dione 
(10b). 
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As shown in Scheme 8, to a rapidly stirred suspension of S-thiol-phenyl-L-
cysteine (9b) in THF was added solid triphosgene in one portion at 45-50 °C. The 
mixture was stirred until the solution becomes homogeneous. The solution was then 
purged with argon overnight into a NaOH bubbler to remove any residual phosgene. The 
solvent was evaporated in vacuo and this provided anhydride 10b. Due to the unstable 
nature of this anhydride, it was stored in the refrigerator under an atmosphere of argon 
and used immediately in a later step without further purification.   
 
2.6. Synthesis of 4-tritylsulfanylmethyl-oxazolidine-2,5-dione (10c). 
 
NH2
SHO
O
Ph
Ph
Ph
OHN
O
O
S
triphosgene, THF
45 ~ 50 oC, 85% yield
CPh3
10c9c
Scheme 9
 
 
As shown in Scheme 9, to a rapidly stirred suspension of S-trityl-L-cysteine (9c) in 
THF was added solid triphosgene in one portion at 45-50 °C. The mixture was stirred until 
the solution becomes homogeneous. The solution was purged with argon overnight into a 
NaOH bubbler to remove any residual phosgene. The solvent was evaporated in vacuo and 
this provided anhydride 10c.  Due to the unstable nature of this anhydride, it was stored in the 
refrigerator under an atmosphere of argon and used immediately in a later step without 
further purification. 
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 2.7. Representative Procedure for Synthesis of Diketopiperazine 
Targets. 
 
     
2.8. Synthesis of 3-(Mercaptomethyl)-2,5-Piperazinedione (12a) and (R)-
3-((Phenyldisulfanyl)methyl)piperazine-2,5-dione (11b). 
 
As shown in Scheme 10, a)  a solution of the N-carboxy-anhydride 10b in THF 
was added dropwise to a vigorously stirred mixture of glycine ethyl ester hydrochloride, 
freshly distilled triethylamine and dry chloroform at –78 °C in a three-neck flask. The 
reaction mixture was allowed to warm to 0 °C over 8 h, and then was allowed to stir at rt 
for 12 h, after which the reaction solution was filtered to remove the triethylamine 
hydrochloride which precipitated. The filtrate was then concentrated under reduced 
pressure (< 40 °C) and the crude dipeptide ester was used for the preparation of the 
diketopiperazine 12a, directly in the next step.  
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b) The crude dipeptide ester 11b was heated in refluxing toluene for 12 h and then 
cooled down to rt and kept at 0 °C for 16 h. The bislactam 12a which precipitated was 
isolated by vacuum filtration, washed with ether and dried under vacuum at 100 °C to 
provide pure diketopiperazine 12a. The filtrate, which resulted, produced from washing 
the desired diketopiperazine was evaporated under vacuum and toluene was added to the 
residue. The toluene solution was heated at reflux for another 40 h (under argon) and then 
the above steps were repeated to collect additional grams of diketopiperazine 12a.  
 
c)  The solution which resulted from step b above was cooled to 0 °C and keep at 
0 °C for 12 h in the refrigerator. The precipitate, which resulted, was filtered and 
provided phenyl-thiol analog 11b.   
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2.9. Synthesis of 3-Tritylsulfanylmethyl-piperazine-2,5-dione (27).  
 
 
 
Was prepared following the procedure for the preparation of 12a. It is important 
to note that the trityl protected thiol group was not cleaved during reflux in toluene as in 
the case of the S-thiol phenyl group, as shown in Scheme 11.  
 
2.10. Representative Procedure for Synthesis of Dialkylated 
Diketopiperazine: Preparation of Triethyloxonium Tetrafluoroborate.79 
 
Note: Triethyloxonium tetra-fluoroborate is an expensive reagent; however, it is 
relatively easy to prepare even on large scale. A three-neck flask, pressure equilibrating 
dropping funnel and a condenser were dried in an oven at 150 °C and assembled while 
hot under an atmosphere of argon. When the equipment had cooled to rt, ether which had 
been previously dried over sodium benzophenone ketyl and boron trifluoride 
diethyletherate were combined [Note: On this scale the colorless BF3 etherate was 
obtained from a freshly opened new bottle. If the reagent was slightly yellow or if the 
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reaction was scaled down, the BF3 etherate needed to be vacuum distilled first]. The 
ethereal solution which resulted was heated to a gentle reflux after which dry 
epichlorohydrin was added dropwise over 1 h. The mixture was heated at reflux for an 
additional 1 h and allowed to stand at rt (under argon) overnight. The ether was removed 
by applying a positive pressure of argon in one neck of the flask while forcing the ether 
out through a filter stick (fritted glass tube) inserted into another neck of the flask and 
into a collection flask. The slightly yellow solid which remained in the flask was rinsed 
twice in the same manner with anhydrous ether to provide a crystalline white solid. The 
solid was not weighed but directly used in the next steps 
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2.11. Synthesis of (3,6-Diethoxy-2,5-dihydro-,pyrazin-2-yl)-
methanethiol (44). 
 
 
 
As shown in Scheme 12, dry CH2Cl2 was added to the flask which contained the 
freshly prepared triethyloxonium tetrafluoroborate from the previous reaction (under 
argon). To this solution was added the diketopiperazine 12a in portions with stirring. 
After 2 h the reaction mixture became homogenous. The solution was stirred at rt under 
argon for 72 h, after which the mixture was added via a cannula to an aq solution of 
NH4OH mixed with ice. The organic layer was washed with a saturated aq solution of 
NaHCO3 and brine after which it was dried (K2CO3). After filtration the solvent was 
removed under reduced pressure to provide the bis-ethoxy lactim ether 44 as a clear 
yellow liquid that was further purified by flash chromatography.   
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2.12. Synthesis of bis-[(3,6-Diethoxy-2,5-dihy-dro-pyrazin-2-yl)-
methanethiol] (46). 
 
 
As shown in Scheme 13, to the bis-ethoxy lactim ether 44 in dry EtOH was added 
a catalytic amount of I2 at rt. The mixture was stirred for 6~ 12 h under air until the 
analysis (TLC, silica gel) indicated the reaction was complete.  The organic solvent was 
evaporated under reduced pressure. The mixture which resulted was dissolved into 
EtOAc, washed with an aq solution of saturated sodium thiosulfate and dried (Na2SO4). 
The solvent was then removed under reduced pressure which provided the cystine 
prodrug dimer 46.  
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2.13. Synthesis of (3R,6R)-6-Benzyl-5-ethoxy-3-(ethylthiomethyl)-1,6-
dihydropyrazin-2(3H)-one (49).  
 
 
 
As shown in Scheme 14, compound 49 was prepared following the procedure for 
preparation of 44 using only 1 equivalent of triethyloxonium tetrafluoroborate added to a 
solution of diketopiperazine 12c.  
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III. Synthesis of Cysteine and Cystine Bioisosteres. 
1. Rationale, Design and Synthesis of Cysteine and Cystine Bioisosteres. 
 
A second strategy that was studied is outlined in Scheme 15, Scheme 16, Scheme 
17, and Scheme 18.  The rationale was to make bioisosteres of the desired amino acids, 
L-cysteine and L-cystine with improved partition coefficients in order to facilitate passive 
delivery through the blood brain barrier and eliminate the need for intra- and extra-
cellular peptidases to liberate the desired amino acids.  As stated before, the bioisostere 
targets are unlikely to be metabolized or cleaved to produce cysteine or cystine; however, 
they will be used to drive the cystine-glutamate antiporter, releasing glutamate into a 
subject's extra-cellular (extra-synaptic) space without increased production of 
glutathione. 
 
The term "bioisostere" refers to a compound which results from the exchange of 
an atom or of a group of atoms with another, broadly similar, atom or group of atoms.  
Such an exchange is termed a "bioisosteric replacement" and is useful to create a new 
compound with similar biological properties to the parent compound.  The bioisosteric 
replacement may be physicochemically or topologically based.  Boisosteric replacement 
generally enhances desired biological or physical properties of a compound without 
making significant changes in chemical structure.  For example, the replacement of a 
hydrogen atom with a fluorine atom at a site of metabolic oxidation in a drug candidate 
may prevent such metabolism from taking place.  Because the fluorine atom is similar in 
size to the hydrogen atom the overall topology of the molecule is not significantly 
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affected, leaving the desired biological activity unaffected.  However, with a blocked 
pathway for metabolism, the drug candidate may have a longer half-life.  Another 
example is aromatic rings, a phenyl -C6H5 ring can often be replaced by a different 
aromatic ring such as thiophene or naphthalene which may improve efficacy or change 
binding specificity of a respective bioisostere. 
 
Outlined in Scheme 15 and Scheme 16 is the conversion of L-cysteine to 
bioisosteres of carboxylic acid groups, while outlined in Scheme 17 and Scheme 18 is a 
pathway to amide bioisosteres.  Cysteine will be protected as previously described above 
to prevent side reactions and converted into the corresponding bioisostere.  
 
In Scheme 15, carboxylic acid bioisosteres, the desired tetrazole intermediates 
56a-56c will be formed (individually) following the intermolecular cyclization of the 
ethylcyanide amides 55a-55c with sodium azide.80, 83  Finally, the preferred tetrazole 
bioisosteres (57a-57c) will be obtained after a simple dealkylation of tetrazoles 56a-56c, 
respectively.80,83   Once the bioisostere is formed, the other functional groups can be 
either protected or modified as shown in the rest of Scheme 15 and continued in Scheme 
16.   
 
In Scheme 17 the 1,2,4-oxadiazole bioisosteres, 67a-67d can be directly 
synthesized from the corresponding protected amino acids using literature 
procedures.80,84,85,86  The 1,2,4-triazole bioisosteres (69a-69e), and the 1,3,4-oxadiazole 
bioisosteres (70a-70e) can  synthesized through a hydrazine intermediate (68) as 
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discussed in the literature.84,85,86  After each bioisostere is synthesized, these compounds 
can be tested for biological activity with the alkylated thiol group intact or reacted with 
either a) catalytic amounts of iodine and pyridine in dichloromethane or b) 
triphenylphospine in methanol to remove the thiol protecting group, as shown in Scheme 
18, to produce the free thiol target monomers (72a-72e).80  Once again, these target 
monomers (72a-72e) can be uses for biological testing as free thiols or further reacted 
with catalytic amounts of iodine in ethanol to form symmetrical dimers (73a-73e).80 They 
may also be reacted with various amino ethyl esters (methyl ester may also be used) to 
produce target compounds (74), which can be prepared as either free thiols (76) or 
symmetrical dimers (75).   
 
The present method to synthesize bioisosteres has many advantages over previous 
routes including, but not limited to: a) same synthetic route leads to both monomers and 
dimers (cysteine and cystine bioisosteres); b) protection of functional groups prevents 
side reactions (e.g., cyclization); c) the initial monomer synthesis eliminates problems 
associated with multiple functional groups; and d) the described route can be easily 
expanded to incorporate minor chemical modifications.  
 
Listed in Table 2 and Table 3 is a list of compounds prepared following Scheme 
15 and Scheme 16, and Scheme 17 and Scheme 18, respectively, by members of the 
Cook group, under the direction of myself and/or synthesized by myself, the primary 
project researcher. Compounds that are “boxed” in each general scheme were actually 
synthesized as shown in the general scheme. After which is a detailed listing of some key 
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reactions and target prodrugs.  After which is a detailed listing of some key reactions and 
target compounds. The complete experimental details are located in Chapter IX – 
Experimental Section, and includes weights, molar quantities, volumes, 
temperatures, and spectral data. 
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Table 2. Carboxylic Acid Bioisosteres from Scheme 15 and Scheme 16 
 
Compound Number: 54c 
Cook Code: N/A 
Promentis Code: N/A 
Chemical Formula: C27H29NO4S 
Molecular Weight: 463.59 
Log P: 5.78 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
 
 
Compound Number: 60e 
Cook Code: WYME-SS-NPh4N 
Promentis Code: Pro-079 
Chemical Formula: C20H20N10O2S2 
Molecular Weight: 496.57 
Log P: 3.09 
Prodrug/Bioisostere: Bioisostere 
Monomer/Dimer: Dimer 
 
 
NHCOPh
SN
N
N NH
NHCOPh
S N
N
NHN
 
Compound Number: 76 
Cook Code: WYME-ST-4NTMS  
Promentis Code: Pro-069 
Chemical Formula: C3H7N5S 
Molecular Weight: 145.0 
Log P: -0.52 
Prodrug/Bioisostere: Bioisostere 
Monomer/Dimer: Monomer 
 
 
NH2
HS N
N
NHN
 
Compound Number: 77 
Cook Code: WY-SS-4NTMS 
Promentis Code: Pro-070 
Chemical Formula: C6H12N10S2 
Molecular Weight: 288.0 
Log P: -0.57 
Prodrug/Bioisostere: Bioisostere 
Monomer/Dimer: Dimer 
 
 
 
  
72 
 
Compound Number: 78 
Cook Code: WYME-NS-5PhN4 
Promentis Code: Pro-083 
Chemical Formula: C10H11N5S 
Molecular Weight: 233.0 
Log P: 2.2 
Prodrug/Bioisostere: Bioisostere 
Monomer/Dimer: Monomer 
 
HN
SPh
N
NHN
N
 
 
 
Table 3. Amide Bioisosteres from Scheme 17 and Scheme 18 
 
Compound Number: 79 
Cook Code: MWL-273 
Promentis Code: Pro-088 
Chemical Formula: C5H11ClN4 
Molecular Weight: 194.69 
Log P: 0.59 
Prodrug/Bioisostere: Bioisostere 
Monomer/Dimer: Monomer 
 
 
HN N
N NH2
HS
HCl
 
Compound Number: 80 
Cook Code: MWL-283 
Promentis Code: Pro-090 
Chemical Formula: C6H13ClN4S 
Molecular Weight: 208.71 
Log P: 1.16 
Prodrug/Bioisostere: Bioisostere 
Monomer/Dimer: Monomer 
 
 
HN N
N NH2
HS
HCl
 
Compound Number: 81 
Cook Code: MWL-249 
Promentis Code: Pro-078 
Chemical Formula: C8H16Cl2N8S2 
Molecular Weight: 359.3 
Log P: -1.32 
Prodrug/Bioisostere: Bioisostere 
Monomer/Dimer: Dimer 
 
H
HN N
N NH3
S
H
NHN
NH3N
S
2 Cl
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Compound Number: 82 
Cook Code: MWL-299 
Promentis Code: Pro-081 
Chemical Formula: C22H22N8O2S2 
Molecular Weight: 494.59 
Log P: 3.95 
Prodrug/Bioisostere: Bioisostere 
Monomer/Dimer: Dimer 
 
HN N
NH HN
O
S
NHN
N HNH
O
S
 
Compound Number: 83 
Cook Code: MWL-258 
Promentis Code: Pro-077 
Chemical Formula: C14H22N8O2S2 
Molecular Weight: 398.51 
Log P: 1.49 
Prodrug/Bioisostere: Bioisostere 
Monomer/Dimer: Dimer 
 
Me
HN N
N NH
S
Me
NHN
NHN
S
O
O
 
Compound Number: 84 
Cook Code: MWL-235 
Promentis Code: Pro-076 
Chemical Formula: C12H24Cl2N8S2 
Molecular Weight: 415.41 
Log P: -2.21 
Prodrug/Bioisostere: Bioisostere 
Monomer/Dimer: Dimer 
 
HN N
N NH3
S
NHN
NH3N
S
2 Cl
 
Compound Number: 85 
Cook Code: MWL-309 
Promentis Code: Pro-085 
Chemical Formula: C16H26N8O2S2 
Molecular Weight: 426.56 
Log P: 2.64 
Prodrug/Bioisostere: Bioisostere 
Monomer/Dimer: Dimer 
 
HN N
N HN
O
S
NHN
NNH
O
S
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Compound Number: 86 
Cook Code: MWL-284 
Promentis Code: Pro-082 
Chemical Formula: C26H30N8O2S2 
Molecular Weight: 550.7 
Log P: 6.44  
Prodrug/Bioisostere: Bioisostere 
Monomer/Dimer: Dimer 
 
HN N
N HN
O
S
NHN
NNH
O
S
 
Compound Number: 87 
Cook Code: WYME-SSI-AB 
Promentis Code: Pro-038 
Chemical Formula: C20H32N6O6S2 
Molecular Weight: 516.63 
Log P: 4.56 
Prodrug/Bioisostere: Bioisostere 
Monomer/Dimer: Dimer 
 
 
 
Compound Number: 88 
Cook Code: WYME-SSI-P 
Promentis Code: Pro-039 
Chemical Formula: C14H26Cl2N6O2S2 
Molecular Weight: 445.43 
Log P: 3.89 
Prodrug/Bioisostere: Bioisostere 
Monomer/Dimer: Dimer 
 
 
 
Compound Number: 89 
Cook Code: MWL-224 
Promentis Code: Pro-073 
Chemical Formula: C10H20Cl2N8S 
Molecular Weight: 387.36 
Log P: -3.12 
Prodrug/Bioisostere: Bioisostere 
Monomer/Dimer: Dimer 
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Compound Number: 90 
Cook Code: MWL-236  
Promentis Code: Pro-074 
Chemical Formula: C14H28Cl2N8S2 
Molecular Weight: 443.46 
Log P: -1.8 
Prodrug/Bioisostere: Bioisostere 
Monomer/Dimer: Dimer 
 
HN N
N NH3
S
NHN
NH3N
S
2 Cl
 
Compound Number: 91 
Cook Code: MWL-220  
Promentis Code: Pro-072 
Chemical Formula: C20H24Cl2N8S2 
Molecular Weight: 511.49 
Log P: -1.09 
Prodrug/Bioisostere: Bioisostere 
Monomer/Dimer: Dimer 
HN N
N NH3
S
NHN
NH3N
S
2 Cl
 
Compound Number: 92 
Cook Code: WYME-SS-iPNPh 
Promentis Code: Pro-075 
Chemical Formula: C28H32N6O4S2 
Molecular Weight: 580.72 
Log P: 7.55 
Prodrug/Bioisostere: Bioisostere 
Monomer/Dimer: Dimer 
 
NHCOPh
SN
N O
NHCOPh
S N
NO
 
Compound Number: 93 
Cook Code: N/A 
Promentis Code: N/A  
Chemical Formula: C16H28N2O8S2 
Molecular Weight: 440.53 
Log P: 1.4 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Dimer 
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Compound Number: 94 
Cook Code: N/A 
Promentis Code: N/A 
Chemical Formula: C31H35N3O3S 
Molecular Weight: 529.69 
Log P: 8.42 
Prodrug/Bioisostere: Bioisostere 
Monomer/Dimer: Monomer 
 
 
 
Compound Number: 95 
Cook Code: N/A 
Promentis Code: N/A 
Chemical Formula: C12H21N3O3S 
Molecular Weight: 287.38 
Log P: 3.11 
Prodrug/Bioisostere: Bioisostere 
Monomer/Dimer: Monomer 
 
 
 
Compound Number: 96 
Cook Code: N/A 
Promentis Code: N/A 
Chemical Formula: C10H18N4O2S 
Molecular Weight: 258.34 
Log P: 1.98 
Prodrug/Bioisostere: Bioisostere 
Monomer/Dimer: Monomer 
 
 
 
Compound Number: 97 
Cook Code: N/A 
Promentis Code: N/A 
Chemical Formula: C20H34N8O4S2 
Molecular Weight: 514.21 
Log P: 4.41 
Prodrug/Bioisostere: Bioisostere 
Monomer/Dimer: Dimer 
 
 
 
Compound Number: 98 
Cook Code: N/A 
Promentis Code: N/A 
Chemical Formula: C11H20N4O2S 
Molecular Weight: 272.37 
Log P: 2.55 
Prodrug/Bioisostere: Bioisostere 
Monomer/Dimer: Monomer 
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Compound Number: 99 
Cook Code: N/A 
Promentis Code: N/A 
Chemical Formula: C22H38N8O4S2 
Molecular Weight: 542.25 
Log P: 5.56 
Prodrug/Bioisostere: Bioisostere 
Monomer/Dimer: Dimer 
 
 
 
Compound Number: 100 
Cook Code: N/A 
Promentis Code: N/A 
Chemical Formula: C15H20N4O2S 
Molecular Weight: 320.41 
Log P: 3.36 
Prodrug/Bioisostere: Bioisostere 
Monomer/Dimer: Monomer 
 
 
 
Compound Number: 101 
Cook Code: N/A 
Promentis Code: N/A 
Chemical Formula: C30H38N8O4S2 
Molecular Weight: 638.25 
Log P: 7.18 
Prodrug/Bioisostere: Bioisostere 
Monomer/Dimer: Dimer 
 
 
 
Compound Number: 102 
Cook Code: N/A 
Promentis Code: N/A 
Chemical Formula: C12H22N4O2S 
Molecular Weight: 286.39 
Log P: 3.04 
Prodrug/Bioisostere: Bioisostere 
Monomer/Dimer: Monomer 
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Compound Number: 103 
Cook Code: N/A 
Promentis Code: N/A 
Chemical Formula: C24H42N8O4S2 
Molecular Weight: 570.77 
Log P: 6.53 
Prodrug/Bioisostere: Bioisostere 
Monomer/Dimer: Dimer 
 
 
 
Compound Number: 104 
Cook Code: N/A 
Promentis Code: N/A 
Chemical Formula: C24H40N6O6S2 
Molecular Weight: 572.74 
Log P: 6.68 
Prodrug/Bioisostere: Bioisostere 
Monomer/Dimer: Dimer 
 
 
 
Compound Number: 105 
Cook Code: N/A 
Promentis Code: N/A 
Chemical Formula: C20H32N6O6S2 
Molecular Weight: 516.63 
Log P: 4.56 
Prodrug/Bioisostere: Bioisostere 
Monomer/Dimer: Dimer 
 
 
 
Compound Number: 106a 
Cook Code: N/A 
Promentis Code: N/A 
Chemical Formula: C10H16N6O2S2 
Molecular Weight: 316.40 
Log P: 1.77 
Prodrug/Bioisostere: Bioisostere 
Monomer/Dimer: Dimer 
 
 
 
Compound Number: 106b 
Cook Code: N/A 
Promentis Code: N/A 
Chemical Formula: C14H24N6O2S2 
Molecular Weight: 372.51 
Log P: 3.89 
Prodrug/Bioisostere: Bioisostere 
Monomer/Dimer: Dimer 
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2.1. Synthesis of (R)-2-(tert-Butoxycarbonylamino)-3-(tritylthio) 
propanoic acid (54c). 
 
 
  As shown in Scheme 19, to a solution of Trt-Cys-OH, 9c,  in dioxane (60 mL)  
and  water was added di-tert-butyldicarbonate at 45 °C, and the solution was adjusted 
with NaOH(4M) until pH = 9.5, and then stirred at the same temperature overnight. Once 
the reaction was done via analysis by TLC (silica gel), water and dioxane were removed 
under reduced pressure. The residue was dissolved into water and extracted with ethyl 
acetate. The aq layer was adjusted to pH = 2 with dilute HCl while in an ice bath, and 
then the aq layer was extracted with ethyl acetate.  The combined ethyl acetate layers 
were washed with water and dried over anhydrous magnesium sulfate. Removal of the 
solvent under reduced pressure yielded a yellow oil. The residue was then dissolved into 
ethyl ether and carefully a 1:1 mixture of ethyl ether and hexane was added with stirring 
to precipitate out the white solid, 54c.   
 
  
80 
 
2.2. Synthesis of N,N’–Bis(tert-Butoxy)carbonylcystine (93). 
 
 
 
As shown in Scheme 20, to a solution of commercial L-cysteine in aq NaOH, a 
solution of di-tert-butyldi-carbonate  in dioxane was added at 0 °C. The reaction mixture 
was stirred at 0 °C for 5 min and then allowed to stir at rt for 12 h. Fifty percent of the 
volume of dioxane was removed under reduced pressure and the mixture was extracted 
with ethyl acetate. The combined aq phases were acidified (pH = 1) with aq HCl (1 M) 
and extracted with ethyl acetate. The combined organic layers were washed with brine, 
dried (Na2SO4), filtered and concentrated under reduced pressure to afford protected 
cystine 93 as white solid.  
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2.3. Synthesis of (R)-tert-Butyl 1-(3-isopropyl-1,2,4-oxadiazol-5-yl)-2-
(tritylthio) ethylcarbamate (94). 
 
 
 
As shown in Scheme 21, to a solution of trityl protected Boc-L-cysteine 54c, 
isobutyl-imidoxine and hydroxysuccimide in THF was added at 0 °C over 15 min to a 
solution of DCC in THF. The mixture was allowed to stir for 16 h while the temperature 
was allowed to warm to rt. The mixture was then cooled to 0 °C and the precipitate which 
formed was removed by filtration. The filtrate was concentrated under vacuum and then 
dissolved into ethyl acetate.  A small amount of precipitate formed and was filtered out. 
The organic layer was washed with a dilute aq sodium bicarbonate solution, brine, dried 
(Na2SO4) and was then removed under reduced pressure to give trityl protected Boc-L-
cysteine acetamidoxime ester as white crystals. This material was taken up in toluene and 
the mixture was heated at reflux for 3 h and the water which formed was removed via a 
Dean-Stark trap. The solvent was removed under vacuum and the residue was purified by 
flash chromatography to form the white crystals of bioisostere monomer 94. 
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2.4. General Procedure for Cleaving Disulfide Bonds on Bioisosteres. 
 
 
As shown in Scheme 22, the bioisostere disulfide (1 mmol) was dissolved in 
ethanol and indium (1.1 mmol) was added in one portion while stirring. Then anhydrous 
NH4Cl (2.2 mmol) was added to the suspension while stirring. The mixture was heated to 
reflux under argon for 4-6 hrs. After full conversion of the starting material was achieved 
via analysis by TLC, the solids were removed by filtration over a bed of celite. The 
solvent was removed under reduced pressure until dryness. The residue was washed well 
with water to dissolve the inorganic salts. The mixture was filtered and dried to yield the 
product. The monomer can be purified by crystallization from dichloromethane (DCM) 
or ethanol. This procedure was used to make bioisostere monomers 96 (R = CH3), 98 (R 
= CH2CH3), 100 (R = Ph) and 102 (R = CH(CH3)2) from their corresponding 
bisbioisosteric dimers 97, 99, 101 and 103.  
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2.5. Synthesis of tert-Butyl (1R,1'R)-2,2'-disulfanediylbis(1-(3-isopropyl-
1,2,4-oxadiazol-5-yl)ethane-2,1-diyl)dicarbamate (104). 
 
 
As shown in Scheme 23, to a solution of Boc-L-cystine 98 isobutyl-imidoxine 
and hydroxysuccimide in THF was added at 0 °C over 15 min to a solution of DCC in 
THF. The mixture was allowed to stir for 16 h while the temperature was allowed to 
warm to 20 °C. The mixture was cooled to 0 °C and the precipitate which formed was 
removed by filtration. The filtrate was concentrated under vacuum and then dissolved 
into ethyl acetate.  The small amount of precipitate which formed was filtered off. The 
organic layer was washed with dilute aq sodium bicarbonate solution, brine, dried 
(anhydrous Na2SO4) and removed under reduced pressure to give Boc-L-cystine 
bis(acetamidoxime) ester as white crystals. This material was taken up in toluene and the 
mixture was heated at reflux for 3 h and the water which formed was removed via a 
Dean-Stark trap. The solvent was removed under vacuum and the residue was purified by 
flash chromatography to provide white crystals of bioisostere dimer 104.    
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2.6. Synthesis of (1R,1'R)-2,2'-Disulfanediylbis(1-(3-methyl-1,2,4-
oxadiazol-5-yl)ethanamine) (106a, 106b). 
 
 
 As shown in Scheme 24, to a solution of 104 (or 105) in DCM, cooled to 0 °C, 
was slowly added TFA. The solution was gradually warmed up to rt and allowed to stir 
for 2 h until analysis by TLC indicated the starting material had disappeared. The solvent 
was removed under reduced pressure and the residue was dissolved into ethyl acetate. 
The solution was washed with saturated aq sodium bicarbonate solution, brine and dried 
(anhydrous Na2SO4). The solvent was removed under reduced pressure and ethyl ether 
was added to the form an oil. Ethyl ether saturated with HCl gas was added at 0 °C until a 
white solid precipitated out. The solid was then collected by filtration and yielded the 
hydrochloride salt of 106b (or 106a).   
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IV. Synthesis of Protected Cysteine and Cystine Analogues 
with Various Groups to Alter the Partition Coefficients. 
1. Rationale, Design and Synthesis of Protected Cysteine and Cystine 
Analogues.  
 
In an unrelated approach (Scheme 25 and Scheme 26) to the two synthetic 
pathways (prodrugs and bioisosteres) described previously, L-cysteine and L-cystine 
were protected as acyl analogues with alkyl esters.  They were synthesized to improve 
their partition coefficient (Log P) and circulatory half life in the blood to determine if 
passive delivery into the brain through the blood brain barrier was feasible.87 Various 
alkyl amides or alkyl esters were incorporated into the target compounds (see 107 and 
112) in Scheme 25 and Scheme 26, respectively.  Symmetrical cystine dimer target 
compounds (see 109 and 113) were synthesized from the corresponding cysteine 
analogues (see 107, 108 and 112) by the addition of a catalytic amount of iodine as 
shown in Scheme 25 and Scheme 26.  The target molecules depicted in Scheme 25 and 
Scheme 26 should result in more exposure and increased brain levels, as compared to 
previous unprotected cysteine and cystine analogues.  
 
It is noteworthy that this approach altered the partition coefficient by completely 
protecting the cysteine/cystine moiety.  Synthetic challenges, such as solubility and 
stability of intermediates which resulted and the target compounds, have previously 
prevented others in the field from obtaining protected analogues in significant quantities, 
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even for research studies.87 Glycine was incorporated into some of these prodrugs, 
Scheme 26, to provide a more efficient method of delivery of both amino acids, cysteine 
and glycine to the cystine-glutamate antiporter in the CNS.  Again, all prodrugs would be 
expected to be hydrolyzed (cleaved) into the corresponding amino acid, cysteine and 
glycine in vivo, by peptidases, esterases and hydrolyases in the brain which were outlined 
earlier in Figure 5.87   
 
Although this method was not intellectually challenging, the concept was based 
on sound principles of medicinal chemistry and should increase the area under the curve 
(AUC) for the corresponding amino acids, cysteine and cystine, which would result in 
more exposure and possibly increased brain levels87.    
 
Listed in Table 4 is a list of compounds prepared following Scheme 25 and 
Scheme 26, by members of the Cook group, under the direction of myself and/or 
synthesized by myself, the primary project researcher. Compounds that are “boxed” in 
each general scheme were actually synthesized as shown in the general scheme. After 
which is a detailed listing of some key reactions and target prodrugs.  The complete 
experimental details are located in Chapter IX – Experimental Section, and includes 
weights, molar quantities, volumes, temperatures, and spectral data. 
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General Synthesis of Protected Analogues with
Various Groups to Alter the Partition Coefficients
Scheme 25
NH2
HOOC
STrt R
2 Cl
O
NEt3/CHCl3, 0
oC
HN
STrt
R2
O
R1O
O
108a, R2 = CH3, R
1 = CH3
108b, R2 = CH3, R
1 = CH2CH3
108c, R2 = CH3, R
1 = CH(CH3)2
108d, R2 = Ph(CH2)n , R
1 = CH3
108e, R2 = Ph(CH2)n , R
1 = CH2CH3
108f, R2 = Ph(CH2)n, R
1=CH(CH3)2
n = 0,1
108g, R2 = Ph(CH2), R
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1) Bu3P, THF/H20
2) R3COCl, Et3N/CHCl3
R1OH
109a, R2 = CH3, R
1 = CH3
109b, R2 = CH3, R
1 = CH2CH3
109c, R2 = CH3, R
1 = CH(CH3)2
109d, R2 = Ph(CH2)n , R
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109e, R2 = Ph(CH2)n , R
1 = CH2CH3
109f, R2 = Ph(CH2)n , R
1 = CH(CH3)2
n = 0,1
HN
S
R2
O
R1O
O
R3
O
110
110a, R3 = CH3
110b, R3 = Ph(CH2)n
n = 0,1
NH2
HOOC
SH
L-cysteine
1) R1OH, con H2SO4
2) R2COCl, pyridine, 0 oC
HN
S
R2
O
R1O
O
R2
O
111
1) MeOH/CH2CL2, cat. I2
2) R2COCl, Nt3/CHCL3, 0
oC
95% yield
83% yield
86% yield
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Table 4. Protected Analogues with Various Groups to Alter the Partition 
Coefficients From Scheme 25 and Scheme 26 
 
 
 
 
 
 
 
 
 
 
 
Compound Number: 108g 
Cook Code: N/A 
Promentis Code: N/A 
Chemical Formula: C30H27NO3S 
Molecular Weight: 481.61 
Log P: 6.17 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
 
 
 
Compound Number: 109d 
Cook Code: WYME-SS-BM 
Promentis Code: Pro-034 
Chemical Formula: C22H24N2O6S2 
Molecular Weight: 476.57 
Log P: 2.8 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Dimer 
 
 
S
HN
O
O
S
NH
O
O
H3C CH3
Ph Ph
OO  
Compound Number: 109e 
Cook Code: WYME-SS-BE 
Promentis Code: Pro-033 
Chemical Formula: C24H28N2O6S2 
Molecular Weight:504.62 
Log P: 3.48 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Dimer 
 
S
NH
O
O
Ph
O
H3C
S
HN
O
O
Ph
O
CH3
 
90 
 
Compound Number: 109f 
Cook Code: WYME-SS-NPiPr 
Promentis Code: Pro-091 
Chemical Formula: C26H32N2O6S2 
Molecular Weight: 532.67 
Log P: 4.11 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
 
S
NH
O
O
Ph
O
S
HN
O
O
Ph
O
 
Compound Number: 112e 
Cook Code: WYME-ST-C9 
Promentis Code: Pro-050 
Chemical Formula: C34H34N2O4S 
Molecular Weight: 566.71 
Log P: 5.62 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
 
S
NHH
N
O
O
C(Ph)3
Ph
OH3C
O
 
Compound Number: 113e 
Cook Code: WYME-11g 
Promentis Code: Pro-003 
Chemical Formula: C30H38N4O8S2 
Molecular Weight: 646.77 
Log P: 1.07 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
 
 
S
NHH
N
O
OPh
OH3C
O
S
HN H
N
O
O Ph
O CH3
O
 
Compound Number: 115 
Cook Code: WYME-10e 
Promentis Code: Pro-001 
Chemical Formula: C19H19NO4S 
Molecular Weight: 357.42 
Log P: 3.37 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
 
S
NH
O
O
Ph
O
H3C
Ph
O  
Compound Number: 116 
Cook Code: WYME-10f 
Promentis Code: Pro-002 
Chemical Formula: C20H21NO4S 
Molecular Weight: 371.45 
Log P: 3.69 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
 
S
NH
O
O
Ph
O
Ph
O  
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Compound Number: 117 
Cook Code: WYME-diA 
Promentis Code: Pro-008 
Chemical Formula: C7H11NO4S 
Molecular Weight: 205.23 
Log P: -1.02 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
 
S
NH
HO
O
H3C
O
CH3
O  
Compound Number: 118 
Cook Code: WYME-SPh-CCO 
Promentis Code: Pro-028 
Chemical Formula: C30H27NO3S 
Molecular Weight: 481.61 
Log P: 6.17 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
 
S
NH
HO
O
O
C(Ph)3
Ph
 
Compound Number: 119 
Cook Code: WYME-SNPS 
Promentis Code:Pro-026 
Chemical Formula: C9H10N2O4S2 
Molecular Weight: 274.32 
Log P: -1.03 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
 
 
S
NH2
OH
O
S
NO2
 
Compound Number: 120 
Cook Code: WYME-SM-tBu 
Promentis Code: Pro-025 
Chemical Formula: 
Molecular Weight: 205.32 
Log P: 0.81 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
 
 
S
NH2
OCH2CH3
O
(H3C)3C
 
Compound Number: 121 
Cook Code: WYME-051707-SSE 
Promentis Code: Pro-036 
Chemical Formula: C10H20N2O4S2 
Molecular Weight: 296.41 
Log P: -0.18 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Dimer 
 
 
S
NH2
O
O
S
NH2
O
O
H3CH2C CH2CH3
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Compound Number: 122 
Cook Code: WYME-060307-SSM 
Promentis Code: Pro-037 
Chemical Formula: C8H16N2O4S2 
Molecular Weight: 268.35 
Log P: -0.86 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Dimer 
 
 
 
S
NH2
O
O
S
NH2
O
O
H3C CH3
 
Compound Number: 123 
Cook Code: WYME-SSNBam 
Promentis Code: Pro-040 
Chemical Formula: C20H22N4O4S2 
Molecular Weight: 446.55 
Log P: 0.97 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Dimer 
  
 
NH
S S
HN
NH2H2N
O O
Ph
O
Ph
O
 
Compound Number: 124 
Cook Code: ME-SBZ 
Promentis Code: Pro-019 
Chemical Formula: C20H20N2O6S2 
Molecular Weight: 448.51 
Log P: 2.28 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Dimer 
 
 
S
HN
OH
O
S
NH
HO
O
Ph Ph
OO  
Compound Number: 125 
Cook Code: WYME-diAcGly 
Promentis Code: Pro-087 
Chemical Formula: C11H18N2O5S 
Molecular Weight: 290.3 
Log P: -1.57 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Monomer 
 
 
S
NHH
N
O
OH3C
O O
O
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2.1. Representative Procedure for the Synthesis of Dimer 113e.  
 
 
 
2.2. Synthesis of Phenyl acetyl-S-trityl-L-cysteine (108g). 
 
As shown in Scheme 27, a solution of phenylacetyl chloride in chloroform was 
added to a suspension of S-trityl-L-csyteine 9c in chloroform containing triethylamine 
cooled in ice. The mixture was allowed to stir at 0–5 °C for 15 min and at rt for 24 h. 
Water was added and pH was adjusted to 1.5 with 5 N aq HCl. The aq phase was 
removed and the organic phase was washed with a saturated aq solution of sodium 
chloride, dried (anhydrous Na2SO4) and concentrated under reduced pressure to give a 
white crystalline solid of the protected cysteine compound 108g. 
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2.3. Synthesis of N-Carbobenzoxy-S-trityl-L-cysteinylglycine ethyl ester 
(112e).  
 
As shown in Scheme 27, phenyl acetyl-S-trityl-L-cysteine 108g and N, N’-
dicyclohexycarbodiimide was added to a solution of glycine ethyl ester hydrochloride in 
chloroform and triethylamine. After the solution was allowed to stir at rt overnight, 
followed by addition of a few drops of 50% acetic acid, the insoluble precipitate of 
dicyclohexylurea was removed by filtration; the filtrate was washed successively with 
dilute hydrochloric acid, potassium hydrogen carbonate and water, dried over sodium 
sulfate and evaporated to dryness.  The residue was treated with ethyl acetate. Some 
undissolved material (dicyclohexylurea) was filtered off and the filtrate was concentrated 
in vacuo to a small volume. A crystalline solid of the glycine coupled protected cysteine 
112e was separated out.   
  
2.4. Synthesis of Bis-[(R)-ethyl 2-(3-mercapto-2-(2-phenylacetamido) 
propanamido)acetate]  (113e). 
 
As shown in Scheme 27, the previously obtained glycine protected cysteine 112e 
was dissolved in methanol and a catalytic amount of iodine was added with stirring, after 
which pyridine was added to the solution with stirring and the final product 113e was 
obtained as a white solid.   
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2.5. Synthesis of N,S-dibenzoyl-L-cysteine ethyl ester (115). 
 
  
As shown in Scheme 28, benzyol chloride was added to a solution of pure L-
cysteine ethyl ester hydrochloride, which was either synthesized as shown above in 
Scheme 28 or purchased commercially, in pyridine precooled to 0 °C.  The solution was 
allowed to stir for 1 h at rt, and then the mixture was poured onto ice. The precipitate was 
collected by filtration and was recrystallized from methanol to provide the dibenzoylated 
cysteine 115.  
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V. Synthesis of Unsymmetrical Disulfide – Heterodimers. 
1. Rationale, Design and Synthesis of Unsymmetrical Disulfides.  
 
As previously described, numerous target compounds have be proposed and 
synthesized.  Target compounds consisting of cysteine and cystine diketopiperazine 
prodrugs, cysteine and cystine bioisosteres, and various cysteine and cystine functionally 
protected analogues (to alter the partition coefficient), including all monomers and 
symmetrical disulfide dimers have been prepared. However, one more important series of 
target compounds have to be described, hetero (unsymmetrical) disulfide dimers.  This 
new series of target compounds could potentially combine the advantages of two 
different previously described target series in an effort to eliminate or reduce any 
potential disadvantages of any of the series described above, moreover, to expand the 
SAR from homodimers to heterodimers.  Any disadvantage of the former would only be 
identified after in vitro and in vivo biology was obtained. Normally this type of mixing 
and matching of different target compounds would be reserved until a larger amount of 
data was obtained for each target series; however, since obtaining preliminary results in 
vitro was key and easier to perform, it was decided to initiate this approach now to 
determine if such unsymmetrical disulfides could realistically be synthesized on large 
enough scale for biological testing.  
 
The synthesis of hetero (unsymmetrical) disulfide dimers (Table 5) was 
preferably accomplished by using a one-pot reaction with 1-chlorobenzotriazole, as 
shown in Scheme 29.88 The free thiol diketopiperazine (12), or theoretically any 
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previously synthesized free thiol, whether diketopiperazine, bioisostere or functionally 
protected cysteine/cystine moieties, can be treated with 1-chlorobenzotriazole and 
benzotriazole in acetonitrile to form sulfenyl chloride intermediate (126).  Upon addition 
of benzotriazole, intermediate (127) is formed and then treated with thiourea at low 
temperature to form intermediate (128).  The addition of thiourea was remove excess 1-
chlorobenzotriazole and prevent homodimers formation upon addition of second thiol.  
Addition of the second desired free thiol will result in the final unsymmetrical disulfide 
dimer (129). 
 
An alternate method would involve using a catalytic amount of iodine in the 
presence of an equal molar amount of any two triphenyl methane protected thiol cysteine 
prodrugs (11). The desired target compound (130) can be separated and purified using 
simple column chromatography.  
 
Listed in Table 5 is a list of compounds prepared following Scheme 29 by 
members of the Cook group, under the direction of myself and/or synthesized by myself, 
the primary project researcher. Compounds that are “boxed” in each general scheme were 
actually synthesized as shown in the general scheme, after which is a detailed listing of 
some key reactions and target prodrugs.  The complete experimental details are 
located in Chapter IX – Experimental Section, and includes weights, molar 
quantities, volumes, temperatures, and spectral data. 
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HN
NH
O
O
SH HN
NH
O
O
SCl HN
NH
O
O
S N
N N
H
Cl
HN
NH
O
O
S
NH2
NH2Cl
HN
NH
O
O
S S R
HN
NH
O
O
S S NH
HN
O
O
N
N
N
H
N
N
N
Cl
BtH
Benzotriazole
BtCl
1-Chlorobenzotriazole
BtCl (2 equiv), BtH (1 equiv),
CH3CN, -78
oC, 20 min
BtH
(NH2)2C=S (3 equiv),
THF, -78oC
RSH (1.5 equiv), rt, 18 h
Example: glycine/cysteine - valine/cysteine
General Synthesis of Unsymmetrical Disulfides88
Scheme 29
R' R' R'
R'R'
127
RSCPh3 (1 equiv), Cat. I2, EtOH, rtHN
NH
O
O
SCPh3
R'
HN
NH
O
O
S S R
R'
Alternative Method
128 129
131
12 126
11
130
60-65% overall yield
45-65% yield
S
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Table 5. Unsymmetrical Disulfide Dimers From Scheme 29 
 
Compound Number: 131 
Cook Code: WYME-ST-GV 
Promentis Code: Pro-054 
Chemical Formula: C13H20N4O4S2 
Molecular Weight:360.45 
Log P: -1.83 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Dimer 
 
 
HN
NHO
O
S
NH
HN O
O
S
 
Compound Number: 132 
Cook Code: WYME-ST-GP 
Promentis Code: Pro-053 
Chemical Formula: C17H20N4O4S2 
Molecular Weight: 408.5 
Log P: -1.04 
Prodrug/Bioisostere: Prodrug 
Monomer/Dimer: Dimer 
 
 
HN
NHO
O
S
NH
HN O
O
S
Ph
 
Compound Number: 133 
Cook Code: WYME-STPh-iPr 
Promentis Code: N/A 
Chemical Formula: C24H33N5O5S2 
Molecular Weight: 535.68 
Log P: 3. 
Prodrug/Bioisostere: Both 
Monomer/Dimer: Dimer (Mixed) 
 
 
 
 
Compound Number: 134 
Cook Code: WYME-STVa-iPr-dBOC 
Promentis Code: N/A 
Chemical Formula: C15H25N5O3S2 
Molecular Weight: 387.52 
Log P: 1.72 
Prodrug/Bioisostere: Both 
Monomer/Dimer: Dimer (Mixed) 
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Compound Number: 135 
Cook Code: VD-MD-01 
Promentis Code: N/A 
Chemical Formula: C25H36N8O4S2 
Molecular Weight: 576.73 
Log P: 5.8 
Prodrug/Bioisostere: Bioisostere 
Monomer/Dimer: Dimer (Mixed) 
 
Compound Number: 136 
Cook Code: VR-MD-02 
Promentis Code: N/A 
Chemical Formula: C15H22Cl2N8S2 
Molecular Weight: 448.08 
Log P: 3.01 
Prodrug/Bioisostere: Bioisostere 
Monomer/Dimer: Dimer (Mixed) 
 
 
 
Compound Number: 137 
Cook Code: WYME-STVa-iPr 
Promentis Code: N/A 
Chemical Formula: C20H33N505S2 
Molecular Weight: 487.64 
Log P: 3.11 
Prodrug/Bioisostere: Bioisostere 
Monomer/Dimer: Dimer (Mixed) 
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2.1. General Procedure for Preparation of Mixed Dimers of 
Diketopiperazines and Bioisosteres: Synthesis of tert-Butyl-(R)-2- 
(2R,5R)-5-benzyl-3,6-dioxopiperazin-2-yl-methyl-disulfanyl-1-(3-
isopropyl-1,2,4-oxadiazol-5-yl)ethylcarbamate (118) and tert-Butyl (R)-
1-(3-isopropyl-1,2,4-oxadiazol-5-yl)-2-(2R,5R)-5-isopropyl-3,6-
dioxopipera-zin-2-yl-methyl-disulfanyl ethylcarbamate (119). 
 
 
 
As shown in Scheme 30 and Scheme 31 above, the trityl protected 
diketopiperazine 29 (or 31), individually, and bioisostere 94 were dissolved in a solution 
of dichloromethane and methanol with stirring.  Pyridine was then added to the mixture 
which resulted and was followed by a solution of iodine in methanol.  The mixture was 
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allowed to stir for 1 h at rt until analysis by TLC (silica gel) indicated that the reaction 
was proceeding slowly by the appearance of a new spot under the starting material (UV 
light).  After stirring for 2 h the mixture was concentrated under reduced pressure and a 
small amount of methanol was added. The solution was allowed to stir an additional 23 
hours, and then washed with a saturated aq sodium thiosulfate solution.  The solvent was 
then removed under reduced pressure. The residue which resulted was dissolved in ethyl 
acetate and the precipitate which resulted was collected by filtration to yield the 
unsymmetrical dimer 118 (or 119), individually, as white solids.  
  
  
103 
 
2.2. General Procedure for Preparation of Unsymmetrical Bis-
Dipiperazinediones (Unsymmetrical Dimers). 
 
2.2.1. Synthesis of (3S,6S)-3-Benzyl-6-(R)-3,6-dioxopiperazin-2-yl-
methyl-disulfanyl-methyl-piperazine-2,5-dione (132).  
 
 
As shown in Scheme 32, an equal molar equivalent of the trityl protected 
diketopiperazines 27 and 28 were dissolved in a solution of methylene chloride and 
methanol with stirring.  Pyridine was then added to the mixture, which resulted, followed 
by a solution of iodine in methanol.  The mixture was allowed to stir for 1 h at rt. No 
precipitate had formed by this time; however, analysis by TLC indicated that the reaction 
was proceeding slowly by the appearance of a new spot under the starting material (UV 
light).  A precipitate began to form within 2 h after concentrating the solution and addition 
of a small amount of methanol. The solution which resulted was allowed to stir an 
additional 23 h and the precipitate which formed was filtered off. The solid was washed 
with cold methanol. The precipitate was filtered and dried to yield the unsymmetrical 
dimer 132 as a yellow solid.  
104 
 
2.2.2. Synthesis of tert-Butyl (R)-2- (2R,5R)-5-benzyl-3,6-
dioxopiperazin-2-yl-methyl-disulfanyl-1-(3-isopropyl-1,2,4-oxadiazol-5-
yl)ethylcarbamate (133). 
 
HN
NH
O
O HN
NH
O
S
O
NHBoc
S
I2/MeOH/CH2Cl2
pyridine, rt
Ph
NHBoc
STrtN
N O
Ph
TrtS
+
N
N
O
94 29 133
Scheme 33
55% yield
 
 
As shown in Scheme 33, an equal molar equivalent of the trityl protected 
diketopiperazine 29 and bioisostere 94 were dissolved in a solution of methylene chloride 
and methanol with stirring.  Pyridine was then added to the mixture, which resulted and 
this was followed by a solution of iodine in methanol. The mixture was allowed to stir for 
1 h at rt until analysis by TLC indicated that the reaction was proceeding slowly by the 
appearance of a new spot under the starting material (UV light).  After stirring for 2 h the 
mixture was concentrated under reduced pressure and a small amount of methanol was 
added. The solution was allowed to stir an additional 23 hours, and then washed with a 
saturated aq sodium thiosulfate solution and the solvent was removed under reduced 
pressure. The residue which resulted was dissolved in ethyl acetate and the precipitate 
which resulted was collected by filtration to yield the unsymmetrical dimer 133 as white 
solid. 
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2.3. General Procedure for the Dealkylation of the Boc Group by 
Chlorotrimethylsilane/Sodium Iodide: Synthesis of (3R,6S)-3-(R)-2-
Amino-2-(3-isopropyl-1,2,4-oxadiazol-5-yl)ethyl-disulfanyl-methyl-6-
isopropylpiperazine-2,5-dione (134). 
 
HN
NH
O
S
O
NHBoc
S
N
N
O
HN
NH
O
S
O
NH2
S
N
N
O
TMSCl/NaI
CH3CN/CH2Cl2
134137
Scheme 34
85% yield
 
 
The reactions were generally carried out on 1 mmol scale in a 10 mL flask and 
flushed continuously with dry argon. As shown in Scheme 34, chlorotrimethylsilane was 
slowly added with continuous stirring to a solution of the corresponding dimer 137 and 
sodium iodide in acetonitrile/dichloromethane. The reaction mixture was allowed to stir 
at rt until the completion of the reaction was indicated on analysis by TLC (silica gel). 
The solvent was removed under reduced pressure and the residue, which resulted, was 
dissolved into the mixed solvent (CH2Cl2/ methanol = 9:1). The solution was washed 
with small amount of saturated aq sodium thiosulfate solution, brine and dried over 
anhydrous Na2SO4. The products were further purified by plate chromatography on silica 
gel (preparative TLC) to yield pure unsymmetrical dimer 134.  
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2.4. General Procedure for the Synthesis of Mixed Dimers using the 
Benzotriazole Method88: [tert-Butyl 1-mercapto-2-(5-phenyl-1H-1,2,4-
triazol-3-yl)propan-2-ylcarbamate]-[(R)-tert-butyl 2-mercapto-1-(5-
methyl-1H-1,2,4-triazol-3-yl)ethylcarbamate]-disulfide (135). 
 
 
As shown in Scheme 35, a solution of triazole monomer 100 was added slowly 
under an inert atmosphere to a stirred solution of benzotriazole and chloro-benzotriazole 
in dichloromethane (DCM) at -78°. After 30 min a solution of thiourea in anhydrous THF 
was added and stirring continued for 30 min. The other triazole monomer 96 in DCM was 
added while the temperature was maintained at -78°C. The solution was allowed to stir 
for 18-20 h, while the mixture slowly warmed to rt. The solvent was removed under 
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reduced pressure and the residue was dissolved in DCM followed by washing with water. 
The organic layer was dried (anhydrous Na2SO4) and the solvent was then removed under 
reduced pressure and the unsymmetrical dimer 135 was purified by chromatography.   
 
2.5. General Procedure for Deprotection of the BOC group and 
Formation of HCl Salt of Mixed-dimers: Synthesis of (R)-2-(R)-2-
Amino-2-(5-methyl-1H-1,2,4-triazol-3-yl)ethyl-disulfanyl-1-(5-phenyl-
1H-1,2,4-triazol-3-yl)ethanamine dihydrochloride (136). 
 
 
As shown in Scheme 36, the unsymmetrical dimer 135 was dissolved in EtOH 
and a saturated solution of anhydrous HCl in EtOH was added. The mixture was stirred 
for 2 h, after which the solvent was removed under reduced pressure. The oily residue 
which formed was dissolved in distilled water and washed with DCM to remove organic 
impurities. The water was then removed under reduced pressure and the gummy residue 
was finally dried under high vacuum to obtain the solid hydrochloride salt of the 
unsymmetrical dimer 136.   
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VI. Methods, Results and Discussion. 
1. In Vivo and In Vitro screening of target cysteine and cystine 
analogues (with Dr Baker). 
 
The radio-labeled cystine uptake and glutamate release assays were conducted in 
order to assess the degree to which the target analogues bind to the cystine/glutamate 
antiporter driving the desired glutamate release. Provided below are the experimental 
protocols of five different in vivo and in vitro screening methods. All in vivo and in vitro 
screening was performed by Dr David Baker and his group at Marquette University, 
Milwaukee, WI.  
 
1.1. Glutamate Sampling and C14-Cystine Uptake. 
 
The initial screening of compounds was performed using an in vitro culture 
system of human glial cells from brain astrocytoma (1321N1) to determine which 
compounds have the most promising profile of action for further study. Although a mixed 
cortical culture was initially proposed for the in vitro work, a human glioma cell line was 
ultimately chosen due to its higher expression of system Xc-cells, which were plated on 
24 well plates coated with poly-D-lysine and laminin and grown in a balanced salt 
solution supplemented with 5% heat inactivated horse serum, 5% fetal bovine serum, 2 
mM glutamine and glucose (total 21mM). Cultures were maintained in humidified 5% 
CO2 incubators at 37oC for 3-4 days before experiments were performed. At this time the 
cultures had formed a single confluent layer.  For experiments, cultures were washed 3 
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times into a Na-free HEPES and HCO3- buffered balanced salt solution. After 1 hour, 
zero time point samples were taken for glutamate analysis by HPLC; at this point test 
compounds were added.  Samples of the media were taken at 1 and 3 hours for glutamate 
analysis by HPLC.  The C14-cystine (0.025 mCi/mL) was then added for 20 minutes. 
Following the C14-cystine exposure, cultures were washed 3 times with ice cold HEPES 
buffered saline solution and dissolved in 250 µL sodium dodecyl sulfate (0.1%).  An 
aliquot (200 µL) was removed and added to scintillation fluid for counting. Values were 
normalized to C14-cystine uptake in untreated controls on the same experimental plate. 
 
1.2. HPLC Analysis of Glutamate. 
 
The concentration of glutamate in the samples was quantified by comparing peak 
heights from samples and external standards using HPLC coupled to fluorescence 
detection. Precolumn derivatization of glutamate with o-pthalaldehyde was performed 
using a Shimadzu LC10AD VP autosampler.  The mobile phase consisted of 17% 
acetonitrile, 100 mM Na2HPO4 and 0.1 mM EDTA, pH of 5.90.  Glutamate was 
separated using a reversed-phase column (4 µm; 150 X 4.6 mm; Phenomenex, Torrance, 
CA), and detected using a Shimadzu 10RF-AXL fluorescence detector with an excitation 
and emission wavelength of 320 and 400 nm, respectively. 
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1.3. Preclinical Assessment of Therapeutic Potential. 
 
Pre-pulse inhibition (PPI) was proposed as the sole behavioral screen; however, 
by reducing the number of compounds synthesized, we were able include a second 
behavioral screen. Thus, behavioral screening of each compound involved a primary 
screen using elevated plus maze (EPM) and a secondary screen using PPI. EPM was 
chosen because it is high throughput, requires a compound to penetrate the blood-brain 
barrier, and is sensitive to increases in cystine-glutamate exchange. For both behaviors, 
N-Acetylcysteine was run to determine a minimum benchmark for an improved 
approach.  For PPI, clozapine was also run as an optimal mark of efficacy.   
 
1.4. Elevated Plus Maze. 
 
Rats were tested in a standard elevated plus maze; testing occurred in a dimly 
illuminated room using only two lights mounted over the maze.  Animals were allowed to 
habituate to the room for at least one hour prior to treatment.  One hour prior to testing, 
rats received a pro-drug (0-100 mg/kg, po).  For testing, the rat was placed in the elevated 
plus maze for five minutes, alternating the starting position between facing an open arm 
and facing a closed arm.  The session was recorded and an observer blind to treatment 
recorded the number of explorations, entries and time spent in the open arm.  
Explorations were defined as the rat placing two feet into an open arm without fully 
entering said arm.  Entries were defined as the rat placing all four feet in an open arm.  
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Time of entry in the open arm was recorded from the time the rat placed four feet in the 
open arm until two of the rats’ feet entered the open square.  
 
1.5. Pre-pulse Inhibition. 
 
Rats were placed on a platform in a sound attenuating chamber 
(10.875”x14”x19.5”) that rested on a motion sensing plate.  During all sessions the 
background noise was held constant at 60 dB.  A matching session was conducted to 
determine the magnitude of the average startle response for each rat.  This session 
consisted of a five minute habituation period followed by 20 trials; 17 trials involved the 
presentation of a single auditory stimulus (pulse stimulus; 50 dB above the background 
noise) and three trials in which a pre-pulse stimulus (12 db above background) was 
presented 100 ms before the pulse auditory stimulus. Rats were then assigned into the 
various treatment groups so that the magnitude of the startle response was equivalent 
across all groups.  Two days later a testing session was conducted to assess sensorimotor 
gating.  One hour prior to testing, rats received a prodrug (0-100 mg/kg, po) and 50 
minutes later acute PCP (0-1.5 mg/kg, sc).   
 
The testing session consisted of a five minute habituation period, after which rats 
received 58 discrete trials; 26 trials during which the pulse stimulus (50 db above 
background) was presented alone, eight trials each in which the pulse stimulus was 
preceded by a prepulse stimulus (5, 10, or 15 db above background) and eight 
background trials with no pulse (No stimulus; background noise only).  The first six pulse 
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alone trials were not included in the average startle stimulus to achieve a relatively stable 
level of startle reactivity.  The percent of pre-pulse inhibition was determined as 100-
(average pre-pulse startle response/average startle stimulus alone) x100. 
  
2.1. N-Acetylcysteine & PCP-Induced Deficits in Pre-pulse Inhibition. 
 
The following data set illustrate the present drawbacks associated with N-
acetylcysteine, specifically the extensive hepatic metabolism and poor blood brain 
permeability.  Depicted in Figure 7 is the impact of N-acetylcysteine administered orally 
(po) on deficits in pre-pulse inhibition produced by phencyclidine.  As described below, 
deficits in pre-pulse inhibition following the administration of phencyclidine represent 
one of the most common preclinical paradigms used to screen potential antipsychotic 
agents.  Oral administration of N-acetylcysteine (administered 60 min prior to testing; n = 
7-10/group), which is subjected to hepatic metabolism, fails to significantly attenuate 
deficits in pre-pulse inhibition produced by phencyclidine (0 NAC + PCP, control). 
 
The data depicted in the Figure 8 illustrate the impact of N-acetylcysteine (n = 5-
6/group; injected 60 min prior to testing) when administered into the intraperitoneal (ip) 
cavity in order to circumvent hepatic metabolism.  N-Acetylcysteine failed to 
significantly restore sensorimotor gating at any of the three pre-pulse stimulus intensities, 
likely a result of poor blood brain permeability. 
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Depicted in Figure 9 is the impact of N-acetylcysteine infused directly into the 
rodent prefrontal cortex, the region thought to underlie sensorimotor gating.  Direct 
infusion of N-acetylcysteine (0-100 microM) circumvents the pharmacokinetic aspects of 
N-acetylcysteine that mitigate its use as a pharmacotherapy for schizophrenia, including 
extensive hepatic metabolism and poor blood brain permeability.  As indicated in Figure 
9, infusion of N-acetylcysteine (10 mg/kg, 30 mg/kg, and 100 mg/kg) into the prefrontal 
cortex significantly restored inhibition of a startle response at each concentration tested (n 
= 6-8/group; * indicates a significant increase relative to PCP rats receiving no NAC, 
Fisher LSD, p < 0.05).  Note, N-Acetylcysteine-induced reversal of the effects of PCP 
compare favorably in comparison to the effect of clozapine, arguably the most effect 
antipsychotic on the market. 
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2.2. PCP Dose-Dependently Alters Pre-pulse Inhibition and Impact of 
N-Acetylcysteine on Sensorimotor Gating Deficits Produced by PCP.   
 
Sensorimotor gating, a process compromised in schizophrenic patients, is often 
measured using pre-pulse inhibition whereby a mild auditory stimulus (pre-pulse, 2-15 db 
above background) precedes (100 ms) a startle-eliciting auditory stimulus (50 dB above 
background) as shown above.  Intact sensorimotor gating will result in suppression of the 
startle reflex when preceded by the pre-pulse. Since improvement in pre-pulse inhibition 
tracks improvement in symptoms that are largely insensitive to current treatments, this 
paradigm has become one of the most commonly used screening paradigms. Illustrated in 
Figure 10 is the capacity of PCP to disrupt pre-pulse inhibition rendering the pre-pulse 
ineffective in suppressing the startle reflex.  PCP is commonly used to disrupt pre-pulse 
inhibition because this abnormality, in addition to negative and cognitive symptoms, is 
insensitive to 1st generation antipsychotics thereby providing predictive validity.   
 
 Illustrated in Figure 11 is the impact of N-acetylcysteine on sensorimotor gating 
deficits produced by phencyclidine administered orally (left) or directly into the 
prefrontal cortex (right), which is likely the therapeutic site of action for cysteine 
prodrugs [n= 6-46/group.  * indicates a significant difference from rats receiving PCP 
only (e.g., no N-acetylcysteine), Fisher LSD, p <  0.05]. 
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2.3. Efficacy of Compounds from Scheme 3 Relative to N-Acetylcysteine 
in Reversing PCP-Induced Deficits in Sensorimotor Gating in Rats.  
 
Illustrated in Figure 12 is a bar graph in which inhibition of a startle response in 
response to a load stimulus (pulse) when preceded by a pre-pulse stimulus (2-15 db above 
background) is depicted. Pre-pulse inhibition is a commonly used paradigm to screen 
antipsychotic agents for use in treatment of schizophrenia. The pre-pulse stimulus 
presented at 15 dB above background reduced the startle response in saline controls (SC; 
n = 46) by > 60% relative to the response elicited following exposure to the pulse only.  
Rats pretreated with phencyclidine only (P; 1,25 mg/kg, SC; n = 42) failed to exhibit a 
reduction in the response elicited by the pulse even when preceded by the pre-pulse 
(regardless of stimulus intensity).  This reflects sensorimotor gating deficits common to 
patients afflicted with schizophrenia.  Rats pretreated (60 min) with N-acetylcysteine (30 
mg/kg, PO) failed to exhibit sensorimotor gating.  Note: Direct delivery of N-
acetylcysteine into the brain reverses phencyclidine-induced deficits in sensorimotor 
gating, which is consistent with clinical trials establishing the antipsychotic efficacy of 
this compound. Rats pretreated (60 min) with the target diketopiperazides synthesized 
earlier depicted in Scheme 3 (n = 7-22/group), most notably target compounds 12a and 
46 (cystine prodrugs) exhibited a significant difference relative to either rats receiving 
PCP alone (P, Fisher LSD, p < 0.05) and/or N-acetylcysteine (N 30 = 30 mg/kg; +, Fisher 
LSD, p < 0.05; S = saline).  Collectively, these data indicate the efficacy of these 
compounds and this synthesis Scheme to generate novel antipsychotics that exceed the 
potential of N-acetylcysteine. 
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2.4. Efficacy of Compounds 44 and 46 (see Scheme 3 earlier) as Novel 
Antipsychotic Agents. 
 
Startle chambers (Kinder Scientific; 10.875”x14”x19.5”) utilized for all 
experiments were housed in a sound attenuating chamber and mounted to a motion 
sensing plate. During all sessions the background noise was held constant at 60 dB by 
presenting white noise through a speaker mounted above the animal.  Rats underwent a 5-
minute habituation session prior to all matching and test sessions. Matching sessions 
were used to determine the magnitude of each rat’s startle response to a loud auditory 
stimulus (pulse; 50 dB above background; 20 ms), which was assessed following the 
presentation of seventeen pulse stimuli (50 dB above background) presented alone and 
three pulse stimuli (50 dB above background) preceded by a mild auditory stimulus (pre-
pulse; 12 dB above background; 20 ms). Rats were then assigned to treatment groups 
such that the magnitude of the startle response was equivalent across all groups.  Test 
sessions consisted of 60 trials, 28 in which the pulse stimulus was presented alone 
(Pulse), 24 trials in which the pulse stimulus was preceded (100 ms) by a mild auditory 
stimulus (Pre-pulse; 2, 6, 15 dB above background), and 8 silent trials (No stimulus; 
background noise only).  The percent pre-pulse inhibition was calculated as the 
magnitude of the startle response when the pulse was preceded by pre-pulse stimuli 
divided by the magnitude of the startle response when only the pulse stimulus is 
presented (x 100).   
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Prior to testing, rats received a cysteine prodrug (0-1 mg/kg, po.; n = 9-15/group) 
and 50 min later an injection of PCP (0-1.25 mg/kg, sc).  Ten minutes later, rats 
underwent the test session as described above.  The novel cysteine prodrug 44, described 
in Scheme 3, administered orally to rodents 60 min prior to testing at a dose of 1 mg/kg 
produced a significant increase in sensorimotor gating as assessed by inhibition of a 
startle response as shown in Figure 13 (* indicates a significant increase relative to PCP 
rats receiving no cysteine prodrug, Fisher LSD, p < 0.05).  Note, these data compare quite 
favorably to the results obtained with oral administration of N-acetylcysteine. 
 
The data depicted in the Figure 14 were collected as described above, except 
bivalent ligand 46, a cystine prodrug dimer, described in Scheme 3 was administered 60 
minutes prior to testing (n=9-11/group).  Analysis of the data demonstrate, oral 
administration of cystine prodrug dimer 46 significantly restored sensorimotor gating at 
the highest pre-pulse intensity. 
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Figure 13 
Impact of Oral Monomer 44 on PCP-Evoked 
Deficits in Pre-pulse Inhibition 
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Figure 14 
Impact of Oral Dimer 46 on PCP-Evoked 
Deficits in Pre-pulse Inhibition 
       SAL                    PCP        PCP + 1 mg/kg 46 
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2.5. Diketopiperazide Bivalent Ligand 1 (see Scheme 3 earlier, dimer) 
Produced a Larger Increase in Glutamate in the Prefrontal Cortex 
Relative to NAC. 
 
Depicted in Figure 15 is a bar graph which illustrates extracellular glutamate in 
the prefrontal cortex (compared to baseline) following administration of cysteine 
prodrugs N-acetylcysteine (60 mg/kg, ip; n = 4) or target dimer 1, cystine prodrug dimer, 
(indicated as NCE in Figure 15) (30 mg/kg, po; n = 3) in rats.  Analysis of these results 
indicated a much larger peak increase in glutamate was obtained for cystine prodrug 
dimer 1 relative to N-acetylcysteine (NAC).  Cystine prodrug dimer 1 was given to the 
animal orally and thereby subjected to potential first-pass metabolism.  Conversely, N-
acetylcysteine was given ip in order to avoid extensive first pass metabolism that would 
occur following oral administration.  Thus, cystine prodrug dimer 1 produced a larger 
relative increase in glutamate in rats as compared to NAC even though NAC was given in 
its preferred route of administration and at twice the concentration.  This increased 
glutamate level indicated that cystine prodrug dimer 1 was successful in elevating 
extracellular cystine levels and driving cystine-glutamate exchange, a phenomenon 
understood to be beneficial in overcoming drug addiction.    
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2.6. Efficacy of Diketopiperazide Dimer 1 (see Scheme 3 earlier) as a 
Novel Antipsychotic Agent.   
 
Illustrated in Figure 16 is a bar graph which depicts inhibition of a startle 
response in response to a load stimulus (pulse) when preceded by a pre-pulse stimulus 
(15 db above background). As described previously, rats pretreated with N-acetylcysteine 
(30 mg/kg, po; n = 5) 60 minutes prior to phencyclidine administration exhibited a trend 
toward improved sensorimotor gating (p = 0.07).  Rats pretreated with target compound 
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1, cystine prodrug dimer, (termed NCE in Figure 16) (30 mg/kg, po; n = 4) exhibited a 
significant improvement in sensorimotor gating relative to PCP controls and rats 
receiving NAC + PCP (* indicates a significant increase relative to PCP rats receiving no 
cysteine prodrug, Fisher LSD, p < 0.05).  Collectively, these data indicate the efficacy of 
cystine prodrug dimer 1 as a novel antipsychotic that exceeds the potential of N-
acetylcysteine. 
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2.7. Efficacy (PO) of Monomers and Dimers from Scheme 4, Relative to 
N-Acetylcysteine in Reversing PCP-Induced Deficits in Sensorimotor 
Gating in Rats.   
 
Illustrated in Figure 17 is a bar graph which depicts the inhibition of a startle 
response in response to a load stimulus (pulse) when preceded by a pre-pulse stimulus (2-
15 db above background).  As described previously, rats pretreated (60 minutes) with 
prodrugs illustrated in Scheme 4 (n = 7-14/group), notably target analogues 1 and 43, 
cystine prodrugs, exhibited a significant difference relative to either rats receiving PCP 
alone (*, Fisher LSD, p < 0.05) and/or N-acetylcysteine (n = 30; 30 mg/kg; +, Fisher 
LSD, p < 0.05).  Collectively, these data indicated the efficacy of these compounds and 
the analogues prepared in Scheme 4 to generate novel antipsychotics that exceed the 
potential of N-acetylcysteine. 
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2.8. Efficacy (PO) of Ligands Synthesized and Illustrated in Scheme 25 
Relative to N-Acetylcysteine in Reversing PCP-Induced Deficits in 
Sensorimotor Gating in Rats.   
 
Depicted in Figure 18 is a bar graph which illustrates the inhibition of a startle 
response in response to a load stimulus (pulse) when preceded by a pre-pulse stimulus (2-
15 db above background). As described previously, rats pretreated (60 minutes) with 
ligands synthesized and illustrated in Scheme 25 (n = 7/group), especially target prodrugs 
109e and 115, cystine prodrugs, exhibited a significant difference relative to either rats 
receiving PCP alone (*, Fisher LSD, p < 0.05) and/or N-acetylcysteine (n = 30; 30 
mg/kg; +, Fisher LSD, p < 0.05).  Collectively, these data indicated the efficacy of these 
prodrugs and the synthetic approach in Scheme 25 to generate novel antipsychotics that 
exceeds the potential of N-acetylcysteine. It appears here, based only on the PPI screen, 
that cystine prodrug 109e is much more potent than cysteine prodrug 115 in the reversal 
of pre-pulse inhibition of startle affected by PCP.  
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2.9. Efficacy (PO) of Cystine Prodrug 112e from Scheme 26 Relative to 
N-Acetylcysteine in Reversing PCP-Induced Deficits in Sensorimotor 
Gating in Rats.   
 
Illustrated in Figure 19 is a bar graph which depicts the inhibition of a startle 
response in response to a load stimulus (pulse) when preceded by a pre-pulse stimulus (2-
15 db above background) with cystine prodrug 112e. As described previously, rats 
pretreated (60 minutes) with the target dimer 112e, a cystine prodrug, synthesized and 
illustrated in Scheme 26 (n = 7) exhibited a significant difference (*) relative to rats 
receiving N-acetylcysteine (n = 30; 30 mg/kg; +, Fisher LSD, p < 0.05).  Collectively, 
these data indicated the efficacy of this compound and the analogues depicted in Scheme 
26 to generate potential novel antipsychotics that exceed the potential of N-
acetylcysteine. 
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2.10. Efficacy (PO) of Mixed Bivalent Ligands that were Prepared and 
Illustrated in Scheme 29 Relative to N-Acetylcysteine in Reversing PCP-
Induced Deficits in Sensorimotor Gating in Rats.   
 
Outlined in Figure 20 is a bar graph which illustrates the inhibition of a startle 
response in response to a load stimulus (pulse) when preceded by a pre-pulse stimulus (2-
15 db above background). As described previously, rats pretreated (60 minutes) with N-
acetylcysteine into the brain reverses phencyclidine-induced deficits in sensorimotor 
gating, which is consistent with clinical trials establishing the antipsychotic efficacy of 
this compound. Rats pretreated (60 minutes) with compounds synthesized and depicted in 
Scheme 29 (n = 7/group), cystine mixed dimers 131 and 132, cystine prodrug 
heterodimers, exhibited a significant difference relative to either rats receiving PCP alone 
(*, Fisher LSD, p < 0.05) and/or N-acetylcysteine (n = 30; 30 mg/kg; +, Fisher LSD, p < 
0.05).  Collectively, these data indicated the efficacy of these compounds and the 
synthesis of ligands in Scheme 29 to generate potential novel antipsychotics that exceeds 
the potential of N-acetylcysteine. 
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VII. Biological Data for Target Compounds. 
  
There are two or three sets of in vitro and in vivo biological data for each of the 
cystine or cysteine related analogues listed below in Table 6.  Examination of the C14 
uptake test indicates ability of the analogue to compete with C14 labeled uptake of cystine 
into the cell.  A decrease in the C14 labeled cystine uptake indicates that the compound is 
competing with and/or restricting C14 labeled cystine uptake into the cell (* indicates a 
significant difference from the control value, with error bars,  p < 0.05).  This decrease in 
C14 labeled cystine uptakes represent a desired effect since the goal is to have the cystine 
/ cysteine related analogues release cystine/cysteine or be active in the antiporter.   
Analysis of the glutamate percent change screen indicates the percent change in 
glutamate after the cell was treated with a solution of the analogue. This change 
represents the activation and turnover of the cystine-glutamate antiporter.  The higher the 
response in the glutamate percent change, compared to the control, the more effective the 
compound is at driving the cystine-glutamate antiporter and increasing glutamate levels 
in the extra-synaptic space which is the desired response. The elevated plus maze is 
reported in seconds and is the time it takes a rat to complete the plus maze after the target 
ligand was administrated.  The elevated plus maze is a study for cognitive deficits or 
enhancements that may be due to the target analogues.  For further information and 
details about each test refer to the Methods and Results Section. 
 
 
 
 
 Table 6. Biological Data for 
Compound Number: 1 
Cook Code: WYME-ST-
Promentis Code: Pro-052
Chemical Formula: C10H14
Molecular Weight: 318.37
Log P: -3.2 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Dimer 
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 Compound Number: 9a
Cook Code: ME-StBu 
Promentis Code: Pro-048
Chemical Formula: C7H15
Molecular Weight: 177.26
Log P:0.21 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
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 Compound Number: 9b
Cook Code: WYME-SSPh
Promentis Code: Pro-044
Chemical Formula: C9H11
Molecular Weight: 229.32
Log P: 1.76 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
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 Compound Number: 9c
Cook Code: WYME-STrt
Promentis Code: Pro-058
Chemical Formula: C22H21
Molecular Weight: 363.47
Log P: 4.39 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
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 Compound Number: 10b
Cook Code: WYME-SSPh
Promentis Code: Pro-045
Chemical Formula: C10H9
Molecular Weight: 255.31
Log P: 2.29 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
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 Compound Number: 12a
Cook Code: WYME-SBGH
Promentis Code: Pro-013
Chemical Formula: C5H8N
Molecular Weight: 160.19
Log P: -1.83 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
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 Compound Number: 12c
Cook Code: WYME-SBPh
Promentis Code: Pro-015
Chemical Formula: C12H14
Molecular Weight: 250.32
Log P: 0.34 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
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 Compound Number: 12d
Cook Code: WYME-SBPr
Promentis Code: Pro-068
Chemical Formula: C8H12
Molecular Weight: 200.26
Log P: -1.13 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
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 Compound Number: 12e
Cook Code: WYME-SBVa
Promentis Code: Pro-018
Chemical Formula: C8H14
Molecular Weight: 202.27
Log P: -0.45 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
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 Compound Number: 17
Cook Code: WYME-051407
Promentis Code: Pro-024
Chemical Formula: C4H9NO
Molecular Weight: 135.18
Log P: -0.66 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
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 Compound Number: 18
Cook Code: WYME-051707
Promentis Code: Pro-021
Chemical Formula: C5H11
Molecular Weight: 149.21
Log P: -0.32 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
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 Compound Number: 19
Cook Code: ME-SEt 
Promentis Code: Pro-023
Chemical Formula: C5H11
Molecular Weight: 149.21
Log P: -0.33 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
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 Compound Number: 20
Cook Code: ME-SPh 
Promentis Code: Pro-027
Chemical Formula: C9H11
Molecular Weight: 197.25
Log P: 1.0 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
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 Compound Number: 21
Cook Code: ME-SBZY 
Promentis Code: Pro-020
Chemical Formula: C10H13
Molecular Weight: 211.28
Log P: 1.07 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
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 Compound Number: 22
Cook Code: WYME-SPhCO
Promentis Code: Pro-029
Chemical Formula: 
Molecular Weight: 225.26
Log P: 0.94 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
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 Compound Number: 23
Cook Code: WYME-SS-am
Promentis Code: Pro-032
Chemical Formula: C6H14
Molecular Weight: 238.33
Log P:-2.69 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Dimer 
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 Compound Number: 24
Cook Code: WYME-ST-
Promentis Code: Pro-061
Chemical Formula: C26H
Molecular Weight: 419.58
Log P: 5.53 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
 
C14 Uptake
 
 
tBu 
 
29NO2S 
 
 
 
 
CPh3
S
H2N
O
O
C(C
 
 
Glutamate Percent Change
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H3)3
 
 
 
 Compound Number: 25
Cook Code: WYME-SBPr6
Promentis Code: Pro-016
Chemical Formula: C14H16
Molecular Weight: 308.42
Log P: 1.55 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
 
C14 Uptake
 
 
 
 
N2O2S2 
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O
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Glutamate Percent Change
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 Compound Number: 26
Cook Code: ME-StBu-6 
Promentis Code: Pro-049
Chemical Formula: C9H16
Molecular Weight: 216.3
Log P: -0.7 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
 
C14 Uptake
C14 Uptake
 
 
 
N2O2S 
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O
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Glutamate Percent Change
 
 
Glutamate Percent Change
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 Compound Number: 27
Cook Code: WYME-ST-
Promentis Code: Pro-051
Chemical Formula: C24H22
Molecular Weight: 402.51
Log P: 3.48 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
 
C14 Uptake
 
 
G6 
 
N2O2S 
 
 
 
 
 
 
Glutamate Percent Change
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 Compound Number: 28
Cook Code: WyME-SB-P6
Promentis Code: Pro-014
Chemical Formula: C18H18
Molecular Weight: 358.48
Log P: 3.01 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
 
C14 Uptake
 
 
 
 
N2O2S2 
 
 
 
 
HN
NHO
O
S
Ph
SP
 
 
Glutamate Percent Change
Elevated Plus Maze 
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 Compound Number: 29
Cook Code: WyME-ST-P6
Promentis Code: Pro-055
Chemical Formula: C31H28
Molecular Weight: 492.63
Log P: 5.65 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
 
C14 Uptake
 
 
 
 
N2O2S 
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Glutamate Percent Change
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 Compound Number: 30
Cook Code: WYME-ST-
Promentis Code: Pro-057
Chemical Formula: C27H26
Molecular Weight: 442.57
Log P: 4.19 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
 
C14 Uptake
 
 
Pr 
 
N2O2S 
 
 
 
 
HN
NO
O
S CP
 
 
Glutamate Percent Change
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 Compound Number: 31
Cook Code: WYME-ST-
Promentis Code: Pro-062
Chemical Formula: C27H
Molecular Weight: 444.59
Log P: 4.86 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
 
C14 Uptake
 
 
V6 
 
28N2O2S 
 
 
 
 
HN
NHO
O
S CP
 
 
Glutamate Percent Change
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 Compound Number: 32
Cook Code: WYME-SBSS
Promentis Code: Pro-017
Chemical Formula: C10H18
Molecular Weight: 262.39
Log P: -0.24 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
 
C14 Uptake
 
 
 
 
N2O2S2 
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S
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Glutamate Percent Change
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 Compound Number: 33
Cook Code: WYME-ST-
Promentis Code: Pro-059
Chemical Formula: C29H
Molecular Weight: 504.71
Log P: 5.08 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
 
C14 Uptake
 
 
S6  
 
32N2O2S2 
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NHO
S
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Glutamate Percent Change
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 Compound Number: 34
Cook Code: N/A  
Promentis Code: Pro-1036
Chemical Formula: C10H18
Molecular Weight: 246.33
Log P: -1.07 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
 
C14 Uptake
 
 
 
N2O3S 
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O
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Glutamate Percent Change
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 Compound Number: 35
Cook Code: N/A 
Promentis Code: Pro-1038
Chemical Formula: C16H22
Molecular Weight: 306.42
Log P: 1.46 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
 
C14 Uptake
 
 
 
N2O2S 
 
 
 
 
HN
NH
O
OStBu
 
 
Glutamate Percent Change
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 Compound Number: 36
Cook Code: WyME-ST-PP
Promentis Code: Pro-056
Chemical Formula: C24H26
Molecular Weight: 498.62
Log P: 1.13 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Dimer 
 
C14 Uptake
 
 
 
 
N4O4S2 
 
 
 
 
 
Glutamate Percent Change
 
164 
 
 
 
 Compound Number: 37
Cook Code: WYME-ST-
Promentis Code: Pro-060
Chemical Formula: C20H34
Molecular Weight: 522.77
Log P: -0.01 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Dimer 
 
C14 Uptake
 
 
SS 
 
N4O4S4 
 
 
 
 
 
Glutamate Percent Change
 
165 
 
 
 
 Compound Number: 38
Cook Code: WYME-ST-
Promentis Code: Pro-064
Chemical Formula: C16H26
Molecular Weight: 402.53
Log P: -0.45 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Dimer 
 
C14 Uptake
 
 
VV 
 
N4O4S2 
 
 
 
 
 
Glutamate Percent Change
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 Compound Number: 39
Cook Code: N/A 
Promentis Code: Pro-1016
Chemical Formula: C12H18
Molecular Weight: 378.42
Log P: -3.93 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Dimer 
 
C14 Uptake
 
 
 
N4O6S2 
 
 
 
 
 
Glutamate Percent Change
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 Compound Number: 40
Cook Code: N/A  
Promentis Code: Pro-1022
Chemical Formula: C12H
Molecular Weight: 346.43
Log P: -2.22 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Dimer 
 
C14 Uptake
 
 
 
18N4O4S2 
 
 
 
 
 
Glutamate Percent Change
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 Compound Number: 41
Cook Code: N/A 
Promentis Code: Pro-1024
Chemical Formula: C18H30
Molecular Weight: 430.59
Log P: 0.39 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Dimer 
 
C14 Uptake
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 Compound Number: 42
Cook Code: N/A 
Promentis Code: Pro-1025
Chemical Formula: C18H30
Molecular Weight: 430.59
Log P: 0.25 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Dimer 
 
C14 Uptake
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S
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O
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Glutamate Percent Change
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 Compound Number: 43
Cook Code: WYME-BFVa
Promentis Code: Pro-005
Chemical Formula: C12H
Molecular Weight: 258.38
Log P: 2.49 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
 
C14 Uptake
 
 
 
 
33N2O2S 
 
 
 
N
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O
SH
 
 
Glutamate Percent Change
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 Compound Number: 44
Cook Code: WYME-0625
Promentis Code: Pro-011
Chemical Formula: C9H16
Molecular Weight: 216.3
Log P: 1.12 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
 
C14 Uptake
 
 
-SBBFGE 
 
N2O2S 
 
 
 
 
N
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O
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Glutamate Percent 
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 Compound Number: 45
Cook Code: WYME-BFPh
Promentis Code: Pro-004
Chemical Formula: C16H
Molecular Weight: 306.42
Log P: 3.28 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
 
C14 Uptake
 
 
 
 
22N2O2S 
 
 
 
N
NEtO
O
SH
Ph
 
 
Glutamate Percent Change
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 Compound Number: 46
Cook Code: WYME-SBB
Promentis Code: Pro-012
Chemical Formula: C18H
Molecular Weight: 430.59
Log P: 2.69 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Dimer 
 
C14 Uptake
C14 Uptake
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Glutamate Percent Change
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 Compound Number: 47
Cook Code: WYME-SSB
Promentis Code: Pro-065
Chemical Formula: C24H42
Molecular Weight: 514.74
Log P: 5.44 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Dimer 
 
C14 Uptake
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N
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Glutamate Percent Change
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 Compound Number: 48
Cook Code: WYME-SSB
Promentis Code: Pro-066
Chemical Formula: C32H42
Molecular Weight: 610.83
Log P: 7.02 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Dimer 
 
C14 Uptake
 
 
-FPP 
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Glutamate Percent Change
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 Compound Number: 49
Cook Code: WYME-STBF
Promentis Code: Pro-047
Chemical Formula: C16H22
Molecular Weight: 306.42
Log P: 2.4 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
 
C14 Uptake
 
 
-PhM 
 
N2O2S 
 
 
 
 
N
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O
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Glutamate Percent Change
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 Compound Number: 50
Cook Code: WYME-SH-
Promentis Code: Pro-080
Chemical Formula: C12H14
Molecular Weight: 250.32
Log P: 0.14 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
 
C14 Uptake
 
 
NPh6  
 
N2O2S 
 
 
 
 
N
NH
SH
O
Ph
 
 
Glutamate Percent Change
Elevated Plus Maze 
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 Compound Number: 51
Cook Code: WYME-ST-N6
Promentis Code: Pro-071
Chemical Formula: C16H22
Molecular Weight:306.4 
Log P: 1.27 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
 
C14 Uptake
 
 
 
 
N2O2S 
 
 
N
NH
S
O
O
Ph
 
 
Glutamate Percent Change
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 Compound Number: 52
Cook Code: WYME-SB-
Promentis Code: Pro-084
Chemical Formula: C19H20
Molecular Weight: 340.4
Log P: 2.11 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
 
C14 Uptake
 
 
GH6NPh 
 
N2O2S 
 
 
 
 
N
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O
SH
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Glutamate Percent Change
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 Compound Number: 53
Cook Code: WYME-ST-N2Ph
Promentis Code: Pro-092
Chemical Formula: C23H
Molecular Weight: 396.5
Log P: 3.23 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
 
C14 Uptake
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N
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O
O
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Glutamate Percent Change
Elevated Plus Maze 
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 Compound Number: 60
Cook Code: WYME-SS-NPh4N
Promentis Code: Pro-079
Chemical Formula: C20H20
Molecular Weight: 496.57
Log P: 3.09 
Prodrug/Bioisostere: Bioisostere
Monomer/Dimer: Dimer 
 
C14 Uptake
 
e 
 
 
N10O2S2 
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N
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Glutamate Percent Change
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 Compound Number: 76
Cook Code: WYME-ST-
Promentis Code: Pro-069
Chemical Formula: C3H7N
Molecular Weight: 145.0
Log P: -0.52 
Prodrug/Bioisostere: Bioisostere
Monomer/Dimer: Monomer
 
C14 Uptake
 
 
4NTMS  
 
5S 
 
 
 
 
NH2
HS N
N
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Glutamate Percent 
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 Compound Number: 77
Cook Code: WY-SS-4NTMS
Promentis Code: Pro-070
Chemical Formula: C6H12
Molecular Weight: 288.0
Log P: -0.57 
Prodrug/Bioisostere: Bioisostere
Monomer/Dimer: Dimer 
 
C14 Uptake
 
 
 
 
N10S2 
 
 
 
 
 
Glutamate Percent 
 
184 
 
Change 
 
 Compound Number: 78
Cook Code: WYME-NS-
Promentis Code: Pro-083
Chemical Formula: C10H11
Molecular Weight: 233.0
Log P: 2.2 
Prodrug/Bioisostere: Bioisostere
Monomer/Dimer: Monomer
 
C14 Uptake
 
 
5PhN4 
 
N5S 
 
 
 
 
HN
SPh
N
NHN
N
 
 
Glutamate Percent Change
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 Compound Number: 79
Cook Code: MWL-273 
Promentis Code: Pro-088
Chemical Formula: C5H11
Molecular Weight: 194.69
Log P: 0.59 
Prodrug/Bioisostere: Bioisostere
Monomer/Dimer: Monomer
 
C14 Uptake
 
 
 
ClN4 
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Glutamate Percent Change
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 Compound Number: 80
Cook Code: MWL-283 
Promentis Code: Pro-090
Chemical Formula: C6H13
Molecular Weight: 208.71
Log P: 1.16 
Prodrug/Bioisostere: Bioisostere
Monomer/Dimer: Monomer
 
C14 Uptake
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Glutamate Percent Change
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 Compound Number: 81
Cook Code: MWL-249 
Promentis Code: Pro-078
Chemical Formula: C8H16
Molecular Weight: 359.3
Log P: -1.32 
Prodrug/Bioisostere: Bioisostere
Monomer/Dimer: Dimer 
 
C14 Uptake
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 Compound Number: 82
Cook Code: MWL-299 
Promentis Code: Pro-081
Chemical Formula: C22H22
Molecular Weight: 494.59
Log P: 3.95 
Prodrug/Bioisostere: Bioisostere
Monomer/Dimer: Dimer 
 
C14 Uptake
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 Compound Number: 83
Cook Code: MWL-258 
Promentis Code: Pro-077
Chemical Formula: C14H22
Molecular Weight: 398.51
Log P: 1.49 
Prodrug/Bioisostere: Bioisostere
Monomer/Dimer: Dimer 
 
C14 Uptake
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 Compound Number: 84
Cook Code: MWL-235 
Promentis Code: Pro-076
Chemical Formula: C12H24
Molecular Weight: 415.41
Log P: -2.21 
Prodrug/Bioisostere: Bioisostere
Monomer/Dimer: Dimer 
 
C14 Uptake
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S
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Glutamate Percent Change
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 Compound Number: 85
Cook Code: MWL-309 
Promentis Code: Pro-085
Chemical Formula: C16H
Molecular Weight: 426.56
Log P: 2.64 
Prodrug/Bioisostere: Bioisostere
Monomer/Dimer: Dimer 
 
C14 Uptake
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 Compound Number: 86
Cook Code: MWL-284 
Promentis Code: Pro-082
Chemical Formula: C26H30
Molecular Weight: 550.7
Log P: 6.44  
Prodrug/Bioisostere: Bioisostere
Monomer/Dimer: Dimer 
 
C14 Uptake
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 Compound Number: 87
Cook Code: WYME-SSI-
Promentis Code: Pro-038
Chemical Formula: C20H32
Molecular Weight: 516.63
Log P: 4.56 
Prodrug/Bioisostere: Bioisostere
Monomer/Dimer: Dimer 
 
C14 Uptake
 
 
AB 
 
N6O6S2 
 
 
 
 
 
Glutamate Percent Change
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 Compound Number: 88
Cook Code: WYME-SSI-
Promentis Code: Pro-039
Chemical Formula: C14H26
Molecular Weight: 445.43
Log P: 3.89 
Prodrug/Bioisostere: Bioisostere
Monomer/Dimer: Dimer 
 
C14 Uptake
 
 
P 
 
Cl2N6O2S2 
 
 
 
 
 
Glutamate Percent Change
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 Compound Number: 89
Cook Code: MWL-224 
Promentis Code: Pro-073
Chemical Formula: C10H20
Molecular Weight: 387.36
Log P: -3.12 
Prodrug/Bioisostere: Bioisostere
Monomer/Dimer: Dimer 
 
C14 Uptake
 
 
 
Cl2N8S 
 
 
 
 
Glutamate Percent Change
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 Compound Number: 90
Cook Code: MWL-236  
Promentis Code: Pro-74 
Chemical Formula: C14H28
Molecular Weight: 443.46
Log P: -1.8 
Prodrug/Bioisostere: Bioisostere
Monomer/Dimer: Dimer 
 
C14 Uptake
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Glutamate Percent Change
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 Compound Number: 91
Cook Code: MWL-220  
Promentis Code: Pro-072
Chemical Formula: C20H24
Molecular Weight: 511.49
Log P: -1.09 
Prodrug/Bioisostere: Bioisostere
Monomer/Dimer: Dimer 
 
C14 Uptake
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Glutamate Percent Change
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 Compound Number: 92
Cook Code: WYME-SS-iPNPh
Promentis Code: Pro-075
Chemical Formula: C28H32
Molecular Weight: 580.72
Log P: 7.55 
Prodrug/Bioisostere: Bioisostere
Monomer/Dimer: Dimer 
 
C14 Uptake
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 Compound Number: 109
Cook Code: WYME-SS-BM
Promentis Code: Pro-034
Chemical Formula: C22H24
Molecular Weight: 476.57
Log P: 2.8 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Dimer 
 
C14 Uptake
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 Compound Number: 109
Cook Code: WYME-SS-BE
Promentis Code: Pro-033
Chemical Formula: C24H28
Molecular Weight:504.62
Log P: 3.48 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Dimer 
 
C14 Uptake
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 Compound Number: 109
Cook Code: WYME-SS-NPiPr
Promentis Code: Pro-091
Chemical Formula: C26H32
Molecular Weight: 532.67
Log P: 4.11 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
 
C14 Uptake
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 Compound Number: 112
Cook Code: WYME-ST-
Promentis Code: Pro-050
Chemical Formula: C34H34
Molecular Weight: 566.71
Log P: 5.62 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
 
C14 Uptake
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 Compound Number: 113
Cook Code: WYME-11g
Promentis Code: Pro-003
Chemical Formula: C30H38
Molecular Weight: 646.77
Log P: 1.07 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Dimer 
 
C14 Uptake
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N4O8S2 
 
 
 
 
 
 
Glutamate Percent Change
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 Compound Number: 115
Cook Code: WYME-10e 
Promentis Code: Pro-001
Chemical Formula: C19H
Molecular Weight: 357.42
Log P: 3.37 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
 
C14 Uptake
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Elevated Plus Maze 
 
 
205 
S Ph
O
 
 
 
 Compound Number: 116
Cook Code: WYME-10f 
Promentis Code: Pro-002
Chemical Formula: C20H
Molecular Weight: 371.45
Log P: 3.69 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
 
C14 Uptake
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 Compound Number: 117
Cook Code: WYME-diA
Promentis Code: Pro-008
Chemical Formula: C7H11
Molecular Weight: 205.23
Log P: -1.02 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
 
C14 Uptake
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 Compound Number: 118
Cook Code: WYME-SPh
Promentis Code: Pro-028
Chemical Formula: C30H27
Molecular Weight: 481.61
Log P: 6.17 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
 
C14 Uptake
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 Compound Number: 119
Cook Code: WYME-SNPS
Promentis Code:Pro-026 
Chemical Formula: C9H10
Molecular Weight: 274.32
Log P: -1.03 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
 
C14 Uptake
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 Compound Number: 120
Cook Code: WYME-SM-
Promentis Code: Pro-025
Chemical Formula: 
Molecular Weight: 205.32
Log P: 0.81 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
 
C14 Uptake
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 Compound Number: 121
Cook Code: WYME-051707
Promentis Code: Pro-036
Chemical Formula: C10H20
Molecular Weight: 296.41
Log P: -0.18 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Dimer 
 
C14 Uptake
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 Compound Number: 122
Cook Code: WYME-060307
Promentis Code: Pro-037
Chemical Formula: C8H16
Molecular Weight: 268.35
Log P: -0.86 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Dimer 
 
C14 Uptake
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 Compound Number: 123
Cook Code: WYME-SSNBam
Promentis Code: Pro-040
Chemical Formula: C20H22
Molecular Weight: 446.55
Log P: 0.97 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Dimer 
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 Compound Number: 124
Cook Code: ME-SBZ 
Promentis Code: Pro-019
Chemical Formula: C20H20
Molecular Weight: 448.51
Log P: 2.28 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Dimer 
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 Compound Number: 125
Cook Code: WYME-diAcGly
Promentis Code: Pro-087
Chemical Formula: C11H18
Molecular Weight: 290.3
Log P: -1.57 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
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 Compound Number: 131
Cook Code: WYME-ST-
Promentis Code: Pro-054
Chemical Formula: C13H20
Molecular Weight:360.45
Log P: -1.83 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Dimer 
 
C14 Uptake
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 Compound Number: 132
Cook Code: WYME-ST-
Promentis Code: Pro-053
Chemical Formula: C17H20
Molecular Weight: 408.5
Log P: -1.04 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Dimer 
 
C14 Uptake
 
 
GP 
 
N4O4S2 
 
 
 
HN
NHO
O
S
O
Ph
 
 
Glutamate Percent Change
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218 
 
Compound Number: 133 
Cook Code: WYME-STPh-iPr 
Promentis Code: N/A 
Chemical Formula: C24H33N5O5S2 
Molecular Weight: 535.68 
Log P: 3. 
Prodrug/Bioisostere: Both 
Monomer/Dimer: Dimer (Mixed) 
 
 
 
C14 Uptake 
N/A 
Glutamate Percent Change 
N/A 
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Compound Number: 134 
Cook Code: WYME-STVa-iPr-dBOC 
Promentis Code: N/A 
Chemical Formula: C15H25N5O3S2 
Molecular Weight: 387.52 
Log P: 1.72 
Prodrug/Bioisostere: Both 
Monomer/Dimer: Dimer (Mixed) 
 
 
HN
NH
O
S
O
NH2
S
N
N
O
 
C14 Uptake 
N/A 
Glutamate Percent Change 
N/A 
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Compound Number: 135 
Cook Code: VD-MD-01 
Promentis Code: N/A 
Chemical Formula: C25H36N8O4S2 
Molecular Weight: 576.73 
Log P: 5.8 
Prodrug/Bioisostere: Bioisostere 
Monomer/Dimer: Dimer (Mixed) 
 
C14 Uptake 
N/A 
Glutamate Percent Change 
N/A 
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Compound Number: 136 
Cook Code: VR-MD-02 
Promentis Code: N/A 
Chemical Formula: C15H22Cl2N8S2 
Molecular Weight: 448.08 
Log P: 3.01 
Prodrug/Bioisostere: Bioisostere 
Monomer/Dimer: Dimer (Mixed) 
 
 
 
C14 Uptake 
N/A 
Glutamate Percent Change 
N/A 
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Compound Number: 137 
Cook Code: WYME-STVa-iPr 
Promentis Code: N/A 
Chemical Formula: C20H33N505S2 
Molecular Weight: 487.64 
Log P: 3.11 
Prodrug/Bioisostere: Bioisostere 
Monomer/Dimer: Dimer (Mixed) 
 
 
 
C14 Uptake 
N/A 
Glutamate Percent Change 
N/A 
  
 Compound Number: 138
Cook Code: WYME-051607
Promentis Code: Pro-006
Chemical Formula: C4H7NO
Molecular Weight: 113.17
Log P: 0.03 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
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 Compound Number: 139
Cook Code: WYME-051607
Promentis Code: Pro-007
Chemical Formula: C6H11
Molecular Weight: 161.22
Log P: 0.63 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
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 Compound Number: 140
Cook Code: WYME-051907
Promentis Code: Pro-022
Chemical Formula: C6H9NO
Molecular Weight: 175.21
Log P: 0.21 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
 
C14 Uptake
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 Compound Number: 141
Cook Code: WYME-SACE
Promentis Code: Pro-086
Chemical Formula: C6H11
Molecular Weight: 161.2
Log P: 0.63 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
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 Compound Number: 142
Cook Code: WYME-052407
Promentis Code: Pro-010
Chemical Formula: C12H
Molecular Weight: 237.32
Log P: 2.53 
Prodrug/Bioisostere: Prodrug
Monomer/Dimer: Monomer
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VIII. Conclusion. 
 
Schizophrenia is debilitating disorder that affects almost 1% of the world's 
population; pharmacotherapy expenditures for this disorder exceed $10 billion dollars/ 
year even though existing medications exhibit a poor safety/efficacy profile. It is 
estimated that 75% of patients discontinue drug treatment, in part due to poor 
safety/efficacy. Analysis of current data set demonstrate that cysteine prodrug NAC 
reverses the behavioral and neurochemical effects of PCP employed to model 
schizophrenia in rodents.   
 
As a result, cysteine prodrugs represent a highly novel approach to treatment of 
schizophrenia. Indeed, these compounds may ultimately be more effective than existing 
medications because these drugs target the pathology underlying schizophrenia and 
reverse behaviors used to model negative symptoms and diminished cognition produced 
by PCP, which are behaviors and symptoms that are not treated with current first line 
medications. Specifically, therapeutic endpoints produced by cysteine prodrugs include 
increasing stimulation of group II metabotropic glutamate receptors and restoration of 
levels of glutathione. The latter effect has the potential to reverse several specific 
abnormalities that have been observed in schizophrenia including increased oxidative 
stress, decreased NMDA receptor function, altered gene expression, and abnormal cell 
proliferation / synaptic connectivity. Because cysteine prodrugs have several advantages 
relative to existing medications, it is possible that these compounds may rapidly gain a 
significant share of the $10+ billion antipsychotic market. 
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Through the use of in vivo and in vitro screening methods, it has been shown that 
dialkylated diketopiperazine cystine prodrug monomers, especially compounds 43 and 44 
(see Figure 21), demonstrates high promise as novel antipsychotic agents.  Furthermore, 
the diketopiperazine cystine prodrug dimers, especially the lead compound 1 and 
dialkylated dimers 46 and 48 (see Figure 21), also has shown promise as novel 
antipsychotic agents by overcoming the detrimental effects of PCP-induced deficits in 
sensorimotor gating by restoring pre-pulse inhibition in multiple screenings.   
 
 
 
Bioisosteres, principally ligands 60e, 81, 84 and 86 (see Figure 22), of cysteine 
and cystine have shown vast improvements over N-Acetylcysteine by competing with C14 
uptake and increasing glutamate levels by driving the cystine/glutamate antiporter.   It has 
also been shown that simple modifications to the cysteine/cystine moiety, especially 
109e, 112e and 115 (see Figure 22), also improved outcomes far greater then N-
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acetylcysteine alone. Once the most effective ligands are determined by screening 
methods, the research would benefit by combining the two such ligands into an 
unsymmetrical disulfide (hetero dimer) in order to enhance their effects and help 
eliminate any disadvantages that we find.  As an early example of this approach, ligands 
131 and 132 (see Figure 22) have shown exciting results in recent screening methods.   
Figure 22
Targets of Interest Based on C14 Uptake and
Glutamate Percent Change Screening Results
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 Upon further review of all target compounds and biological data a pattern 
becomes apparent and some general comments can be made about the structure activity 
relationships between the target compounds and observed biological data.  Target 
compounds that are closely related to either cysteine and/or cystine by being either one or 
two biological metabolic steps from cysteine/cystine tend to be highly active, especially 
target compounds 9a, 9b, 9c, 10b, 21, 24, 115, 118, 119, 121, 122, and 124 (see Figure 
23).  
 
This observation is reasonable because the human glial cells used in the in vitro 
testing have the ability to metabolize compounds.  Therefore, target compounds closely 
related to cysteine and/or cystine will be metabolized quickly to their parent compounds 
cysteine/cystine.  Since metabolism can take place in the in vitro cells, other compounds 
incorporated into the target compounds, such as glycine or serine, which can be liberated 
upon metabolism, consequently showed higher than average biological results, especially 
target compounds 34 and 112e (see Figure 23).  Glycine and serine are known 
modulators of the cystine/glutamate antiporter and increases the antiporter’s sensitivity to 
cystine activity.  
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Dialkylated diketopiperazine target compounds, 43, 45, 46, and 48 (see Figure 
24), tend to exhibit higher than average biological results as compared to other 
diketopiperazine target compounds.    This observation may well be explained by the 
ability of the human glial cell to rapidly metabolize the dialkylated diketopiperazine 
target compounds in vitro to their parent compounds cysteine/cystine. Dialkylated 
diketopiperazine compounds are more sensitive to hydrolysis and ring opening then their 
parent diketopiperazine.  However, despite this trend, there were some dialkylated 
diketopiperazine target compounds that did not perform well in vitro, especially target 
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compounds 44 and 47 (see Figure 24). Diketopiperazine target compounds tended to 
have relatively lower than average biological activity.  This may be due to the cells 
inability or slower metabolism of such target compounds.    
  
 
  
Highly lipophilic substitutions, especially phenyl groups, on either the linear type 
(non-ring containing) or diketopiperazine type target compounds tended to show a higher 
than average biological response in vitro then other polar substituents as shown in the 
data for target compounds 21, 43, 45, 48, 50, 51, 112e, 115, 118, and 124 (see Figure 
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25). Although increased lipophilicity tended to exhibit higher biological activity, it was 
also apparent that isopropyl groups, especially isopropyl esters, tended to have the least 
activity in vitro, as seen in the data for target compounds 88, 90, 92, and 109f (see Figure 
26). This may be due to the cells inability or slower metabolism of such isopropyl 
substituted target compounds.    
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Bioisostere target compounds, especially 1,2,4-triazole bioisosteres,  tend to 
exhibit higher than average biological activity as shown in the data for target compounds 
81, 84, 86, and 89 (see Figure 27).  These results can be explained by the target 
compound’s ability to drive the cystine/glutamate antiporter in its administered form in 
the in vitro human glial cell experiments.  However, some bioisosteres such as 
oxadiazoles, especially 1,3,4-oxadiazole 87 (see Figure 27),  tended to show lower than 
average biological results.  The lack of required biological metabolism to produce an 
active compound is an important step forward in producing ligands to drive the 
cystine/glutamate antiporter and should be studied further.    
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IX. Experimental Section.  
 
 Melting points were taken on a Thomas-Hoover melting point apparatus or an 
Electrothermal model IA8100 digital melting point apparatus and are uncorrected.  
Microanalyses were performed on a Perkin-Elmer 240C carbon, hydrogen, and nitrogen 
analyzer.  All samples submitted for CHN analyses were first dried under high vacuum 
for a minimum of 6 h using a drying pistol with isopropyl alcohol as the solvent with 
phosphorus pentoxide in the drying bulb.  Proton and carbon high resolution nuclear 
magnetic resonance spectra were obtained on a Bruker 300-MHz NMR spectrometer or a 
GE 500-MHz NMR spectrometer.  The low resolution mass spectra (EI/CI) were 
obtained on a Hewlett-Packard 5985B gas chromatography-mass spectrometer, while 
high resolution mass spectra were recorded on a VG Autospec (Manchester, England) 
mass spectrometer.  Infra-red spectra were recorded on a Nicolet MX-1 FT-IR or a Perkin 
Elmer 1600 Series FT-IR spectrometer.  Analytical thin layer chromatography plates used 
were E. Merck Brinkmann UV-active silica gel (Kieselgel 60 F254) on plastic.  Silica gel 
60A, grade 60 for flash and gravity chromatography was purchased from E. M. 
Laboratories. Some high resolution mass spectra where carried out at the Centers for 
Mass Spectrometry, Texas A and M or the Chemistry Department of Kansas. The 
experimental data for some compounds have been published; see patent references 89, 
90, 91, 92, 93, 94.  
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Preparation of 4-Methylbenzenesulfenyl Chloride.  
 
Under a nitrogen atmosphere, N-chloro-succinimide (48.1 g, 0.36 mole) was 
slurried in CH2Cl2 (200 mL).  While this solution was stirred at rt, 4-methylbenzenethiol 
(29.8 g, 0.24 mole) was added (2 g initial addition to start reflux and the remainder at a 
rate to maintain the reflux for approximatly 10 min). The clear solution which resulted 
was then stirred at rt for 30 min. A small amount of precipitate which formed was 
removed by filtration. The filtrate, assumed to contain the theoretical quantity of 4-
methylbenzenesulfenyl chloride (38.1 g, 0.24 mole), was used immediately and directly 
in the next step. Alternatively, 4-methylbenzene-sulfenyl chloride was isolated by 
evaporation to a solid in vaccuo and used in the next step.   
    
Representative Procedure for the Synthesis of the Bis-Dipiperazinedione 
(Symmeterical Dimers): Bis-[2,5-Piperazinedione, 3-(mercaptomethyl)-] 
(1). 
 
The trityl protected diketopiperazine 27 (1.5 g, 3.73 mmol) was dissolved in a 
solution of CH2Cl2 (20 mL) and CH3OH (40 mL) with stirring.  Pyridine (1.2 mL, 15 
mmol) was then added to the mixture which resulted and this was followed by addition of 
a solution of iodine (0.97 g, 3.8 mmol) in CH3OH (5 mL).  The mixture was allowed to 
stir for 1 h at rt. No precipitate had formed by this time; however, analysis by TLC (silica 
gel) indicated that the reaction was proceeding slowly by the appearance of a new spot 
under the starting material (UV light).  A precipitate began to form within 2 h after 
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concentrating the solution to a volume of 10 mL and CH3OH (30 mL) was added to result 
in a total volume of 40 mL.  The solution was then stirred an additional 23 h and the 
precipitate which formed was removed by filtration. The solid was washed with cold 
CH3OH and then decolorized by shaking with a solution of 10% aq sodium bisulfite (10 
mL). The precipitate was filtered and dried to yield diketopiperazine dimer 1 as a white 
solid (680 mg, 57%). 1: m.p. > 300 °C. 1H NMR (300 MHz， DMSO-d6) δ 3.11-3.21 (m, 
2H), 3.70 (d, 1H, J = 0.96 Hz), 3.73 (d, 1H, J = 0.99 Hz), 4.11 (s, 1H), 8.17 (s, 1H), 8.19 
(s, 1H); 13C NMR (75.5 MHz, DMSO- d6): δ 44.0, 45.2, 54.8, 166.7, 167.1; HRMS m/z 
(M+H)+ calcd. 319.0535, found 319.0533.  
 
(R)-2-Amino-3-(phenyldisulfanyl)propanoic acid (9b). 
 
 Powdered sodium bicarbonate (30 g, 0.36 mol) was added to a solution of L-
cysteine hydrochloride monohydrate (47 g, 0.3 mol) in absolute EtOH (900 mL) was 
added at 0 °C in one portion. Phenylsulfenyl chloride (50 g, 0.345 mol) was then added 
dropwise with stirring to the mixture. After the complete addition of the sulfenyl 
chloride, the reaction mixture was allowed to stand at rt and the sodium chloride which 
was produced during the reaction was removed by filtration. After the mixture was 
brought to alkaline pH by the addition of pyridine (38 mL) into the filtrate, the fine 
precipitate which formed was allowed to stand for a couple of hours, then filtrated and 
washed well with EtOH and dried to provide the crude product as a white solid. After 
recrystallization from aq HCl solution (0.5 N, 4000 mL), the final ligand S-thiol-phenyl-
L-cysteine (9b) was obtained (52 g) in 76% yield as colorless plates. 9b: m.p. 192 °C 
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(decomp). 1H NMR (300 MHz, CD3CO2D): δ 3.53-3.76 (m, 2H), 4.89 (t, 1H), 7.26-7.88 
(m, 5H); 13C NMR (75.5MHz, CD3CO2D): δ 35.5, 52.5, 127.6, 128.5, 129.1, 129.3, 
133.5, 171.6. This material was employed directly in a later step.  
 
2-Amino-3-tritylsulfanyl-propionic acid (S-Trityl-L-cysteine) (9c). 
 
 L-Cysteine hydrochloride (100 g, 0.634 mol) and trityl chloride (270 g, 0.969 
mol) were allowed to stir in DMF (400 mL) for 2 days at rt. A 10% aq sodium acetate 
solution (3.5 L) was then added dropwise and the white precipitate which formed was 
filtered and washed with distilled water. Afterward the residue was stirred in acetone at 
50 °C for 30 min, after which it was cooled to 0 °C and filtered. The precipitate which 
formed was washed with a small amount of acetone as well as diethyl ether and dried in 
vaccuo. S-Trityl-L-cysteine 9c (205 g, 89%) was obtained as a white powder. 9c: m.p. 
192 °C (decomp) ; 1H NMR (300 MHz, DMSO-d6) δ 2.45 (dd, 1H, J = 9 Hz, 12 Hz), 
2.58 (dd, 1H, J = 4.4 Hz, 12 Hz), 2.91 (m, 1H), 7.22-7.36 (m, 15H); 13C NMR (75.5 
MHz, DMSO- d6): δ 33.8, 53.7, 66.4, 127.1, 127.8, 128.1, 128.4, 129.5, 144.5, 168.4. 
This material was directly used in a later step without further purification.  
 
(R)-4-(Phenyldisulfanyl)methyl-oxazolidine-2,5-dione (10b). 
 
 To a rapidly stirred (over-head stirrer) suspension of S-thiol-phenyl-L-cysteine 
9b (57.5 g, 0.25 mol) in THF (250 mL) was added solid triphosgene (26 g, 88 mmol) in 
one portion at 45-50 °C (before addition, remove the heating mantle). When the 
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temperature dropped to 45 °C, put the heating mantle back on and maintain the inside 
temperature around 45-50 °C until the solution becomes homogeneous. After the removal 
of the heating mantle, the solution was purged with argon overnight into a NaOH 
bubbler to remove any residual phosgene. The solvent was evaporated in vaccuo and 
this provided anhydride 10b (55 g) in 85% yield. 10b: m.p. 217 °C (decomp) ; 1H NMR 
(300 MHz, CDCl3) δ 2.90-2.98 (m, 1H), 3.30 (d, 1H, J = 12 Hz), 4.68 (d, 1H, J = 9 Hz), 
6.01 (s, 1H), 7.34-7.58 (m, 5 H); 13C NMR (75.5MHz, CD3Cl3): δ 39.4, 56.5, 128.3, 
128.9, 129.5, 135.2, 150.8, 167.7.  Due to the unstable nature of this anhydride it was 
stored in the refrigerator overnight under an atmosphere of argon and used immediately 
the next day without further purification.   
 
4-Tritylsulfanylmethyl-oxazolidine-2,5-dione (10c). 
 
This intermediate (10c) was prepared following the procedure for preparation of 10b 
and obtained as a brown oil in 85% yield. 10c: 1H NMR (300 MHz, CDCl3) δ 2.70-2.85 
(m, 2H), 3.47-3.56 (m, 1H), 5.62 (s, 1H), 7.07-7.73 (m, 15H). This material was directly 
used in a later step without further purification.  
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Representative Procedure for Synthesis of Diketopiperazine Targets: 3-
(mercaptomethyl)-2,5-Piperazinedione (12a). 
 
a)  A solution of the N-carboxy-anhydride 10b (35.7 g, 0.14 mol) in THF (160 
mL) was added dropwise to a vigorously stirred (overhead stirrer) mixture of glycine 
ethyl ester hydrochloride (28 g, 0.16 mol), freshly distilled triethylamine (20.4 g, ~ 28 mL, 
0.20 mol) and dry chloroform (240 mL) at –78 °C in a three-neck flask (2 L). The 
reaction mixture was allowed to warm to 0 °C over 8 h, and then was allowed to stir at rt 
for 12 h, after which the reaction solution was filtered to remove the triethylamine 
hydrochloride which precipitated. The filtrate was then concentrated under reduced 
pressure (< 40 °C) and the crude dipeptide ester was used for the preparation of the 
diketopiperazine 12a without further purification. 1H NMR (300 MHz, CDCl3): δ 1.29 (t, 
3H), 1.93 (br, 2H), 2.74-2.82 (m, 1H), 3.40 (dd, 1H), 3.73 (dd, 1H), 4.03-4.19 (m, 2H), 
4.19-4.26 (m, 2H), 7.34-7.58 (m, 5H).  This material was used directly in the next step. 
 
b) The crude dipeptide ester (37.6 g, 0.12 mol) was heated in refluxing toluene 
(1000 mL) for 12 h and then cooled to rt and kept at 0 °C for 16 h. The bislactam 12a 
which precipitated was isolated by vacuum filtration, washed with ether (3 x 150 mL), 
and dried under vacuum at 100 °C to provide pure diketopiperazine 12a (10.0 g) in 45% 
yield. The filtrate produced from washing the desired diketopiperazine was evaporated 
under vacuum and toluene (800 mL) was added to the residue. The toluene solution, 
which resulted, was heated at reflux for another 40 h (under argon) and then the above 
steps were repeated to collect another 5-8 grams of diketopiperazine 12a (combined 
243 
 
yield, 73%). 12a: m.p. 258 °C; 1H NMR (300 MHz, DMSO-d6): δ 3.09-3.26 (m, 2H), 
3.68-3.88 (m, 2H), 4.10 (s, 1H), 8.17 (s, 1H), 8.19 (s, 1H); 13C NMR (500 MHz, DMSO-
d6): δ 43.5, 44.7, 54.3, 166.2, 166.6; EIMS (m/e, relative intensity) 160(M+, 12), 140(5), 
126(72), 114(100), 97(20), 85(30). HRMS m/z C5H8N2O2S (M+H)+ calcd. 161.1942, 
found 161.1956. 
 
(R)-3-(Phenyldisulfanyl)methyl-piperazine-2,5-dione (11b). 
 
The solution which resulted from step b above, from compound 12a, was cooled 
to 0 °C and keep at 0 °C for 12 h. The precipitate which resulted was filtered and 
provided phenyl-thiol analog 11b in 30% yield. 11b:  1H NMR (300 MHz, DMSO-d6): δ 
3.09-3.21 (m, 2H), 3.65-3.82 (m, 2H), 4.10 (s, 1H), 7.11-7.55 (m, 5H), 8.18 (s, 1H), 8.20 
(s, 1H); 13C NMR (75.5 MHz, DMSO-d6): δ 43.5, 47.8, 54.2, 125.6, 127.7, 128.2, 129.5, 
166.2, 166.6; EIMS (m/e, relative intensity) 268 (M+, 55), 250(35), 218(68), 159(66), 
141(80), 126(70). HRMS m/z C11H12N2O2S2 (M+H)+ calcd. 269.0340, found 269.0348. 
  
(3R,6R)-3-Benzyl-6-(mercaptomethyl)piperazine-2,5-dione (12c). 
 
This dione 12c was prepared in 75% yield following the procedure for preparation 
of 12a and obtained as a light yellow solid. 12c: m.p. > 265 oC (decomp.) ; 1H NMR (300 
MHz, DMSO-d6) δ 1.26 (d, J =6.99 Hz, 1H), 3.05-3.49  (m, 2H), 3.66-3.89 (m, 3H), 4.10 
(s, 1H), 7.13-7.31 (m, 5H), 8.23 (s, 1H), 8.28 (s, 1H); 13C NMR (75.5 MHz, CDCl3) δ 
19.0, 37.9, 44.7, 48.1, 51.2, 54.4, 126.5, 129.1, 129.4, 165.9, 166.5. EIMS (m/e, relative 
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intensity) 250 (M+, 10), 216(12), 160(5), 113(11), 91(100). HRMS m/z C12H14N2O2S 
(M+H)+ calcd. 251.0776, found 251.0801. 
 
(6R)-3-Isopropyl-6-(mercaptomethyl)piperazine-2,5-dione (12e). 
 
This isopropyl analogue was prepared in 74% yield following the procedure for 
preparation of 12a and gave dione as a white solid. 12e: m.p. > 275 °C ; 1H NMR (300 
MHz, DMSO-d6) δ 0.84 (dd, J = 7.14, 6.63 Hz, 3H), 0.94 (dd, J = 8.07, 6.9 Hz, 3H), 
2.17-2.20 (m, 1H), 3.07-3.18 (m, 2H), 3.73 (s, 1H), 4.22 (s, 1H), 8.12 (s, 1H), 8.18s (s, 
1H); 13C NMR (75.5 MHz, CDCl3) δ 17.5, 18.8, 42.9, 53.9, 59.7, 166.7, 167.2; HRMS 
m/z C10H18N2O2S2 (M - H)+  calcd 201.0698, found 201.0691.  
 
(3R,8aR)-3-(Phenyldisulfanyl)methyl-hexahydropyrrolo[1,2-a]pyrazine-
1,4-dione (25).  
 
This phenyldisulfanyl analogue was prepared in 82% yield following the 
procedure for preparation of 11b and gave dione 25 as a yellow solid. 25: m.p. 120 °C ; 
1H NMR (300 MHz, CDCl3) δ 1.66-2.02 (m, 1H), 2.03-2.11 (m, 2H), 2.36 (m, 1H), 2.80-
2.89 (m, 1H), 3.54-3.62 (m, 3H), 4.07-4.10 (m, 1H), 4.39 (dd, J = 1.83, 1.77 Hz, 1H), 
6.35 (s, 1H), 7.28-7.57 (m, 5H); 13C NMR (75.5 MHz, CDCl3) δ 22.5, 28.2, 38.5, 45.4, 
53.3, 59.1, 127.8, 128.6, 129.2, 135.6, 164.3, 169.0. HRMS m/z C14H16N2O2S2 (M+H)+ 
calcd. 309.0653, found 309.0635.  
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3-Tritylsulfanylmethyl-piperazine-2,5-dione (27).  
 
This trityl analogue was prepared following the similar procedure for preparation 
of 12a. 27: m.p. 225 – 227 °C. [α]D26 = +7.8 ° (c = 1.05, CHCl3). 1H NMR (300 MHz, 
CDCl3) δ 2.73-2.91 (m, 2H), 3.12 (d, 1H, J = 12.3 Hz), 3.95 (s, 1H), 5.80 (s, 1H), 5.82 (s, 
1H), 7.20-7.62 (m, 15H). 13C NMR (75.5 MHz, CDCl3): δ 35.9, 44.8, 53.0, 126.9, 128.1, 
129.4, 144.0, 166.6. HRMS m/z C24H22N2O2S (M+H)+ calcd. 402.1402, found 402.1398. 
This material was directly used in a later step without further purification.  
 
(6R)-3-(tert-Butylthiomethyl)-6-(mercaptomethyl)piperazine-2,5-dione 
(32). 
 
This dione was prepared in 70% yield following the procedure for preparation of 
12a and gave dione 32 as a yellow solid. 32: m.p. > 280 °C (decomp.) ; 1H NMR (300 
MHz, DMSO-d6) δ 1.25 (s, 9H), 2.88-2.92 (m, 1H), 3.03-3.10 (q, J = 7.5 Hz, 1H), 3.18-
3.21 (m, 1H), 3.51 (d, J  = 14.4 Hz, 1H), 4.14 (s, 2H), 8.13 (s, 1H), 8.24 (s, 1H); 13C 
NMR (75.5 MHz, CDCl3) δ 31.1, 32.1, 43.2, 47.8, 54.1, 54.9, 166.3, 170.8; EIMS (m/e, 
relative intensity) 262 (M+, 30), 228(40), 206(45), 173(50), 160(70), 126(100);  HRMS 
m/z C10H18N2O2S2 (M + H)+ calcd 263.0482, found 263.0489.  
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(3S,6S)-3-Benzyl-6- (2R,5R)-5-benzyl-3,6-dioxopiperazin-2-yl-methyl-
disulfanyl-methyl-piperazine-2,5-dione (36).  
 
This benzyl analogue was prepared in 63% yield following the procedure for 
preparation of 1 employing starting material 29 and gave dione 36 as a yellow solid. 36: 
m.p. > 280 oC (decomp.); 1H NMR (300 MHz, CDCl3) δ 1.29 (s, 9 H), 2.85-2.92 (m, 2 
H), 3.10-3.13 (m, 2 H), 4.14 (s, 2 H), 8.12 (s, 2 H); 13C NMR (75.5 MHz, CDCl3): δ 31.1, 
32.1, 42.5, 43.2, 53.9, 54.1, 166.2, 166.3. HRMS m/z C24H22N2O2S (M+H)+ calcd. 
403.1402, found 403.1415.  
 
(3R,6S)-3-(tert-Butylthiomethyl)-6-(((((2R,5S)-5-(tert-Butylthiomethyl)-
3,6-dioxo-piperazin -2-yl)methyl) disulfanyl)methyl)piperazine-2,5-
dione (37).  
 
This S-tert-butyl dione dimer was prepared in 65% yield following the procedure 
for preparation of 1, using S-trityl, S’-tert-butyl dione starting material 33 and gave dione 
37 as a yellow solid. 37: m.p. 278 oC ; 
1
H NMR (300 MHz, CDCl3) δ 1.29 (s, 9 H), 2.85-
2.92 (m, 2 H), 3.10-3.13 (m, 2 H), 4.14 (s, 2 H), 8.12 (s, 2 H); 13C NMR (75.5 MHz, 
CDCl3): δ 31.1, 32.1, 42.5, 43.2, 53.9, 54.1, 166.2, 166.3. HRMS m/z C20H34N4O4S4 
(M+H)+ calcd. 523.1463, found 523.1448.  
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(3R,3'R,6R,6'R)-6,6'-Disulfanediylbis(methylene)bis(3-
isopropylpiperazine-2,5-dione) 38. 
 
This dione (38) was prepared in 65% yield following the procedure for 
preparation of 1, using S-trityl dione starting material 31 and obtained as a white solid 
(38):  m.p. 270 oC ;  1H NMR (300 MHz, CDCl3) δ 0.86 (d, J = 6.75 Hz, 3 H), 0.96 (d, J 
=7.05 Hz, 3 H), 2.17-2.21 (m, 1 H), 3.07-3.19 (m, 2 H), 3.72 (s, 1 h), 4.33 (s, 1 H), 8.11 
(s, 1 H), 8.17 (s, 1 H);  13C NMR (75.5 MHz, CDCl3): δ 17.5, 18.8, 31.4, 42.9, 53.9, 59.7, 
166.7, 167.2; HRMS m/z (M+H)+ calcd. 403.1474, found 403.1479.  
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Representative Procedure for Synthesis of Dialkylated 
Diketopiperazine: Preparation of Triethyloxonium tetrafluoroborate.79 
 
Note: Triethyloxonium tetra-fluoroborate is an expensive reagent; however, it is 
relatively easy to prepare even on large scale. A three-neck flask (500 mL), pressure 
equilibrating dropping funnel (125 mL) and a condenser were dried in an oven at 150 °C 
and assembled while hot under an atmosphere of argon. When the equipment had cooled 
to rt, ether [(100 mL) which had been previously dried over sodium benzophenone ketyl] 
and boron trifluoride diethyletherate (91 g, ~87 mL, 64 mmol) were combined [Note: On 
this scale the colorless BF3 etherate was obtained from a freshly opened new bottle. If the 
reagent was slightly yellow or if the reaction was scaled down, the BF3 etherate required 
vacuum distillation first].  
 
The ethereal solution which resulted was heated to a gentle reflux after which dry 
epichlorohydrin (48.8 g, ~ 41 mL, 51.8 mmol) was added dropwise over 1 h. The mixture 
was heated at reflux for an additional 1 h and allowed to stand at rt (under argon) 
overnight. The ether was removed by applying a positive pressure of argon in one neck of 
the flask while forcing the ether out through a filter stick (fritted glass tube) inserted into 
another neck of the flask and into a collection flask. The slightly yellow solid which 
remained in the flask was rinsed twice in the same manner with anhydrous ether (3 x 50 
mL) to provide a crystalline white solid. The solid was not weighed but directly used in 
the next step. The following sequence was based on the yield of this reaction process at 
the level of 80-85%. 
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(3,6-Diethoxy-2,5-dihydro-,pyrazin-2-yl)-methanethiol (44). 
 
Dry CH2Cl2 (100 mL) was added to the flask (500 mL) which contained the 
freshly prepared triethyloxonium tetrafluoroborate (~42 g, 336 mmol) from the previous 
reaction (under argon). To this solution was added the dry diketopiperazine 12a (5 g, 31.2 
mmol) in portions with stirring (overhead stirrer). After 2 h the reaction mixture became 
homogenous. The solution was allowed to stir at rt under argon for 72 h after which the 
mixture was added via a cannula to an aq solution of NH4OH (14%, 100 mL) mixed with 
ice (100 g). The organic layer was washed with a dilute aq solution of 0.1 N NaHCO3 (2 
x 50 mL) and brine (80 mL), after which it was dried (K2CO3). After filtration the solvent 
was removed under reduced pressure to provide the bis-ethoxy lactim ether 44 as a clear 
yellow liquid that was further purified by flash chromatography (EtOAc : hexane = 1:4) 
in 71% yield (4.8 g, 22 mmol). 44: [α]D26 = +52.2 ° (c = 2.5, CHCl3). 1H NMR (300 MHz, 
CDCl3) δ 1.32-1.36 (m, 6 H), 3.27-3.30 (m, 3 H), 4.08-4.22 (m, 6 H), 4.39 (s, 1H); 13C 
NMR (75.5 MHz, CDCl3): δ 14.7, 46.3, 47.5, 56.1, 61.5, 61.6, 162.7, 163.6; HRMS m/z 
C9H16N2O2S (M+H)+ calcd. 217.2982, found 217.2990.  
 
Bis[(3,6-Diethoxy-2,5-dihy-dro-pyrazin-2-yl)-methanethiol] (46). 
 
To the bis-ethoxy lactim ether 44 (400 mg, 1.85 mmol) in dry EtOH (10 mL) was 
added a catalytic amount of I2 (50 mg, 10 % mmol) at rt. The mixture was allowed to stir 
for 6~ 12 h under air until the analysis (TLC, silica gel) indicated the reaction was 
complete (new spot appeared under S.M. on the TLC plate). The organic solvent was 
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removed under reduced pressure. The mixture which resulted was dissolved into EtOAc 
(20 mL), washed with a saturated aq solution of sodium thiosulfate (5 ~ 10 mL) and dried 
(Na2SO4). The solvent was then removed under reduced pressure which provided the 
dimer 46: 
1
H NMR (300 MHz, CDCl3) δ 1.32-1.36 (m, 6 H), 3.27-3.30 (m, 3 H), 4.08-
4.22 (m, 6 H), 4.39 (s, 1H); 13C NMR (75.5 MHz, CDCl3): δ 14.7, 46.3, 47.5, 56.1, 61.5, 
61.6, 162.7, 163.6; The NMR spectra was identical to its monomer except the S-H bond 
had disappeared. HRMS m/z C18H30N4O4S2 (M+H)+ calcd. 431.1787, found 431.1790. 
 
1,2-Bis(2R,5R)-3,6-diethoxy-5-isopropyl-2,5-dihydropyrazin-2-yl-
methyl-disulfane (47). 
 
This disulfane (47) was prepared in 60% yield following the procedure for 
preparation of 46, using starting material 43 and gave 47 as a colorless liquid. 47: 
1
H 
NMR (300 MHz, CDCl3) δ 0.76-0.78 (m, 3 H), 1.06-1.09 (m, 3 H), 1.25-1.31 (m, 6 H), 
2.18-2.23 (m, 1 H), 2.82-3.01 (m, 1 H), 3.21-3.45 (m, 1 H), 3.54-3.70 (m, 2 H), 4.07-4.33 
(m, 4 H); 13C NMR (75.5 MHz, CDCl3): δ 14.2, 17.3, 31.1, 31.7, 45.2, 55.3, 60.5, 60.7, 
161.0, 163.1; HRMS m/z C24H42N4O4S2 (M+H)+ calcd. 515.2726, found 515.2731.  
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1,2-Bis(2R,5R)-5-benzyl-3,6-diethoxy-2,5-dihydropyrazin-2-yl-methyl-
disulfane (48). 
 
The dimer (48) was prepared in 65% yield following the procedure for 
preparation of 46, using starting material 45 and obtained (48) as a yellow liquid. 48: 1H 
NMR (300 MHz, CDCl3) δ 1.26-1.35 (m, 6 H), 2.45-2.57 (m, 1 H), 3.05-3.22 (m, 2 H), 
3.50-3.82 (m, 1H), 4.07-4.18 (m, 5 H), 4.32-4.38 (m, 1H), 7.06-7.28 (m, 5 H); 13C NMR 
(75.5 MHz, CDCl3): δ 14.3, 39.6, 42.9, 43.0, 54.9, 57.1, 60.7, 60.8, 126.2, 126.5, 127.8, 
137.0, 162.2, 162.6; The NMR spectra was identical to its monomer except the S-H bond 
had disappeared. HRMS m/z C32H42N4O4S2 (M+H)+ calcd. 611.2681, found 611.2677.  
 
(3R,6R)-6-Benzyl-5-ethoxy-3-(ethylthiomethyl)-1,6-dihydropyrazin-
2(3H)-one (49).  
 
This benzyl analogue (49) was prepared in 30% yield following the procedure for 
preparation of 44 using only 1 equiv of triethyloxonium tetrafluoroborate and starting 
material 12c, in which 49 was obtained as a yellow solid. 49: m.p. 118 oC ; 
1
H NMR (300 
MHz, CDCl3) δ 1.19 (t, J = 7.41 Hz, 3 H), 1.30 (t, J = 7.08 Hz, 3 H), 2.37-2.45 (m, 3 H), 
2.82-3.01 (m, 1 H), 2.95 (d, J = 3.09 Hz, 1 H), 3.03 (d, J = 3.12 Hz, 1 H), 3.23 (q, J = 
32.6, 5.1 Hz, 2  H), 4.14-4.19 (m, 2 H), 4.46-4.47 (m, 1 H), 6.19 (s, 1 H), 7.17-7.29 (m, 5 
H); 13C NMR (75.5 MHz, CDCl3): δ 14.1, 14.5, 25.7, 35.4, 39.8, 50.6, 60.0, 61.6, 126.5, 
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127.8, 130.2, 136.7, 157.8, 170.1; HRMS m/z C16H22N2O2S (M+H)+ calcd. 305.1515, 
found 305.1522.  
 
(R)-2-(tert-Butoxycarbonylamino)-3-(tritylthio)propanoic acid (54c). 
 
  Di-tert-butyldicarbonate (41 g, 187 mmol) was added to the solution of trt-cys-
OH (22.68 g, 62.5 mmol) in dioxane (60 mL) and water (125 mL) at 45 °C, and the 
solution was adjusted with NaOH (4 M) until pH = 9.5. It was then allowed to stir at the 
same temperature overnight, after which, the water and dioxane were removed under 
reduced pressure. The residue was dissolved in water (150 mL) and extracted with EtOAc 
(2 x 100 mL) . The aq layer was adjusted to pH = 2 with dilute aq HCl while in an ice 
bath and then the aq layer was extracted with EtOAc.  The combined EtOAc layers were 
washed with water and dried over anhydrous magnesium sulfate. The removal of the 
solvent under vacuum yielded a yellow oil. The residue was then dissolved into ethyl 
ether and a 1:1 mixture of ethyl ether and hexane were carefully added while stirring to 
precipitate out the white solid in 60% yield. 54c: 1H NMR (300 MHz, CDCl3): δ1.46 (s, 
9H), 2.69 (br, 2H), 4.21 (s, 1H), 4.97 (s, 1H), 7.20-7.44 (m, 15H), 10.2 (br, 1H); 13C 
NMR (75.5 MHz, CDCl3): δ 28.1, 33.5, 52.4, 144.1, 155.4, 175.1. HRMS m/z 
C27H29NO4S (M+H)+ calcd. 464.1817, found 464.1815.  
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N, N’ –Bis(tert-Butoxy)carbonlycystine (93). 
 
A solution of di-tert-butyldicarbonate (41 g, 0.187 mol, 3 equiv) in dioxane (60 
mL) was added at 0 °C to a solution of commercial L-cysteine (15 g, 0.06 mol) in aq 
NaOH (1 M; 125 mL). The reaction mixture which resulted was allowed to stir at 0 °C 
for 5 min and then at rt overnight. Half the volume of dioxane was removed under 
reduced pressure and the mixture which remained was extracted with EtOAc (3 x 50 
mL). The combined aq phases were brought to pH = 1 with an aq solution of HCl (1 M) 
and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with 
brine, dried (anhydrous Na2SO4), filtered and concentrated under reduced pressure to 
afford protected cystine in 65% yield as white solid. 93: m.p. 148 ~ 151 °C. 1H NMR 
(DMSO-d6): δ 1.46 (s, 9H), 2.84-2.92 (m, 1H), 3.07-3.13 (m, 1H), 7.19 (d, 1H, J = 9Hz), 
12.8 (s, 1H); 13C NMR (75.5MHz, DMSO-d6): δ 28.5, 53.0, 54.1, 78.6, 85.9, 155.7, 
172.8. This material was employed directly in a later step. 
 
(R)-tert-Butyl-1-(3-isopropyl-1,2,4-oxadiazol-5-yl)-2-(tritylthio) 
ethylcarbamate (94). 
 
A solution of DCC (3.56 g, 17.28 mmol) in THF (20 mL) was added to a solution 
of trityl protected Boc-L-cysteine 54c, (3.7 g, 8 mmol), isobutyl-imidoxine (1.75 g, 17.16 
mmol ), hydroxysuccimide (19.7 g, 17.16 mmol) in THF (50 mL) at 0 °C over 15 min. 
The mixture was allowed to stir for 16 h while the temperature was allowed to warm to rt. 
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The mixture was then cooled to 0 °C and the precipitate which formed was removed by 
filtration. The filtrate was concentrated under vacuum and then dissolved into EtOAc (50 
mL).  The small amount of precipitate that formed was filtered off. The organic layer was 
washed with a dilute aq solution of 0.1 N NaHCO3, brine, dried (anhydrous Na2SO4) and 
removed under reduced pressure to give the trityl protected Boc-L-cysteine 
acetamidoxime ester as white crystals. This material was taken up in toluene (200 mL) 
and the mixture which resulted was heated at reflux for 3 h; the water which formed was 
removed by a Dean-Stark trap. The solvent was removed under vacuum and the residue 
was purified by flash chromatography (hexane/EtOAc = 9:1) to form white crystals in 
71% yield. 94 :  1H NMR (300 MHz, CDCl3): δ1.15 (d, 6H, J = 3Hz), 1.44 (s, 9H), 2.67 
(br, 1H), 3.03-3.07 (m, 1H), 4.18 (s, 1H), 5.03 (s, 1H), 7.23-7.46 (m, 15H), 8.76 (s, 1H); 
13C NMR (75.5 MHz, CDCl3): δ 19.6, 27.6, 28.1, 54.3, 67.1, 80.6, 126.7, 128.4, 129.4, 
144.4, 155.3, 170.3, 177.6. HRMS m/z C31H35N3O3S (M+H)+ calcd. 530.2399, found 
530.2387.  
 
General Procedure for the Cleavage of Disulfide Bonds on Bioisosteres: 
Used for the Synthesis of Ligands 96, 98, 100 and 102. 
 
The bioisosteric disulfide (1 mmol) (97, 99, 101 or 103) was dissolved in 10 mL 
of EtOH and indium (1.1 mmol) was added in one portion with stirring. Then anhydrous 
NH4Cl (2.2 mmol) was added to the suspension while stirring. The mixture which 
resulted was heated to reflux under argon for 4-6 hrs. After 4-6 hrs the solids were 
removed by filtration over a bed of celite. The solvent was removed under reduced 
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pressure until dryness. The residue was washed well with water to dissolve the inorganic 
salts. The mixture was filtered and dried to yield the product. The monomer (see below) 
can be purified by crystallization from dichloromethane (DCM) or EtOH. Yield 85-90%. 
 
(R)-tert-Butyl-2-mercapto-1-(5-methyl-1H-1,2,4-triazol-3-yl) 
ethylcarbamate  [R = CH3]  (96). 
 
The carbamate (96) was prepared using the general procedure described above for 
the cleavage of disulfide bonds of bioisosteres starting with dimer 97 which was 
converted into monomer 96:1H NMR (300 MHz, CDCl3) δ 6.44 (d, 1H), 5.30 (s, 1H), 
3.37 – 3.78 (m, 2H), 2.93 (s, 3H), 1.48 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 158.2, 
155.8, 128.1, 127.8, 127.5,  81.0, 45.2, 28.3, 13.3 ppm. HRMS (ESI, M++H, 
C10H19N4O2S) calc.: 259.1229, found: 259.1237 and (M++Na, C10H18N4O2SNa) calcd. 
281.1048, found 281.1056. 
 
(R)-tert-Butyl-1-(5-ethyl-1H-1,2,4-triazol-3-yl)-2-mercapto 
ethylcarbamate [R = CH2CH3] (98). 
 
The ethyl carbamate (98) was prepared using the general procedure described 
above for the cleavage of disulfide bonds of bioisosteres starting with dimer 99 which 
was converted into monomer 98: 1H NMR (300MHz, CDCl3) δ 6.21(d,1H), 5.09(s, 1H), 
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2.94-3.54(m,2H), 2.79 – 2.87 (q, J=7.5, 2H), 1.45(s, 9H), 1.27-1.34(t, J=7.5,3H). HRMS 
(ESI, M++H, C11H21N4O2S) calcd. 273.1385, found: 273.1392. 
 
(R)-tert-Butyl-2-mercapto-1-(5-phenyl-1H-1,2,4-triazol-3-
yl)ethylcarbamate [R = Ph] (100). 
 
The phenyl analogue (100) was prepared using the general procedure described 
above for the cleavage of disulfide bonds of bioisosteres starting with dimer 101 which 
was converted into monomer 100: 1H NMR (300MHz, CDCl3) δ 7.94-8.01(d,2H), 
7.46(s,3H), 6.23(s,1H), 5.13(s,1H),2.95-3.64(m, 2H), 1.48(s,9H); HRMS (ESI, M++H, 
C15H21N4O2S) calcd. 321.1385, found: 321.1391. 
 
(R)-tert-Butyl-1-(5-isopropyl-1H-1,2,4-triazol-3-yl)-2-
mercaptoethylcarbamate [R = CH(CH3)2] (102). 
 
The isopropyl analogue (102) was prepared using the general procedure described 
above for the cleavage of disulfide bonds of bioisosteres starting with dimer 103 
converted to 102: 1H NMR (300 MHz, CDCl3) δ 6.44 (d, 1H), 5.16 (s, 1H), 2.81 – 3.66 
(m, 3H), 1.48 (s, 9H), 1.37(s,6H); 13C NMR (75 MHz, CDCl3) δ 159.3, 155.8, 142.1, 
133.7,  81.1, 57.2, 39.8, 28.3, 21.5 ppm. HRMS (ESI, M++H, C12H23N4O2S) calc.: 
287.1542, found: 287.1547 and (M++Na, C12H22N4O2SNa) calcd. 309.1361, found 
309.1354. 
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tert-Butyl (1R,1'R)-2,2'-disulfanediylbis(1-(3-isopropyl-1,2,4-oxadiazol-
5-yl)ethane-2,1-diyl)dicarbamate (104). 
 
A solution of DCC (1.78 g, 8.64 mmol) in THF (10 mL) was added to a solution 
of Boc-L-cystine, previously prepared above, 93, (1.8 g, 4 mmol), isobutyl-imidoxine 
(875 mg, 8.58 mmol ), hydroxysuccimide (987 mg, 8.58 mmol) in THF (20 mL) was 
added at 0 °C over 15 min. The mixture which resulted was allowed to stir for 16 h while 
the temperature was allowed to warm to 20 °C. The mixture was then cooled to 0 °C and 
the precipitate which formed was removed by filtration. The filtrate was concentrated 
under vacuum and then dissolved into EtOAc (50 mL).  The small amount of precipitate 
which formed was filtered off. The organic layer was washed with a dilute aq solution of 
0.1 N sodium bicarbonate, brine, dried (anhydrous Na2SO4) and removed under reduced 
pressure to give Boc-L-cystine bis(acetamidoxime) ester as white crystals. This material 
was taken up in toluene (100 mL) and the mixture was heated at reflux for 3 h; the water 
which formed was removed by a Dean-Stark trap. The solvent was removed under 
vacuum and the residue was purified by flash chromatography (hexane/EtOAc = 9:1) to 
furnish white crystals in 73% yield as white solid. 104:  m.p. 130 ~ 131 °C. 1H NMR (300 
MHz, CDCl3): δ 1.33 (d, 6H, J = 4.5 Hz), 1.46 (s, 9H), 3.03-3.13 (m, 1H), 3.25 (d, 2H, J 
= 3Hz), 5.32 (s, br, 1H), 5.51 (s, br, 1H); 13C NMR (75.5 MHz, CDCl3): δ 20.2, 26.6, 
28.2, 42.1, 47.8, 80.8, 154.6, 175.0, 176.8. HRMS m/z C24N40N6O6S2 (M+H)+ calcd. 
573.2451, found 573.2445.  
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tert-Butyl (1R,1'R)-2,2'-disulfanediylbis(1-(3-methyl-1,2,4-oxadiazol-5-
yl)ethane-2,1-diyl)dicarbamate (105). 
 
The dicarbamate (105) was prepared in 50% yield following the above procedure 
for 104, except the solvent was replaced with DMF to dissolve actetamidoxine. 105: m.p. 
138 ~ 140 °C. 1H NMR (500 MHz, CDCl3): δ 1.40 (s, 9H), 2.35 (s, 3H), 3.23 (s, 2H), 
5.27 (s, 1H), 5.82 (s, 1H); 13C NMR (500 MHz, CDCl3): δ 11.8, 28.5, 42.2, 48.0, 81.0, 
155.2, 167.6, 176.7. HRMS m/z C24H40N6O6S2 (M + H)+ calcd 517.1903, found 517.1912. 
 
(1R,1'R)-2,2'-Disulfanediylbis(1-(3-methyl-1,2,4-oxadiazol-5-
yl)ethanamine) (106a). 
 
 TFA (5 mL) was slowly added to a solution of acetetamidoxine 105 (120 mg, 
0.23 mmol) in DCM (5 mL) which had been cooled to 0 °C.  The solution was allowed to 
gradually warmed to rt while stirring and then allowed to stir for 2 h until analysis by 
TLC (silica gel) indicated the starting material had disappeared. The solvent was 
removed under reduced pressure and the residue was dissolved in EtOAc (20 mL), 
washed with a saturated aq solution of sodium bicarbonate, brine and dried (anhydrous 
Na2SO4). The solvent was removed and ethyl ether (2 mL) was added into the oil which 
had formed. Ethyl ether saturated with anhydrous HCl gas was added at 0 °C until a 
white solid precipitated out. The solid was then collected by filtration and yielded the 
hydrochloride salt of 106a in 92% yield. 106a: 1H NMR (300 MHz, CDCl3): δ 2.40 (s, 
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3H), 3.07-3.16 (m, 1H), 3.26-3.34 (m, 1H), 4.55-4.59 (m, 1H); 13C NMR (75.5 MHz, 
CDCl3): δ 11.3, 43.9, 48.0, 167.1, 179.3. HRMS m/z C10H16N6O2S2 (M + H)+ calcd 
317.0854, found 317.0850. 
 
(1R,1'R)-2,2'-Disulfanediylbis(1-(3-isopropyl-1,2,4-oxadiazol-5-
yl)ethanamine) (106b). 
 
The oxadiazole (106b) was prepared in 89% yield following the procedure for 
preparation of 106a. 106b: 1H NMR (300 MHz, CDCl3): δ1.34 (d, 6H, J = 3Hz), 2.8 (br, 
2H), 3.08-3.15 (m, 1H), 3.26-3.34 (m, 2H), 4.70 (br, 1H); 13C NMR (75.5 MHz, CDCl3): 
δ 20.3, 28.0,, 44.1, 48.2, 170.5, 179.6. HRMS m/z C14H24N6O2S2 (M+H)+ calcd. 
373.1402, found 373.1418. 
 
Phenyl acetyl-S-trityl-L-cysteine (108g). 
 
A solution of phenylacetyl chloride (1.8 g, 12 mmol) in chlorform (20 mL) was 
added to a suspension of S-trityl-L-csyteine 9c (4.4 g, 12 mmol) in chloroform (92 mL) 
containing triethylamine (2.7 g, 26.4 mmol) cooled in ice.  The mixture which resulted 
was allowed to stir at 0–5 °C for 15 min. and then at rt for 24 hrs. Water was added (100 
mL) and the pH was adjusted to 1.5 with a 5 N aq solution of HCl. The aq phase was 
removed and the organic phase was washed with a saturated aq solution of sodium 
chloride (100 mL), dried (anhydrous Na2SO4) and concentrated in vaccuo to give a white 
crystalline solid (4.9 g) in 85% yield. 108g:  m.p. 60-62 °C ; [α]D = +21.8 ° (c 2, 
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CH3OH); 1H NMR (300 MHz, CDCl3): δ 2.60-2.71 (m, 2 H), 3.5 (s, 1 H), 4.15-4.23 (m, 1 
H), 5.92 (d, J =  6.48 Hz, 1 H), 7.21-7.33 (m, 20 H); );  13C NMR (75.5 MHz, CDCl3): δ 
32.9, 43.1, 51.4, 67.8, 126.8, 127.2, 127.4, 127.8, 127.9, 128.4, 128.9, 129.1, 129.4, 
144.1, 171.5, 172.5.  This material was used directly in the next step. 
  
N-Carbobenzoxy-S-trityl-L-cysteinylglycine ethyl ester (112e).  
 
Phenyl acetyl-S-trityl-L-cysteine 108g (4.8 g, 10 mmol) and N, N’-
dicyclohexycarbodiimide (2.1 g, 10 mmol) were added to a solution of glycine ethyl ester 
hydrochloride (1.25 g, 9 mmol) in chloroform (50 mL) and triethylamine (1.25 mL). 
After the mixture was allowed to stir at rt for 12 h, this was followed by addition of a few 
drops of 50% aq acetic acid and the insoluble precipitate of dicyclohexylurea (1.7 g) 
which formed was removed by filtration. The filtrate was washed with dilute solutions of 
0.1 N aq hydrochloric acid, 0.1 N potassium hydrogen carbonate and water, dried over 
anhydrous sodium sulfate and evaporated to dryness in vaccuo.  The residue was treated 
with EtOAc. Some undissolved material (dicyclohexylurea, 0.5 g) was filtered off and the 
filtrate was concentrated in vaccuo to a small volume. Crystalline 112e was filtered off in 
85 % yield. 112e:  m.p. 152 oC; 1H NMR (300 MHz, CDCl3): δ 1.23-1.32 (m, 3 H),  2.57-
2.62 (m, 2 H), 3.53 (s, 1 H), 3.87-3.91 (m, 2 H), 4.13 (d, J = 6.18 Hz, 1 H), 4.15-4.23 (m, 
2 H), 5.91 (d, J = 7.41 Hz, 1 H), 6.55 (s, 1 H), 7.21-7.45 (m, 20 H);  13C NMR (75.5 
MHz, CDCl3): δ 14.0, 33.0, 41.3, 43.3, 51.9, 61.4, 67.0, 126.8, 127.3, 127.9, 128.9, 
129.3, 129.5, 134.1, 144.3, 169.1, 169.9, 171.1. HRMS m/z C34H34N2O4S (M+H)+ calcd. 
567.2239, found 567.2245.  
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Bis-[(R)-ethyl 2-(3-mercapto-2-(2-phenylacetamido) 
propanamido)acetate]  (113e). 
 
The dimer (113e) was prepared in 72% yield following the procedure employed 
for preparation of dimer 1 and obtained as a yellow solid. 113e: m.p. 98 oC; 1H NMR 
(300 MHz, CDCl3);  δ1.27-1.31 (m, 1 H), 2.79-2.87 (m, 1 H), 3.00-3.07 (m, 1 H), 3.64 (s, 
2 H), 3.68-3.76 (m, 1 H), 3.96-4.16 (m, 1 H), 4.04-4.23 (m, 2 H), 5.52-5.58 (m, 1 H), 
6.56 (d, J = 9.15 Hz, 1 H), 7.25-7.35 (m, 5 H), 8.40-8.44 (s, 1 H); 13C NMR (75.5 MHz, 
CDCl3): δ 14.1, 41.1, 43.1, 46.3, 53.0, 61.2, 127.2, 128.6, 129.5, 134.2, 169.1, 170.5, 
171.5. HRMS m/z C30H38N4O8S2 (M+H)+ calcd. 647.2131, found 647.2136.  
   
N,S-Dibenzoyl-L-cysteine ethyl ester (115). 
 
Benzyol chloride (10 mL) was added to a solution of pure L-cysteine ethyl ester 
hydrochloride (7.5 g, 40 mmol) in pyridine (30 mL) precooled to 0 °C. After stirring for 1 
h at rt, the mixture was poured onto ice. The precipitate which formed was collected by 
filtration and was recrystallized from CH3OH in 88% yield (12 g). 115: m.p. 81 oC ; 1H 
NMR (300 MHz, CDCl3): δ 1.41 (t, J = 6 Hz, 3 H), 3.40-3.48 (m, 1 H), 3.68-3.75 (m, 1 
H), 4.15 (q, J = 7.11, 7.17 Hz, 2 H), 4.62-4.70 (m, 1 H), 7.48-7.57 (m, 5 H), 7.66-7.69 
(m, 1 H), 7.84-7.93 (m, 4 H), 9.02 (d, J = 7.8 Hz, 1 H); 13C NMR (75.5 MHz, CDCl3): δ 
14.4, 29.9, 52.6, 61.4, 127.2, 127.7, 128.7, 129.5, 132.0, 133.8, 134.5, 136.4, 166.8, 
170.5, 191.0; HRMS m/z C19H19NO4S (M+H)+ calcd. 358.1113, found 358.1106.  
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 (3S,6S)-3-Benzyl-6-(R)-3,6-dioxopiperazin-2-yl-methyl-disulfanyl-
methyl-piperazine-2,5-dione (132).  
 
The trityl protected diketopiperazine 27 (246 mg, 0.5 mmol) and diketopoperazine 
28 (201 mg, 0.5 mmol) were dissolved in a solution of CH2Cl2 (5 mL) and CH3OH (10 
mL) with stirring.  Pyridine (0.3 mL, 3.75 mmol) was then added to the mixture which 
resulted, followed by a solution of iodine (126 mg, 0.5 mmol) in CH3OH (3 mL).  The 
mixture was allowed to stir for 1 h at rt. No precipitate had formed by this time; however, 
analysis by TLC (silica gel) indicated that the reaction was proceeding slowly by the 
appearance of a new spot under the starting material (UV light).  A precipitate began to 
form within 2 h after concentrating the solution to a volume of 2 mL.  Methanol (5 mL) 
was added to result in a total volume of 7 mL. The solution was allowed to stir an 
additional 23 h and the precipitate was filtered off. The solid which formed was washed 
with cold CH3OH. The precipitate was filtered off and dried to yield dimer 132 as a 
yellow solid (120 mg, 60%) in > 95% pure form. 132: 1H NMR (300 MHz, DMSO-d6) δ 
2.89-2.91 (m, 2 H), 3.09-3.21 (m, 3 H), 3.33-3.87 (m, 4 H), 4.11 (s, 1 H), 4.21 (s, 1 H), 
7.13-7.36 (m, 5 H), 8.07 (s, 1 H), 8.32 (s, 2 H), 8.58 (s, 1 H); 13C NMR (75.5 MHz, 
DMSO-d6) δ 42.3, 42.6, 43.1, 44.7, 53.3, 54.2, 54.3, 55.8, 127.2, 128.2, 130.6, 136.4, 
165.9, 166.1, 166.5. HRMS m/z C17H20N4O4S2 (M+H)+ calcd. 409.0926, found 409.0932.  
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tert-Butyl-(R)-2-(2R,5R)-5-benzyl-3,6-dioxopiperazin-2-yl-methyl-
disulfanyl-1-(3-isopropyl-1,2,4-oxadiazol-5-yl)ethylcarbamate (133). 
 
The trityl protected diketopiperazine (29, 315 mg, 0.64 mmol) and bioisostere 
(94, 340 mg, 0.64 mmol) were dissolved in a solution of CH2Cl2 (5 mL) and CH3OH (10 
mL) with stirring.  Pyridine (0.4 mL, 5.12 mmol) was then added to the mixture which 
resulted, followed by a solution of iodine (357 mg, 1.4 mmol) in CH3OH (3 mL).  The 
mixture which resulted was allowed to stir for 1 h at rt until analysis by TLC (silica gel) 
indicated that the reaction was proceeding slowly by the appearance of a new spot under 
the starting material (UV light).  After allowing to stir for 2 h, the mixture was concentrated 
in vaccuo to a volume of 2 mL and CH3OH (5 mL) was added to result in a total volume 
of 7 mL. The solution was allowed to stir an additional 23 h and then washed with a 
saturated aq solution of sodium thiosulfate after which the solvent was removed under 
reduced pressure. The residue which resulted was dissolved in EtOAc (5 ~ 10 mL) and 
the precipitate which resulted was collected by filtration to yield the product as a white 
solid (or purified by preparative chromatography after washing with a low polar solvent) 
133: 1H NMR (300 NMR, DMSO-d6) δ 1.04 (d, 6H, J = 3Hz), 1.38 (s, 9H), 2.68-3.15 
(m, 6 H), 4.21 (s, 1H), 4.44-4.47 (m, 1H), 7.13-7.26 (m, 5 H), 8.13 (s, 1 H), 8.35 (s, 1 H), 
10.7 (s, 1 H); 13C NMR (75.5 NMR, DMSO-d6) δ 19.0, 28.5, 38.8, 43.2, 53.2, 55.1, 55.8, 
78.8, 127.1, 128.5, 130.6, 136.4, 155.7, 166.0, 166.5, 171.8, 177.5. HRMS (ESI, M++H, 
C24H33N5O5S2) calcd. 536.2001, found: 536.2019. 
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General Procedure for the Dealkylation of the Boc Group by 
Chlorotrimethylsilane/Sodium Iodide: (3R,6S)-3-(R)-2-Amino-2-(3-
isopropyl-1,2,4-oxadiazol-5-yl)ethyl-disulfanyl-methyl-6-
isopropylpiperazine-2,5-dione (134). 
 
These reactions were generally carried out on 1 mmol scale in a 10 mL flask 
which was flushed continuously with dry argon.  Chlorotrimethylsilane (27 mg, 0.25 
mmol) was added to a solution of the corresponding dimer 137 (0.25 mmol) and sodium 
iodide (37.5 mg, 0.25 mmol) in acetonitrile/dichloromethane (5 mL, 2:1) slowly with 
continuous stirring. The reaction mixture which resulted was allowed to stir at rt until the 
completion of the reaction indicated by analysis by TLC (silica gel). The solvent was 
removed under reduced pressure and the residue which resulted was dissolved in a mixed 
solvent (CH2Cl2/ CH3OH = 9:1). The solution was washed with small amount of a 
saturated aq sodium thiosulfate solution, brine and dried (anhydrous Na2SO4). The 
products were further purified by plate chromatography on silica gel (preparative TLC) to 
yield pure amine in over 85% yield. 134: 1H NMR (300 NMR, DMSO-d6) δ 0.86 (d, 3 H, 
J = 6.3 Hz), 0.96 (d, 3 H, J = 6.9 Hz),1.23-1.30 (dd, 6 H), 2.20-2.25 (m, 1 H), 3.10-3.19 
(m, 2 H), 3.28-3.30 (m, 2 H), 3.25-3.51 (m, 1 H), 3.51-3.57 (m, 1 H), 4.23 (s, 1 H), 5.09 
(s, 1 H), 7.09-7.42 (m, 1 H), 8.13-8.22 (m, 1 H). HRMS m/z C15H25N5O3S2 (M+H)+ calcd. 
388.1399, found 388.1401. 
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General Procedure for the Synthesis of Mixed Dimers using the 
Benzotriazole Method: [tert-Butyl 1-mercapto-2-(5-phenyl-1H-1,2,4-
triazol-3-yl)propan-2-ylcarbamate]-[(R)-tert-Butyl 2-mercapto-1-(5-
methyl-1H-1,2,4-triazol-3-yl)ethylcarbamate]-disulfide (135). 
 
Triazole monomer 100 (2 mmol) was added slowly under an inert atmosphere to a 
solution of benzotriazole (2 mmol) and chlorobenzotriazole (4 mmol) in dichloromethane 
(DCM) (15 mL) at -78°C with stirring. After stirring for 30 min, a solution of thiourea (6 
mmol) in anhydrous THF (5mL) was added and the mixture which resulted was allowed 
to stir for 30 min. The other triazole monomer 96 (2 mmol) in DCM was then added 
while the temperature was maintained at -78°C. The solution was allowed to stir for 18-
20 hr, while the mixture slowly warmed to rt. The solvent was removed under reduced 
pressure and the residue was dissolved in DCM followed by washing with water (30 mL 
x 3 times). The organic layer was dried (anhydrous Na2SO4) and the solvent was then 
removed under reduced pressure. The dimer was purified by flash chromatography (yield 
60-65%).  (VR-MD-01) (135): 1H NMR (300 MHz, CDCl3) δ 8.33-8.51 (d, 2H), 7.34 (s, 
3H), 5.30 (bs, 2H), 2.97 – 3.61 (m, 4H), 2.43 (s, 3H), 1.47 (s, 18H); HRMS (ESI, M++H, 
C25H37N8O4S2) calcd. 577.2379, found: 577.2369 and (M++Na, C25H36N8O4S2Na) calcd. 
599.2199, found 599.2194. 
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General Procedure for Deprotection of the Boc group and Formation of 
the HCl Salt of Mixed-Dimers: (R)-2-(R)-2-Amino-2-(5-methyl-1H-
1,2,4-triazol-3-yl)ethyl-disulfanyl-1-(5-phenyl-1H-1,2,4-triazol-3-
yl)ethanamine dihydrochloride (136). 
 
The BOC-protected mixed-dimer 135 (0.2 mmol) was dissolved in EtOH (5 mL) 
and a saturated solution of anhydrous HCl in EtOH (5 mL) was added. The mixture was 
allowed to stir for 2 h after which the solvent was removed under reduced pressure. The 
oily residue which formed was dissolved in distilled water (15 mL) and washed with 
DCM (3 x 10 mL) to remove organic impurities. The water was then removed under 
reduced pressure and the gummy residue was finally dried under high vacuum to obtain 
the solid hydrochloride salt (99% yield). (VR-MD-02) (136): 1H NMR (300 MHz, 
CDCl3) δ 7.74-7.76 (d, 2H), 7.47 (s, 3H), 4.88 (bs, 2H), 3.14 – 3.23 (m, 4H), 2.27 (s, 3H). 
 
tert-Butyl (R)-1-(3-isopropyl-1,2,4-oxadiazol-5-yl)-2-(2R,5R)-5-
isopropyl-3,6-dioxopipera-zin-2-yl-methyl-disulfanyl-ethylcarbamate 
(137).  
 
The ethyl carbamate (137) was prepared following the procedure described above 
for 133 by using the starting materials, bioisostere 94 and diketopiperazine 31.  137.: 1H 
NMR (300 NMR, DMSO-d6) δ 0.96 (d, 3 H, J = 6.6 Hz), 1.07 (d, 3 H, J = 7.2 Hz),1.34 
(s,3 H), 1.36 (s, 3 H), 1.48 (s, 9 H), 2.48-2.51 (m, 1 H), 2.84-2.92 (m, 1 H), 3.09-3.13 (m, 
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1 H), 3.28-3.30 (m, 2 H), 3.42-3.47 (dd, 1 H), 4.37 (s, 1 H), 5.38 (s, 1 H), 5.57 (s, 1 H), 
6.58 (s, 1 H), 6.82 (s, 0.33 H), 6.96 (s, 0.66 H); 13C NMR (75.5 NMR, DMSO-d6) δ 18.8, 
21.1, 26.8, 28.3, 31.4, 42.8, 47.9, 53.2, 60.3, 60.4, 81.1, 154.8, 166.8, 171.2, 175.2, 176.8.  
HRMS m/z C20H33N5O5S2 (M+H)+ calcd. 488.1923, found 488.1928. 
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I.   Introduction. 
1. General Background Information.  
 
GABAA/BzR chloride ion channels comprise the major inhibitory 
neurotransmitter system in the central nervous system (CNS).  This central role carries with 
it a direct influence on many diseases of the CNS.  Alterations in GABAA function from controls 
are known to occur in many anxiety disorders1-6 including panic disorder5, epilepsy,7a 
hypersensitive behavior,7b phobias6, schizophrenia8, alcoholism9, Angleman’s syndrome,7b and 
Rhett’s syndrome,10 as well as effects which lead to/or complicate drug abuse.11  GABA  
receptors are divided into three main classes: (1) GABAA receptors, which are members 
of the ligand-gated ion channel superfamily; (2) GABAB receptors,which are members of 
the G-protein linked receptor superfamily; and (3) GABAC receptors, also members of the 
ligand-gated ion channel superfamily, but their distribution is confined to the retina.12 
Benzodiazepine receptor ligands do not bind to GABAB and GABAC receptors, but only 
to an allosteric modulatory site on GABAA receptors.13 
  
 The GABAA /BzR chloride ion channel is a pentameric protein polymer mainly 
constructed from α, β, and γ subunits.13  A total of 21 subunits, 8 different types (6α, 4β, 
4γ, 1δ, 1pi, 1θ, 1ε and 3ρ) have been cloned and sequenced from the mammalian CNS.14-
16
  The exact subunit composition of most GABAA receptors is now known.  All these 
polypeptides possess an approximate molecular mass of 50 kD and are structurally 
related.  Each subunit consists of a large extracellular region, which contains several 
potential glycosylation sites and a characteristic “cys-loop” formed by a covalent bond 
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between two conserved cysteines.  This extracellular region is also important because of 
its contribution to the agonist GABA and modulatory benzodiazepine binding sites.  The 
protein then traverses the lipid bilayer four times and has a large intracellular loop located 
between transmembrane regions 3 and 4 (M3 and M4).  This intracellular region contains 
possible phosphorylation sites necessary for regulation of the receptor.  The homology 
within each subunit class is about 60 – 80 %, while the homology between subunit 
classes is about 30 – 40 %.  Depiced in Figure 1 is the proposed topology of a single 
GABAA receptor subunit.  The pentameric structure of a ligand-gated ion channel is 
shown in Figure 2.17-19  
 
Figure 1. Proposed topology of a GABAA receptor subunit. The extracellular 
domain begins with the N-terminus and M1-M4 represent the four transmembrane 
domains.  Figure reprinted with permission.17, 19 
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Figure 2. Longitudinal (A) and cross-sectional (B) schematic representations of a 
ligand-gated ion channel.  The numbers 1-4 refer to the M1-M4 segments.  The 
M2 segment contributes to the majority of the pore lining within the membrane 
lipid bilayer.  Figure reprinted with permission.18, 22 
 
 
 
 Studies by molecular cloning have shown that at least 3 types (2α, 2β and 1γ) of 
subunits are required to construct a fully functional recombinant GABAA/BzR chloride 
channel which mimics the biological, electrophysiological and pharmacological 
properties of native GABAA/BzR chloride channels.20, 21  It would be most desirable if 
each subtype only interacted with specific molecules [the α and β subunits are involved in 
the interaction with GABA, whereas the α and γ subunits are proposed to contain the 
binding site for benzodiazepines located between them (see Figure 3)]. 
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Figure 3. Absolute subunit arrangement of the α1β2γ2 GABAA receptor 
when viewed from the synaptic cleft.  The GABA binding sites are located at 
the β+α- subunit interfaces and the Bz modulatory binding site is located at 
the α+γ- subunit interface.  The part of the schematically drawn subunits 
marked by the + indicates loop C of the respective subunits.22, 23 
 
 
 
  
Before the cloning of the GABAA receptor gene family, the benzodiazepine 
binding site was historically subdivided into two subtypes, BENZODIAZEPINE1 and 
BENZODIAZEPINE2, on the basis of radioligand binding studies on synaptosomal rat 
membranes.24  The BENZODIAZEPINE1 subtype has been shown to be 
pharmacologically equivalent to a GABAA receptor comprising the α1 subunit in 
combination with a β subunit and γ2 subunit.  This is the most abundant GABAA receptor 
subtype and is believed to represent almost half of all GABAA receptors in the brain, as 
stated.25-27 
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 Subtype assemblies which contain an α1 subunit (α1β2/3γ2) are present in most 
areas of the brain and are thought to account for 40-50% of GABAA  receptors in the rat 
brain.28  Subtype assemblies containing α2 and α3 subunits, respectively, are thought to 
account for about 25% and 17% of the GABAA  receptors in the rat brain, respectively.  
Subtype assemblies containing an α5 subunit (α5β3γ2) are expressed predominately in 
the hippocampus with some in the spinal cord and are thought to represent about 5% of 
GABAA receptors in the rat brain.14, 29-35 
 
 As indicated above, two other major populations are the α2β(2/3)γ2 and α3β(2/3)γ2 
subtypes.  Together these constitute approximately 35% of the total GABAA  receptor 
population.28  Pharmacologically this combination appears to be equivalent to the 
BENZODIAZEPINE2 subtype as defined previously by radioligand binding on 
synaptosomal membranes, although the BENZODIAZEPINE2 subtype may also include 
certain α5-containing subtype assemblies.24 The exact physiological role of these 
subtypes has hitherto been unclear because no sufficiently selective agonists or 
antagonists were known.14, 36 
 
 A characteristic property of all known GABAA receptors is the presence of 
a number of modulatory sites, one of which is the benzodiazepine binding site.36  The 
benzodiazepine binding site is the most explored of the GABAA receptor modulatory 
sites.  The 1, 4-benzodiazepines, which are employed to treat anxiety disorders as well as sleep 
disorders, exhibit anxiolytic, anticonvulsant, muscle relaxant/ataxic, sedative-hypnotic and 
amnestic effects.1-11, 37   In general, BDZs as a class offer many benefits as drug therapy.38 
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For example, they are rapidly absorbed from the gastrointestinal tract and normally reach 
maximum blood concentrations within one to two hours of ingestion.  They readily cross 
the blood-brain barrier, and are rapidly distributed within the brain.  Electrophysiological 
changes attributed to certain BDZs can be detected as early as five minutes after 
intravenous injection.39  At clinically relevant doses the BDZs do not induce significant 
liver microsomal enzymes that often can result in drug-drug interactions.40 
  
 In general, benzodiazepines lack serious toxicity even when overdosed.41, 42  
Unfortunately, BDZs produce many side effects such as drowsiness, somnolence, fatigue, 
ataxia, lethargy, sedation, muscle-relaxation, amnesia and tolerance to the anticonvulsant 
effects which limit their use as chronic anticonvulsant agents.41, 43-44  These side effects 
along with the issue of tolerance, which develops from the extended use of these agents 
both in animal models and patients, has been studied in detail.41-47 
  
 The principal composition of GABAA/BzR subtypes is defined as α1β3γ2, α2β3γ2, 
α3β3γ2, α4β3γ2, α5β3γ2, and α6β3γ2; however, in many cases the β3 subunit has been 
replaced with a β2 subunit with no loss in BzR binding or efficacy.16, 48-50  The distinct 
cellular and subcellular location of individual receptor subtypes suggests that they exhibit 
specific functions in the brain that can be selectively modulated by subtype specific 
drugs.51  A few ligands from the classes of the 1,4- benzodiazepines and the 3-
substituted-β-carbolines have been shown to exhibit some α1, α5 or α4/α6 subtype 
selectivity and serve as lead compounds in many studies.52-55  The synthesis of new 
compounds which are capable of modulating responses produced by the above receptors 
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has been made possible by the development of an isoform model of the 
GABAA/benzodiazepine receptor complex as well.14,36, 56, 57 
  
 The ligands which interact at the GABAA/BzR binding site comprise three 
types: positive allosteric modulators (agonists), negative allosteric modulators (inverse 
agonists) and antagonists, all of which can bind with high affinity.58  Agonist binding to 
the receptor opens an intrinsic chloride ion channel, typically hyperpolarizing the cell 
membrane or at least opposing depolarization, thereby inhibiting neuronal transmission.  
Benzodiazepine BS ligands such as diazepam (Valium), chlordiazepoxide (Librium) and 
alprazolam (Xanax) are allosteric modulators, unable to induce channel openings 
themselves, but function to vary the frequency and not the channel opening times.59, 60  
Positive allosteric modulators at the benzodiazepine binding site (agonists) increase this 
frequency, while negative allosteric modulators (inverse agonists) decrease the frequency.  
Currently, it is not clear whether benzodiazepine BS ligands allosterically modulate 
GABA affinity or channel gating.  Recent studies61 support the view that high-affinity 
classical benzodiazepines modulate α1β2γ2 GABAA receptors via allosteric coupling to 
channel gating.62, 63  Further studies are needed to determine whether the mechanism of 
modulation varies in different receptor subtypes. 
  
 The concept of receptor multiplicity has been extremely valuable in that different 
receptor subtypes reside within anatomically distinct regions of the brain and are 
responsible for different physiological and pathological processes (Table 1).51, 64-65 
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These distinctions have thus become a motivation for the design of subtype selective 
ligands in order to elicit a single specific response.51, 66-73  Differences observed in the 
action of such drugs may be due to subtype-selective affinity and absolute and/or relative 
subtype-selective efficacy.74   Development of ligands with selective efficacy at one or 
more receptor subtypes and/or ligands with selective binding affinity at one receptor 
subtype will result in a better understanding of which subtype mediates which neuronal 
response.75  
  
Table 1. Action of benzodiazepines at GABAA  α(1-6)β3γ2 receptor subtypes.87 
 
Subtype Associated Effecta 
α1 Sedation, anterograde amnesia, some anticonvulsant 
action, ataxia; in large part, addiction 
α2 Anxiolytic, hypnotic (EEG), anticonvulsant and some 
muscle relaxation (at higher doses) 
α3 Anxiolytic action, some muscle relaxation at higher doses 
α4 Diazepam-insensitive site 
α5 Cognition, temporal and spatial memory  
(maybe memory component of anxiety) 
α6 Diazepam-insensitive site 
a) Updated at ISHC meeting Scotland, Glasgow, August, 2011.  
 
 Overall, the design, synthesis and biological evaluation of αxβ3(or β2)γ2 (x=1-6) 
subtype selective agents will provide the pharmacological tools necessary to determine 
which GABAA/BzR subtype mediates which physiological response.75  This will also 
provide entry into potential therapeutic agents to treat anxiety disorders, sleep disorders, 
epilepsy, enhance cognition in age-associated memory impairment in the absence of 
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deleterious side effects, as well as provide a potential new approach to treat drug 
addiction.14, 56, 76 
  
 It is now believed that agents acting as benzodiazepine agonists at GABAA/α2, 
GABAA/α3, and/or GABAA/α5 receptors (schizophrenia) will possess desirable CNS 
properties.  Ligands which are modulators of the benzodiazepine binding site of the 
GABAA receptor by action as benzodiazepine agonists are referred to hereinafter as 
“GABAA receptor agonists.”  The GABAA/α1-selective (α1β2γ2) agonists alpidem and 
zolpidem are clinically prescribed as hypnotic agents, suggesting that at least some of the 
sedation associated with known anxiolytic drugs which act at the BENZODIAZEPINE1 
binding site is mediated through GABAA receptors containing the α1β2γ2 subunit. 
 Accordingly, it is felt GABAA/α2, and GABAA/α3 receptor agonists rather than 
GABAA/α1 agonists will be effective in the treatment of anxiety or convulsant disorders 
with a reduced propensity to cause sedation.57 Also, agents which are antagonists or 
inverse agonists at α1 receptors might be employed to reverse sedation effected by α1 
agonists.77 
  
 The GABAA/BzR receptors which contain the α5 subunit are of minor abundance 
(5%) in the whole brain, but are significantly expressed in the hippocampus, where they 
comprise 15-20% of the diazepam-sensitive GABAA  receptor  population51, 56, 78 and  are  
predominantly coassembled with β3 and γ2 subunits.32, 51  This has been confirmed by in 
situ hybridization and immunohistochemical studies which indicated that the 
hippocampus was relatively enriched in α5 containing GABAA receptors compared to 
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other brain areas.78,79  Interest in BzR/GABAA α5 subtypes has been stimulated recently 
by the report of Möhler et al.29, 80 on α5 ″knock in″ mice.  In brief, this group has 
provided strong evidence that hippocampal extrasynaptic α5 GABAA receptors play a 
critical role in associative learning and memory. 29, 80 
  
  In addition, an α5 subtype selective  inverse  agonist was shown by Bailey et al.76 
to be important in the acquisition of fear conditioning and provided further evidence for 
the involvement of hippocampal GABAA/benzodiazepine receptors in learning and 
anxiety.30  A selective α5 inverse agonist81 might have therapeutic utility as an agent  to  
enhance cognition without the unwanted side effects associated with activity at other 
receptor subtypes.30,81-82  Most drugs currently used in the treatment of cognitive 
deficiency act through the cholinergic system and have moderate clinical efficacy.  The 
GABAA α5 subtype selective inverse agonists may offer an alternative mechanism for the 
symptomatic treatment of memory impairment associated with Alzheimer's disease and 
related dementias.3,56,83-84   This has later been supported by the work of DeLorey et al. 
with α5 selective inverse agonists,82 and antagonists as well as by Mckernan et al. and 
Atack et al.85-86 Recently, Savic et al have published several papers on PWZ-029, an α5 
subtype selective partial inverse agonist, which enhanced cognition in the passive 
avoidance paradigm (hippocampal-driven) in the Morris water maze and other 
paradigms.87 
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2. Molecular Modeling. 
  
 In recent years a unified pharmacophore/receptor model for agonists, antagonists 
and inverse agonists at the Bz BS was developed using the techniques of chemical 
synthesis, radioligand binding and receptor mapping.88-89  The overlap of these different 
modulators within the Bz BS has been supported by experimental data.90-92  Using this 
ligand-based pharmacophore/receptor model and the α1β2γ2 GABAA receptor models,23, 
93
 the experimental data of recent and past years have been evaluated and definite trends 
with regard to the orientation of the regions of the protein relative to the descriptors of the 
pharmacophore/receptor model have been identified and are presented in this work.  The 
need to define such an orientation has been established,94 since it permits inspection of 
ligand docking studies and the identification of possible roles specific residues may have 
within the benzodiazepine BS.  These roles may then be explored in future studies 
involving covalent labeling, site-directed mutagenesis and structure-activity relationships, 
all of which contribute to the rational design of subtype specific modulators of the 
benzodiazepine BS of GABAA  receptors. 
  
 More than 166 agonists, antagonists and inverse agonists at the benzodiazepine 
BS,88, 89 which encompassed 15 structural families, were used for generating the unified 
pharmacophore/receptor model.87  Although the relative affinities, efficacies and 
functional effects displayed by various ligands from the same structural class at the 
diazepam sensitive and diazepam insensitive benzodiazepine binding sites were taken 
into account, the approximate locations of descriptors (hydrogen bond donor sites, 
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hydrogen bond acceptor sites, lipophilic regions, and regions of steric repulsion) were 
based primarily on in vitro binding affinities.  Ligands from different structural classes 
were then superimposed on each other to satisfy the same descriptors, which resulted in 
the unified pharmacophore receptor model.22   Briefly, the pharmacophore/receptor model 
consists of two hydrogen bond donating descriptors (H1 and H2), one hydrogen bond 
acceptor descriptor (A2) and one lipophilic descriptor (L1).  In addition to these 
descriptors, there are lipophilic regions of interaction (L2, L3 and LDi) as well as regions 
of negative steric repulsion (S1, S2 and S3).  While occupation of L2 and/or L3 as well as 
interactions at H1, H2, and L1 are important for positive allosteric modulation, inverse 
agonists only require interactions with the H1, L1, and A2 descriptors of the 
pharmacophore/receptor model for potent activity in vivo.89, 95-98  The LDi descriptor is a 
region of lipophilic interaction, for which the difference between the diazepam sensitive 
(DS) and the diazepam insensitive (DI) subtype pharmacophore receptor models is most 
pronounced.  Depicted in Figure 4 are the relative locations of the different descriptors 
and regions of the model. 
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Figure 4. Relative locations of the descriptors and regions of the unified 
pharmacophore/ receptor model.  The pyrazolo[3,4-c]quinolin-3-one CGS-9896 
(dotted line), a diazadiindole (thin line), and diazepam (thick line) aligned within 
the unified pharmacophore/receptor model for the Bz BS.  H1 and H2 represent 
hydrogen bond donor sites within the Bz BS while A2 represents a hydrogen bond 
acceptor site necessary for potent inverse agonist activity in vivo.  L1, L2, L3 and 
LDi are four lipophilic regions and S1, S2, and S3 are regions of negative steric 
repulsion. LP = lone pair of electrons on the ligands. 
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 Moreover, pharmacophore/receptor models for 6 recombinant GABAA/ BzR 
subtypes (αxβ3γ2, x = 1-6) have been established via an SAR ligand mapping approach 
(Figure 5).81, 83   This study was based on the affinities of 166 BzR ligands at 6 distinct 
(α1-6β3γ2) recombinant GABAA/BzR receptor subtypes; the ligands were taken from at 
least twelve different structural families.  Examination of the included volumes indicated 
that the shapes of binding pockets for α1, α2 and α3 subtypes are very similar to each 
other.  Region L2 for the α5 containing subtype appeared to be larger in size than the 
analogous region of the other receptor subtypes.  Region LDi, in contrast, appeared to be 
larger in the α1 subtype than in the other subtypes.34, 57, 85, 99-100  Moreover, region L3 in 
the α6 subtype is either very small or nonexistent in this diazepam insensitive “DI” 
subtype as compared to the other subtypes (see Figure 5 for details).  Preliminary results 
for the α4-containing receptor subtype (DI) indicated that region L3 in the α4 subtype 
suffered a similar fate.  With the aid of these models, several series of ligands have been 
prepared and evaluated pharmacologically to determine the extent of interactions at 
different anchor points individually and/or simultaneously in order to search for GABAA/ 
benzodiazepine receptor subtype selective ligands. 
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Figure 5. Orthogonal views of the overlap of the included volumes of the 
pharmacophore/receptor models for α1β3γ2 and the other five receptor subtypes 
(α2β3γ2, α3β3γ2, α4β3γ2, α5β3γ2, and α6β3γ2, respectively). 
 
 
  
The pharmacophore models have been incorporated into a homolosy model of the 
α1β3γ2 subtype, the model for WYS8 (α1β3γ2) and recently expanded by Ernst ad 
Sieghart in 2012.87a-d  The refined receptor binding model by Sieghart and Ernst is very 
In grey is the included volume of the  α1 subtype
while depicted in black is the volume of the  α2 
subtype.
In grey is the included volume of the  α1 subtype
while depicted in black is the volume of the  α3 
subtype.
In grey is the included volume of the  α5 subtype
while depicted in black is the volume of the  α1 
subtype.
In grey is the included volume of the  α1 subtype
while depicted in black is the volume of the  α4 
subtype.
In grey is the included volume of the  α1 subtype
while depicted in black is the volume of the  α6 
subtype.
In grey is the included volume of the  α4 subtype
while depicted in black is the volume of the  α6
subtype.
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similar to that reported by Cook87a-d and provides much of the insight into design of new 
ligands in this research.  
 
3. Objectives of This Research. 
 
 One goal of this research was to design a quick and easy method to prefect the 
synthesis of benzodiazepines by allowing the reactions to be scaled up to multigram to 
kilogram size reactions, which has been accomplished.  Another goal of this research was 
to reduce liver metabolism, increase bioavailabilty and increase duration of action of the 
imidazo benzodiazepines, Xe-II-053 and HZ-166, the former of which was in Phase I 
trials (BMS) as an anxiolytic several years ago. The commonly present ester moiety on 
most imidazo benzodiazepines is often responsible for the increase in liver metabolism, 
low bioavailability and decreased duration of action. The ester moiety is rapidly 
metabolized to the carboxylic acid by serum (rats, mice) and hepatic enzymes (humans); 
afterwhich, the carboxylic acid metabolite undergoes further metabolism by hepatic 
enzymes, CYP-450’s, to the acyl glucuronide, which in turn hinders passage through the 
blood-brain barrier and the metabolite form is rapidly excerted by the body.  Replacement 
of the ester with a series of ester bioisosteres should provide ligands with much better 
pharmacokinetic properties and microsomal stability.  
 
 The term "bioisostere" refers to a compound which results from the exchange of 
an atom or of a group of atoms with another, broadly similar, atom or group of atoms.  
Such an exchange is termed a "bioisosteric replacement" and is useful to create a new 
293 
 
compound with similar biological properties to the parent compound but with much 
better pharmacokinetic properties.  The bioisosteric replacement may be 
physicochemically or topologically based.  Boisosteric replacement generally enhances 
desired biological or physical properties of a compound without making significant 
changes in chemical structure.  For example, the replacement of a hydrogen atom with a 
fluorine atom at a site of metabolic oxidation in a drug candidate may prevent such 
metabolism from taking place.  Because the fluorine atom is similar in size to the 
hydrogen atom the overall topology of the molecule is not significantly affected, leaving 
the desired biological activity unaffected.  However, with this retarted pathway for 
metabolism, the drug candidate may have a longer half-life.  Another example is aromatic 
rings, a phenyl -C6H5 ring can often be replaced by a different aromatic ring such as 
thiophene or naphthalene which may improve efficacy or change binding specificity of a 
respective bioisostere. 
 
Since α1β3γ2 GABAAergic subtypes are principally responsible for the sedative, 
ataxic and amnestic side effects of benzodiazepine receptor ligands as well as abuse 
potential,87a-d,101, 102  poor affinity and/or efficacy at these subtypes are a requirement here 
for ligands.  Based on molecular modeling 22 and the ability of BzR ligand PWZ-029 to 
enhance cognition,102-103 a series of new subtype selective ligands which had been 
previously designed and synthesized were converted into ester related bioisosteres.  
Furthermore, recently developed non-sedating anticonvulsants that target specific α2 or 
α2/α3 GABAA receptor subtype(s) involved in mediation of the anticonvulsant action but 
not the sedative action3, 104 were also converted into ester related bioisosteres in order to 
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study the stability on liver microsomes. The selectivity for GABAA receptor-subtypes 
may be achieved by selective efficacy.1 Those ligands which are agonists with subtype 
selectivity for α2- and α3-GABAA receptors that also have reduced agonistic and/or 
exhibit antagonistic activity at α1-GABAA receptors should provide ligands with 
analgesic, anxiolytic, and anticonvulsant properties, but with reduced sedative, ataxic and 
amnestic side effect, as well as little or no abuse lability.3, 104 
 
II.   Results and Discussion. 
1.1. An Improved Process for the Synthesis of 4H-Imidazo-[1,5-a]-[1,4]-
Benzodiazepines. 
 
 Imidazo[1,5-a][1,4]benzodiazepines are well documented to exhibit potent 
activity at GABAA/Bz receptors.  This series belongs to one of the very few chemical 
families which have been extensively investigated for GABAA/Bz receptor mediated 
activity.22, 105  Flumazenil (Ro 15-1788), an imidazo[1,5-a][1,4]benzodiazepine, was 
earlier shown to bind to central GABAA receptors with little or no intrinsic agonist 
activity,  but with the ability to block the activity of an agonist or inverse agonist at 
GABAA/Bz receptors.105  It is employed principally as an antidote to reverse the effects 
of exogenous benzodiazepines.106  More recently ligands such as flumazenil have been 
shown to behave as weak inverse agonists or weak agonists depending on the biological 
paradigm employed.  Many procedures have been reported, to date, to synthesize this 
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imidazo-type of structure.107-108  Most of them have been achieved in low yield through 
an iminophosphate/chloride intermediate. 
  
 As part of a program directed toward the development of clinically relevant 
imidazo[1,5-a][1,4]-benzodiazepines,22, 109  the construction of the imidazo-ring was 
considered a crucial step for the synthesis of gram quantities of imidazobenzodiazepine 
analogues.  The previous process of using ethyl isocyanoacetate and 
iminophosphorochlorides/chlorides110-111 was employed coupled with different solvents 
and bases, but the yields of these reactions were very low (15-30%).  Since this step was 
highly convergent and at the very end of the synthetic route, it affected the overall 
economy of the route in a deleterious manner.  It was, therefore, of interest to improve 
the annulation sequence for this series of CNS-active ligands. 
  
 Certainly, a one-pot annulation process for the construction of 
imidazobenzodiazepines had been developed. 110-111   This procedure permitted the 
condensation of the less stable iminophosphates with ethyl isocyanoacetate under basic 
conditions without isolation of the less stable iminophosphates and the pre-formation of 
the carbanion of ethyl isocyanoacetate.  For instance, Watjen et al.110a had reported the 
formation of iminophosphates by using NaH or LDA in DMF, and then directly reacting 
this mixture with ethyl isocyanoacetate and potassium tert-butoxide to offer the imidazo 
molecules in 47% yield.  Ian Fryer et.al.110 b, c  had reported the use of  potassium tert-
butoxide as the base in both steps, and DMF as well as THF were chosen as solvents in 
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these cases; however, this process gave the ligands in only 44% yield.  The latest report 
from Fryer’s procedure gave the target imidazobenzo framework in only 30% yield.111  
 
1.2. Scope and Limitations. 
 
 To improve the one-pot annulation reaction the procedure was modified and after 
many attempts it was found the ratio of the reagent combination and reaction temperature 
were critical for good yields on a consistent basis.  As shown in Scheme 1, the initial 
amount of potassium tert-butoxide used to form the iminophosphates should be kept at 
1.1 equivalents as compared to the amides (1a-k).  The yield of the reaction was much 
lower if more potassium tert-butoxide (>1.1 equivalents) was employed.  The amount of 
diethyl chlorophosphate (used as received) employed was only slightly higher (1.3 
equivalents) than the potassium tert-butoxide to convert all the starting amide into the 
desired iminophosphates (2a-k).  Importantly, the addition of ethyl isocyanoacetate, 
followed by the second addition of potassium tert-butoxide should be carried out at low 
temperature (-35oC is recommended).  However, a temperature lower than -35oC (such as 
-78oC) was also acceptable in this procedure and the second addition of potassium tert-
butoxide was kept at 1.1 equivalents.  This procedure made the separation of the product 
much easier, which was critical for gram scale reactions.  Most of the desired 
imidazobenzodiazepines were precipitated from diethyl ether after workup for no 
chromatography was needed.    
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Scheme 1 
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 A variety of different amidobenzodiazepines (1a-h) were chosen as substrates for 
this study (See Table 2).  The 5-phenyl-benzodiazepines (1a-f) and N-methyl-6-oxo-
benzodiazepines (1g-h) readily condensed with ethyl isocyanoacetate to give the desired 
imidazobenzodiazepines (3a-k) in 70-89% yield in this improved process.  The 
substituents in ring-A such as F, Cl and Br of 1a-h did not affect the yield of the process.  
The chiral α-substituted amidobenzodiazepines (1c-e, and 1i), which are more hindered 
than their unsubstituted parents (1a-b and 1f-1j), also gave the imidazo analogues in 70-
81% yield.  In the case of optically active substrates (1c-e, and 1i), this procedure 
provided the desired imidazo analogues without loss in optical activity.  The R and S 
isomers have much different BzR/GABAergic receptor binding profiles.112  All of these 
reactions can be scaled up with no difficulty.  When this process was employed for 
reactions of tert-butyl isocyanoacetate, the corresponding imidazobenzodiazepine 3k was 
obtained in 70% yield.  
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Table 2. Examples of imidazo-[1,5-a]-[1,4]-benzodiazepines obtained using the new 
procedure.113 
 
Starting material           Product                                                Yield(%)       Scale(g)    
1a                                    3a                                                          87                     11 
 
 
 
1b                                    3b                                                          77                     15    
 
 
 
1c                                    3c                                                           74                     10 
 
 
 
1d                                    3d                                                           73                    3.6 
 
 
1e                                     3e                                                           72                      1 
 
 
 
 
1f                                     3f                                                            75                     5 
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Table 2 (continued). Examples of imidazo-[1,5-a]-[1,4]-benzodiazepines obtained using 
the new procedure.113 
Starting material           Product                                                Yield(%)       Scale(g)    
1g                                    3g                                                          75                    2 
 
 
 
1h                                    3h                                                          89                  15    
 
 
 
1i                                      3i                                                          81                  15 
 
 
 
1j                                     3j                                                          72                  15 
 
 
1k                                    3k                                                          70                 20 
 
 
 In summary, an efficient, practical, improved, one-pot annulation reaction for the 
construction of potent BzR active imidazobenzodiazepines was developed.  A variety of 
substrates were successfully employed in this procedure.  This one-pot process required 
neither the isolation of the unstable intermediates nor does it require the preformation of 
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the carbanion of the isocyanacetate.  Moreover, potassium tert-butoxide is safer and 
easier-to-handle for scale-up, as compared to other bases such as NaH, LHMDS and 
LDA.  In addition, no chromatography was required for this process.113 
 
2.  Synthesis of the Bioisosteric Imidazobenzodiazepine EMJ-I-026 (5) 
and Analogues for Lead Compounds. 
 
 The ethyl ester 4 (XHe-II-053), lead compound, was treated with sodium hydride 
and N´-hydroxyisobutyrylimidamide in the presence of dry THF and dried 4Ao molecular 
sieves to provide the isopropyl bioisostere 5 (EMJ-II-026) in 45% yield, as shown in 
Scheme 2. Other bioisosteric analogues, such as the methyl bioisostere 6 (EMJ-I-024) 
and ethyl bioisostere 7 (EMJ-I-025) was also synthesized using the same method.  
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 Binding affinity at αxβ3γ2 GABAA/BzR subtypes for EMJ-I-026 (5) 
 
 
 
 
Values are reported in nM. ND = Not Determined. 
 
 
 The C-3 substituted ligand EMJ-I-026 (5) is a classical bioisostere of the orally 
active, nonsedating, anxiolytic XHE-II-053 (4).  Because this α2/α3 Gabaergic receptor 
subtype selective ligand, XHE-II-053, was anxiolytic in rodents, dogs and primates with 
no sedative, amnestic, or ataxic side effects, it was decided to make C-3 ester analogues 
for SAR studies.  Such alpha2/alpha3 Gabaergic receptor subtype selective ligands 
considered here would lack ester linkages and would be less sensitive to hydrolysis by 
esterases in animals or humans.  The compound, EMJ-I-026, exhibited selective efficacy 
for the GABAA/α2, GABAA/α3, and/or GABAA/α5 receptors relative to the GABAA/α1 
receptors (see Figure 6).  This isopropyl bioisostere 5 desirably exhibited functional 
α1 α2 α3 α4 α5 α6 
5000 135 1027 ND 152 5000 
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selectivity at α2, α3 and α5 subtypes with very little efficacy at α1β2γ2 subtypes at 100 
nM (physiologically relevant concentration).  In mice (light/dark paradigm) it 
demonstrated anxiolytic activity with sedative activity due to decreased efficacy at 
GABAA/α1 receptors when given i.p.    
 
 Gabaergic receptor subtype selective anxiolytics act preferably by selectively or 
preferentially activating (as agonists or partial agonists) the GABAA/α2 receptors and/or 
GABAA/α3 receptors as compared to the GABAA/α1 receptors.  A selective or 
preferential therapeutic agent will exhibit less binding affinity or less functional efficacy 
at GABAA/α1 receptors, as compared to the GABAA/α2 or GABAA/α3 receptors. 
Alternatively, the agent might bind to GABAA/α1, GABAA/α2 and GABAA/α3 receptors 
with a comparable affinity but exerts preferential efficacy of receptor activation at 
GABAA/α2 and GABAA/α3 receptors, as compared to the GABAA/α1receptors.  In fact, 
in the case of XHe-II-053, this ligand had no efficacy at this GABAA/α1receptors subtype 
and was probably an antagonist at this subtype, a very desirable profile. 
 
 
2.1. In Vitro Electrophysiological Studies on EMJ-I-026 (5) for Efficacy 
at BzR/GABAergic Subtypes. 
 
The efficacy of EMJ-I-026 (5) on GABAA receptors was assessed (Ramerstorfer 
et al.)114  by two-electrode voltage clamp experiments in the cRNA injected Xenopus 
oocytes that functionally expressed several subtype combinations of GABAA 
receptors.114-118   Data from the electrophysiology indicated (in oocytes) at physiological 
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concentrations (100 nM, -7) that EMJ-I-026 (5) was an agonist at α2, α3, and α5 subtypes, 
but was nearly silent at α1 subtypes.  This, as mentioned, was a very desirable profile.  At 
higher concentrations of EMJ-I-026 (5; 1-10 µM) this ligand was a potent agonist at α2, 
α3 and α5 subtypes with weak agonist efficacy at the less desirable α1 subtypes.  This 
ligand (EMJ-I-026 5) exhibited more than 10-fold selective efficacy for the GABAA/α2, 
GABAA/α3, and/or GABAA/α5 receptors relative to the GABAA/α1 receptors (refer to 
Figure 6).  This compound also exhibited functional selectivity in vivo, for it 
demonstrated anxiolytic activity with no sedative/ ataxic effects due to decreased efficacy 
at GABAA/α1 receptors.  Because this agent was a nonsedating anxiolytic in vivo in 
rodents and the ester bioisostere should be more stable in vivo, this ligand is under study 
in a primate “conflict” model as an anxiolytic.  
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Figure 6. Oocyte Efficacy and In Vitro Receptor Binding Data of EMJ-I-026 (5).  The 
log[M] at -7 is close to physiologically relevant concentrations of EMJ-I-026. 
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values are reported in nM. ND = Not Determined. 
 
Figure 6 is continued on the next page. 
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Figure 6. Continued. 
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Values are reported in µM, n = 3-4 oocytes. 
 
 
 10nM  100nM  1µM  10µM  
α1  103±4  107±4  150±10 268±13 
α2  112±4  160±3  281±13 429±31 
α3  119±8  195±5   381±45 581±25 
α5  110±5  175±66 291±13 432±33 
 
Figure 6 is continued on the next page. 
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Figure 6. Continued. 
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2.2. The Light/Dark and Locomotor Activity Assay on EMJ-I-026 (5). 
 
The light/dark assay was a test that was used to measure “anxiolytic-like behavior” 
in rodents.  Increased time spent in the light area compared to vehicle indicated anti-
anxiety effects.  DZ represents the diazepam control.  Diazepam was significantly 
anxiolytic as compared to vehicle, as expected.  Doses (1, 10 and 100 mg/kg) of the EMJ-
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I-026 (22) ligand showed significant anxiolytic activity at 10 and 100mg/kg.  Locomotor 
activity was a measure of the animal’s activity related to sedation, but not a direct 
measure of sedation; even though many laboratories use “suppression of locomotor 
activity” as a measure of sedation.  DZ again represents the diazepam control.  DZ 
significantly reduced locomotor activity over vehicle, i.e. an indicator of sedation, while 
EMJ-I-026 at doses of 10 and 100mg/kg significantly increased locomotor activity (refer 
to Figure 7).  From this data, it was clear that EMJ-I-026 (5) did not decrease locomotor 
activity in rodents in this paradigm of J. Crawley executed in the laboratory of Rowlett et 
al. This data indicated in these mice, there appeared to be no effects from ataxia nor 
sedation.  This indicated that EMJ-I-026 was a nonsedating anxiolytic and illustrated the 
ester function in these molecules can be replaced with a more stable ester bioisostere and 
still retain anxiolytic activity. 
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Figure 7. The Light/Dark Test and Locomotor Activity Test on EMJ-I-026 (5). 
 
Based on the binding affinity of EMJ-I-026 (5) as well as its important anxio-
selective activity (no sedation/ataxia), it was decided to prepare analogues of EMJ-I-026 
(5).  Based on the success of ligands EMJ-I-026 (5) and YT-III-231 (8), Figure 8, the 
ligands YT-III-40 (9) and YT-III-41 (10) were designed and synthesized (see below for 
their metabolic stability on microsomal enzymes).  
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Figure 8. Binding affinity at αxβ3γ2 GABAA/BzR subtypes (values are reported in nM) 
for YT-III-231 (8). 
 
N
N
N
COOEt
8 YT-III-231
 
Screening 
No. α1 α2 α3 α4 α5 α6 
1 51.09 61.46 26.34 ND 9.124 ND 
2 19.83 23.65 19.87 ND 1.105 ND 
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2.3. Acid/Base Stability Studies on EMJ-II-026 (5). 
 
 In order to test the stability of the bioisostere EMJ-II-026 (5) compared to the 
ethyl ester XHe-II-053 (4), both compounds where subjected to different extremes of pH 
values to simulate stomach and intestinal conditions for up to 60 hrs and analyzed by 
TLC for hydrolysis products.  According to the information below in Table 3, it is clear 
that chemical hydrolysis of the ethyl ester XHe-II-053 (4) would take more time (> 48 hrs) 
to occur than the compound would normally be exposed to in vivo. However, with time, 
the ethyl ester XHe-II-053 (4) did begin to hydrolyze, which resulted, in formation of the 
carboxylic acid, whereas the bioisostere analogue EMJ-I-026 (5) was completely stable to 
both acidic and basic conditions for the 60 hrs.  
 
Table 3. Acid/Base Stability Studies of XHe-II-053 (4) and EMJ-I-026 (5). 
 
 
  
Compound pH 1 hr 2 hr 5 hr 10 hr 24 hr 48 hr 60 hr
2 A N/A A N/A A N/A A N/A A N/A A N/A A N/A
2 B NR B NR B NRq B NR B NR B NR B NR
10 A N/A A N/A A N/A A N/A A N/A A N/A A N/A
10 B NR B NR B NR B NR B NR B NR B NR
2 A NR A NR A NR A NR A NR A NR - small 
smearing of spot A
NR - small 
smearing of spot
2 B NR B NR B NR B NR B NR B NR B NR
10 A NR A NR A NR A NR A NR A NR - small 
smearing of spot A
NR - small 
smearing of spot
10 B NR B NR B NR B NR B NR B
95% 053 
(RF=0.3) and 
5% RF=0.2
B
80% 053 
(RF=0.3) and 
20% RF=0.2
EMJ-I-026 = 0.8
B  =  1 mL of Buffer and 1 mL of MeOH and 2 mg of compound XHe-II-053 = 0.3
Acid = Baseline to 0.2 smear
N/A = no spot because compound would not go into solution
EMJ-I-026
5
XHe-II-053
4
A  =  2 mL of Buffer and 2 mg of compound Common RF values for compounds
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2.4. In Vitro Metabolic Stability of XHe-II-053 (4) and EMJ-I-026 (5). 
 
In humans XHe-II-053 (4) was largely transformed into the inactive metabolite 
XHe-II-053 Acid (4) via hepatic enzymes and then to a glucuronide, which resulted, in 
sub-optimal pharmacokinetics (BMS unpublished results). The synthesis of the related 
bioisostere EMJ-II-026 (5) was an effort to circumvent the metabolic liability of the 
compound on human liver microsomes versus the control anxiolytic 4, in an effort to 
develop nonsedating anxiolytics with longer half lives in humans. Research with a CRO 
by Methridion (unpublished results) had already shown 4 and 5 were stable in human 
blood, brain and kidney.  
 
A metabolic stability study of these compounds was undertaken at SRI 
International by Dr. Ng and coworkers as a collaborative project funded by National 
Institute of Mental Health (NIMH). In this study the test articles were incubated with 
pooled human liver microsomes which represented 150 human livers and the aliquots 
were analyzed at various time points using LC-MS/MS. The results from this study are 
shown in Table 4.  Significant metabolic liability was observed at both 1 and 10 µM for 
XHe-II-053 4 (less than 14% remaining at 30 min). The corresponding carboxylic acid 
control of 4, i.e. carboxylic acid 11, Figure 9, was recovered unchanged during the test 
period. Additionally, all the compounds when incubated with heat-inactivated human 
liver microsomes underwent no significant change in the % remaining of any of the 
compounds, which indicates the ligands were all stable under the control incubation 
conditions.  Analysis of these results indicated that the main site of metabolism on human 
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livers was due to the pendant ethyl ester moiety, which was not unexpected but designed 
earlier as a method of clearance (metabolic switching) to prevent buildup of the drug in 
vivo (patients). 
 
Figure 9. Carboxylic Acid of XHe-II-053 
 
 
 
 
Table 4: In Vitro Metabolic Stability of Compounds 4, 5 and 11 Using Human Liver 
Microsomes by SRI International 
 
Test Article Time, 
min 
Mean % Remaining vs T = 0 mina 
1 µMb 10 µMb 
 
15 41.4 47.6 
4 30 11.2 13.9 
 
60 1.5 1.7 
4 with HIc microsomes 60 107.4 101.8 
 
15 100.0 109.2 
5 30 109.7 108.0 
 
60 90.8 96.6 
5 with HIc microsomes 60 137.5 118.9 
 
15 107.6 95.3 
11 30 110.4 94.8 
 
60 110.7 94.8 
11 with HIc microsomes 60 105.8 97.2 
 
a % remaining at T =0 is 100% 
b Samples were assayed in duplicates 
c
 HI = Heat Inactivated, for control purposes 
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Based on these findings it was decided to design and synthesize novel analogues 
with bioisosteric replacement of the labile ethyl ester moiety analogues to that of the lead 
analogue XHe-II-053 (4). Previously, in the case of GABAA modulators in the 
benzodiazepine series of compounds, it had been demonstrated that replacement of the 
ethyl ester at the 3-position by a 1,2,4-oxadiazole moiety resulted in higher intrinsic 
efficacy at benzodiazepine receptors as compared to the corresponding ethyl esters.110a
 
 
Substituted 1,2,4-oxadiazoles are also metabolically stable and slightly less lipophilic 
than the corresponding ester derivatives,110d hence compound 5 had been synthesized.  
Substituted 1,2,4-oxadiazole analogue 5 (EMJ-I-026) was significantly stable as 
compared to 4 (XHe-II-053), as expected, based on medicinal chemistry precedents. 
 
2.5. Synthesis of YT-III-40 (9). 
 
 In the design of the following ligands the goal was to choose ligands with good 
α2/α3 Gabaergic receptor subtype selectivity or efficacy as the lead to synthesize ligands 
that lack ester linkages and are thus relatively insensitive to hydrolysis by esterases in 
vivo.  It was known the 2´ substituent (-F) should increase affinity at BzR BS and the 
replacement of the ester, if compatible, should render this ligand a long-lived α2/α3 
selective agonist. 
  
 The ethyl ester 12, was treated with sodium hydride and N´-
hydroxyisobutyrylimidamide in the presence of dry THF and dry 4Ao molecular sieves to 
provide the isopropyl bioisostere 9 (YT-III-40) in 45% yield, as shown in Scheme 3.  
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Binding affinity at αxβ3γ2 GABAA/BzR subtypes. 
 
 
Values are reported in nM. ND = Not Determined. 
 
Unfortunately, this molecule, it was felt, was too large to fit in the receptor 
binding pocket of α2/α3 subtypes.  However, a second explanation as regards the lack of 
affinity of 9 may stem from a screen at UNC done by the rapid screening technique 
which may have resulted in erroneous results, this is being investigated.  The laboratory 
at UNC was having trouble transfecting the α2 and α3 related HEK cells for receptor 
binding hence the results at α2 and α3 subtypes maybe completely wrong.  At the same 
time the transfection of the α1 and α5 related HEK cells were going well so the data at α1 
and α5 subtypes is reliable.  
 
 
α1 α2 α3 α4 α5 α6 
1454 2576 3543 ND 112.6 ND 
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2.6. Synthesis of YT-III-41(10). 
 
The ligand 10 was a hybrid of EMJ-I-026 (5) and YT-III-231 (8).  This synthesis 
was aimed at the design of a ligand which had both α2/α3 and α5 subtype selectivity 
while avoiding activity at α1 subtypes, as well as resistant to esterase hydrolysis.  The 
ethyl ester 8 (YT-III-231) was treated with sodium hydride and N´-
hydroxyisobutyrylimidamide in the presence of dry THF and dry 4Ao molecular sieves to 
provide the isopropyl bioisostere 10 (YT-III-41) in 45% yield, as shown in Scheme 4. 
 
 
  
 
 
Binding affinity at αxβ3γ2 GABAA/BzR subtypes. 
 
 
Values are reported in nM. ND = Not Determined. 
α1 α2 α3 α4 α5 α6 
3052 745.7 510.8 ND 416.8 ND 
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 This molecule may be too large to fit in the binding pocket, however, again this 
molecule was analyzed by the rapid screening technique which may not be accurate.  As 
mentioned before, this is being reinvestigated and rescreened as well because the α2 and 
α3 subtypes were not expressed correctly at UNC.   
 
2.7. Synthesis of YT-III-42 (14). 
 
 Because the initial studies on YT-II-76 (13; 2370 fold α5 over α1, Figure 10) 
demonstrated potent subtype selectivity at α5 subtypes, it was decided to convert this 
cyclopropyl substituted imidazobenzodiazepine into an ester bioisostere to retard ester 
metabolism (hydrolysis).  The ethyl ester 13 (YT-II-76), prepared earlier, was treated 
with sodium hydride and N´-hydroxyisobutyrylimidamide in the presence of dry THF 
and dry 4Ao molecular sieves to provide the isopropyl bioisostere 14 (YT-III-42) in 45% 
yield, as shown in Scheme 5, analogues to previous chemistry. 
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Figure 10. Binding affinity at αxβ3γ2 GABAA/BzR subtypes for YT-II-76 (13). 
 
 
 
Screening 
No. α1 α2 α3 α4 α5 α6 
1 95.34 2.797 0.056 ND 0.04 ND 
2 101.1 1.897 5.816 ND 11.99 ND 
  3* 6.71 29.28 81.82 ND 7.72 ND 
* This run was carried out by the rapid screening technique and may not be accurate 
because of the lack of reliability at the α2 and α3 subytpes. 
Values are reported in nM.  ND = Not Determined. 
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Binding affinity at αxβ3γ2 GABAA/BzR subtypes. 
Screening 
No. 
α1 α2* α3* α4 α5 α6 
1 382.9 16.83 44.04 ND 9.77 ND 
2 154.1 532.9 529 ND 143.7 ND 
* These run was carried out by the rapid screening technique and may not be accurate 
because of the lack of reliability at the α2 and α3 subytpes. 
Values are reported in nM.  ND = Not Determined. 
 
From the initial data on ligand 14 (YT-II-42), it was 40 fold more selective for α5 
subtypes over α1 subtypes and certainly more selective at α2 and α3 subtypes as 
compared to α1 subtypes.  This was a very good binding profile.  The second set of data 
was determined by the rapid screening technique and may be flawed, as previously stated.   
More data will have to be obtained on this ligand in vitro to determine its real potential. 
The efficacy on oocytes at α1, α2, α3 and α5 ion channels must be obtained on HEK cells 
before proceeding further. 
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2.8. Synthesis of YT-III-44 (16). 
 
   Recently, Sieghart et al. have demonstrated the chiral imidazobenzodiazepine (SH-053-
2´-F-S-CH3) 15 binds with selective efficacy at α2, α3 and α5 subtypes with very little efficacy at 
α1 subtypes at physiologically relevant concentrations (100 nM).  Moreover, its R-enantiomer 
(SH-053-2´-F-R-CH3) bound potently only at α5 subtypes and had a different biological 
profile.114 Moreover,  Fischer  and Rowlett have demonstrated in the conflict model in rhesus 
monkeys that SH-053-2´-F-S-CH3 was a non-sedating anxiolytic, while the R-isomer was largely 
inactive.  For this reason, it was decided to alter the esterase labile ester function in 15 to the more 
stable isopropyl bioisostere in 16 (YT-III-44). This was to potentiate the duration of action of 
these ligands in vivo, as described in previous cases.  The R-enantiomer of 8-phenyl substituted 
imidazobenzodiazepines exhibits subtype selective α5 agonist properties and could be used by 
Savic et al. to study amnesia and the effect of α5 agonists on cognition. It was also active in PPI 
(Baker et al. unpublished results) and the MAM model in rodents of schizophrenia, hence both S 
and R isomers are important for potential leads for treatment of schizophrenia (resets gating in 
CNS).  
 
 It was known the S-enantiomers of 3-substituted 1,4-benzodiazepines were more 
active than the R-isomers.119, 120  This has been supported by the published work on the 
framework constrained 4,5-disubstituted pyrroloimidazobenzodiazepines; the S-
enantiomers were much more potent in vitro than the R-isomers.121  As mentioned above 
in the previous work, the pharmacophoric descriptors H1, H2 and A2 in the  
pharmacophore/receptor models of the 6 major BzR have been shown to be very  
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similar.121  Consequently, it was felt, the major differences in the topology of these 
subtypes may stem from asymmetry/or lack thereof in the lipophilic pockets designated 
L1, L2, L3 and LDi.57, 121-123   The optically active ligands were designed to enhance/probe 
these differences.  According to computer modeling, the S-enantiomers of these agents fit 
the computer model very well, while the phenyl ring of the R-isomer protruded out of the 
pharmacophore included volume of the α1, α2 and α3 subtypes, which interacted 
negatively with the receptor protein.122, 123  The R-isomer did fit the α5 subtype to a 
somewhat better degree.  The R-isomer, therefore, may be less active or inactive based on 
modeling.   Based on the previous work of Shengming Huang and Savic 114 it was 
expected that the (S)-4-methyl ligands would provide better subtype selective affinity and 
efficacy at α2, α3 and/or α5 subtypes while the (R)-4 enantiomers would interact only 
with α5β2γ2 receptor subtypes important in schizophrenia.   
  
 The 2’-F,(S)-CH3 substituted ester 15 was treated with sodium hydride and N´-
hydroxyisobutyrylimidamide in the presence of dry THF and molecular sieves to provide 
the isopropyl bioisostere 16 (YT-III-44) in 45% yield, as shown in Scheme 6. 
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Binding affinity at αxβ3γ2 GABAA/BzR subtypes. 
 
 
 
* These runs were carried out by the rapid screening technique and may not be accurate 
because of the lack of reliability at the α2 and α3 subtypes at UNC. 
Values are reported in nM.  ND = Not Determined. 
 
It is clear that YT-III-44 (16) binds to BzR subtypes but it binds more potently to 
α1 and α5 subtypes in contradiction to the expected affinities.  Because this was 
determined by the rapid screening mechanism which may be invalid, efforts are 
underway to rescreen this ligand in a more classical sense.   Because the ester bioisosteres 
YT-III-40 (9), YT-III-41 (10), YT-III-42 (14), and YT-III-44 (16) did not bind as 
potently to BzR as desired, a number of other analogues were designed with groups 
known to withstand ester hydrolysis in other cases.  For this approach the lead ligand to 
be modified was chosen from the α2/α3 subtype selective ligands already shown to be 
non-sedating anxiolytics in vivo. 114 This work is being carried out by new students in 
Milwaukee.  
α1 α2 α3 α4 α5 α6 
37.83 9717* 373.9* ND 24.04 ND 
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III. Conclusion. 
   
 In this study it was clear that the improved method for synthesizing 
benzodiazepines was successful. This was based on the number and quantities of 
numerous compounds synthesized utilizing the improved method.   Although the efficacy 
of XHe-II-053 (4) was decreased in Phase I because of the metabolism of the C-3 ester to 
the acid, the bioisostere EMJ-I-026 (5) has been shown to exhibit non-sedating anxiolytic 
activity in mice as well as a binding/oocyte profile in vitro consistent with a non-sedating 
anxiolytic.  Based on this success seven bioisosteric analogues were designed in order to 
circumvent any potential metabolic liability in humans of the previously described ligand. 
In fact, the bioisosteric analogues were much more stable in human liver microsomes 
than XHe-II-053 (4) again indicating these bioisosteres are potential nonsedating 
anxiolytics as well as useful for treatment of anxiety disorders in human populations.  
 
Gratifyingly, ligand 5 was clearly an efficacious α3 Bz/GABAergic receptor 
subtype selective ligand at pharmacologically relevant doses (approximately 100 nM) and, 
presumably, provides an agent to study physiologically processes mediated by α3 
subtypes including anxiety, and on addition was much more stable in human liver 
microsomes. In this regard α3 subtype selective ligand oxadiazole 5 (EMJ-I-026) has 
been evaluated in the light dark paradigm and clearly was a nonsedating anxiolytic in 
mice, wherein this ligand was anxiolytic with no sedative properties, in vivo, as compared 
to diazepam. This study indicated that the ester function in these molecules can be 
replaced with a metabolically more stable ester bioisostere and the ligand still retains 
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anxiolytic activity. The in depth study of these ligands in animal models and other 
receptor systems are underway and will be reported in due course, especially since the α2 
and α3 receptor binding data at UNC was not reliable at this time due to problems in 
transfection of the α2 and α3 HEK cells (B. Roth, private communication). 
 
IV. Screening Methods. 
1. Computer Modeling Methods. 
 
 The core structures of the ligands were taken from available X-ray 
crystallographic coordinates or generated using the SYBYL fragment library.22, 124  The 
structures which resulted were energy minimized using MM2 (molecular mechanics 
program 2) or MMFF (Merck molecular force field), and the subsequent Monte Carlo 
conformational searches were carried out on MacroModel 6.0 on a Silicon Graphics 
Personal Iris 4D/35 workstation or a Silicon Graphics Octane SI 2P 175 R10000 
workstation, respectively.  The low energy conformations were then fully optimized via 
molecular orbital calculations at the 3-21G basis set with torsional angles fixed.  The 
structures which resulted were further calibrated with 6-31G* single point calculations at 
an “SCF=TIGHT” convergence criteria via Gaussian 92125 on a Silicon Graphics Indigo 
R4400 workstation, or Gaussian 94126 on a Silicon Graphics Octane SI2P175R10000 
workstation.34 
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2. Competition Binding Assays (With Dr. Majumder and Dr. Roth). 
 
 Competition binding assays were performed in a total volume of 0.5 mL at 4 °C 
for 1 hour using [3H]flunitrazepam as the radiolabel.  For these binding assays, 20-50 mg 
of membrane protein harvested with hypotonic buffer (50 mM Tris-acetate, pH 7.4 at 4°C) 
was incubated with the radiolabel as previously described (Choudhary et al., 1992).  
Nonspecific binding was defined as radioactivity bound in the presence of 100 µM 
diazepam and represented less than 20% of total binding.  Membranes were harvested 
with a Brandel cell harvester followed by three ice-cold washes onto polyethyleneimine-
pretreated (0.3%) Whatman GF/C filters.  Filters were dried overnight and then soaked in 
Ecoscint, a liquid scintillation cocktail (National Diagnostics; Atlanta, GA).  Bound 
radioactivity was quantified by liquid scintillation counting.  Membrane protein 
concentrations were determined using an assay kit from Bio-Rad (Hercules, CA) with 
bovine serum albumin as the standard.  
 
3. Preparation of Cloned mRNA (with Dr. R. Furtmüller, Dr. 
Ramerstorfer and Dr. W. Sieghart).114-117 
 
 The cloning of GABAA receptor subunits α1, β3 and γ2 into pCDM8 expression 
vectors (Invitrogen, CA) has been described elsewhere. 22, 115-118, 127  GABAA receptor 
subunit α4 was cloned in an analogous way.  The cDNAs for subunits α2, α3and α5 were 
gifts from P. Malherbe and were subcloned into a pCI-vector.  The cDNA for the α6 
subunit was a gift from P. Seeburg and was subcloned into the vector pGEM-3Z 
326 
 
(Promega).  After linearizing the cDNA vectors with appropriate restriction 
endonucleases, capped transcripts were produced using the mMessage mMachine T7 
transcription kit (Ambion, TX).  The capped transcripts were polyadenylated using yeast 
poly (A) polymerase (USB, OH) and were diluted and stored in diethylpyrocarbonate-
treated water at –70°C. 115-118 
 
4. Functional Expression of GABAA Receptors (with Dr. R. Furtmüller, 
Dr.  Ramerstorfer and Dr. W. Sieghart).114,115  
 
 The methods used for isolating, culturing, injecting and defolliculating 
the oocytes were identical with those described by E. Sigel.128, 129  Mature female 
Xenopus laevis (Nasco, WI) were anaesthetized in a bath of ice-cold 0.17 % Tricain 
(ethyl-m-aminobenzoate, Sigma, MO) before decapitation and removal of the frog ovary.  
Stage 5 to 6 oocytes with the follicle cell layer around them were singled out of the ovary 
using a platinum wire loop.  Oocytes were stored and incubated at 18°C in modified 
Barths medium [MB, containing 88 mM NaCl, 10 mM HEPES-NaOH (pH 7.4), 2.4 mM 
NaHCO3, 1 mM KCl, 0.82 mM MgSO4, 0.41mM CaCl2, 0.34 mM Ca(NO3)2] that was 
supplemented with 100 Units/mL penicillin and 100 µg/mL streptomycin.  Oocytes with 
follicle cell layers still around them were injected with 50 nL of an aq solution of the 
cRNA.  This solution contained the transcripts for the different alpha subunits and the 
beta 3 subunit at a concentration of 0.0065 ng/nL as well as the transcript for the gamma 
2 subunit at 0.032 ng/nL.  After injection of the cRNA, oocytes were incubated for at 
least 36 h before the enveloping follicle cell layers were removed. 
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 To this end, oocytes were incubated for 20 minutes at 37 °C in MB that contained 
1 mg/mL collagenase type IA and 0.1 mg/mL trypsin inhibitor I-S (both Sigma).  This 
was followed by osmotic shrinkage of the oocytes in doubly concentrated MB medium 
supplied with 4 mM Na-EGTA.  Finally, the oocytes were transferred to a culture dish 
containing MB and were gently pushed away from the follicle cell layer which stuck to 
the surface of the dish.  After removal of the follicle cell layer, oocytes were allowed to 
recover for at least 4 h before being used in electrophysiological experiments.114,115  
 
 
5. Electrophysiological Experiments (with Dr. R. Furtmüller, Dr 
Ramerstorfer and Dr. W. Sieghart) .114,115 
 
 For electrophysiological recordings, oocytes were placed on a nylon-grid in a bath 
of Xenopus Ringer solution [XR, containing 90 mM NaCl, 5 mM HEPES NaOH (pH 7.4), 
1 mM MgCl2, 1 mM KCl and 1 mM CaCl2].  The oocytes were constantly washed by a 
flow of 6 mL/min XR which could be switched to XR containing GABA and/or drugs.  
Drugs were diluted into XR from DMSO solutions which resulted in a final concentration 
of 0.1 % DMSO perfusing the oocytes.  Drugs were preapplied for 30 seconds before the 
addition of GABA, which was coapplied with the drugs until a peak response was 
observed.  Between two applications, oocytes were washed in XR for up to 15 minutes to 
ensure full recovery from desensitization.  For current measurements the oocytes were 
impaled with two microelectrodes (2–3 mΩ) which were filled with 2 mM KCl. 
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 All recordings were performed at room temperature (rt) at a holding potential of –
60 mV using a Warner OC-725C two-electrode voltage clamp (Warner Instruments, 
Hamden, CT).91, 92  Data were digitized, recorded and measured using a Digidata 1322A 
data acquisition system (Axon Instruments, Union City, CA).  Results of concentration 
response experiments were fitted using GraphPad Prism 3.00 (GraphPad Software, San 
Diego, CA).  The equation used for fitting concentration response curves was Y=Bottom 
+ (Top-Bottom)/(1+10^((LogEC50-X)*HillSlope)); X represents the logarithm of 
concentration, Y represents the response; Y starts at Bottom and goes to Top with a 
sigmoid shape.  This is identical to the "four parameter logistic equation."114 
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V. Experimental Section. 
 
 Melting points were taken on a Thomas-Hoover melting point apparatus or an 
Electrothermal model IA8100 digital melting point apparatus and are uncorrected.  
Microanalyses were performed on a Perkin-Elmer 240C carbon, hydrogen, and nitrogen 
analyzer.  All samples submitted for CHN analyses were first dried under high vacuum 
for a minimum of 6 h using a drying pistol with isopropyl alcohol as the solvent with 
phosphorus pentoxide in the drying bulb.  Proton and carbon high resolution nuclear 
magnetic resonance spectra were obtained on a Bruker 300-MHz NMR spectrometer or a 
GE 500-MHz NMR spectrometer.  The low resolution mass spectra (EI/CI) were 
obtained on a Hewlett-Packard 5985B gas chromatography-mass spectrometer, while 
high resolution mass spectra were recorded on a VG Autospec (Manchester, England) 
mass spectrometer.  Infra-red spectra were recorded on a Nicolet MX-1 FT-IR or a Perkin 
Elmer 1600 Series FT-IR spectrometer.  Analytical thin layer chromatography plates used 
were E. Merck Brinkmann UV-active silica gel (Kieselgel 60 F254) on plastic.  Silica gel 
60A, grade 60 for flash and gravity chromatography was purchased from E. M. 
Laboratories. 
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7-Chloro-4-methyl-3,4-dihydro-1H-benzo-[e]-[1,4]-diazepine-2,5-dione 
(1h).  
  
A mixture of 5-chloroisatoic anhydride (20.0 g, 101 mmol) and sarcosine (9.02 g, 
101 mmol) in DMSO (160 mL) was heated at 150 °C for 5 hr, cooled to rt and poured 
into ice water (750 mL) to furnish a light brown precipitate.  This solid was collected by 
filtration, washed with water (3 × 200mL) and dried.  The benzodiazepine 1h (19g, 84.0% 
yield) was obtained as a light brown solid.   This material was used directly in a later step.  
The spectral data were identical to the published values.130 
 
General Procedure for the Synthesis of Imidazo-[1,5-a]-[1,4]-
Benzodiazepines.  
 
Potassium t-butoxide (t-BuOK; 1.1 mmol) was added to a solution of the 
amidobenzodiazepine 1(a-j) (1.0 mmol) in anhydrous THF (20 mL) at 0 oC and this was 
allowed to stir for 20 min.  The reaction mixture, which resulted, was cooled to -35 oC 
and diethylchlorophosphate (1.3 mmol) was added slowly.  After stirring this mixture at 0 
oC for 30 min, the mixture was cooled to -78 oC and ethyl isocyanoacetate (1.1 mmol) 
was added and this followed by addition of t-BuOK (1.1 mmol).  The second addition can 
be run at -35 oC instead of -78 oC with the same result. After allowing the reaction 
mixture to stir at rt for 4 h, the reaction was quenched with a saturated solution of aq 
NaHCO3 (30 mL) and extracted with EtOAc (3x 50 mL).  The combined organic layers 
were dried (Na2SO4), concentrated and the product was precipitated from ether to give 
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most of the imidazobenzodiazepine.  The mother liquor was purified by flash 
chromatography on silica gel (gradient elution, 40%-60% EtOAc in hexane) to afford 
additional imidazobenzodiazepine (yields 70-89%; see Table 2). 
 
Large Scale Procedure for the Synthesis of Imidazo-[1,5-a]-[1,4]-
Benzodiazepine (3j). 
 
 Potassium t-butoxide ( t-BuOK; 6.88g, 61.33 mmol) was added to a solution of 1j 
(15g, 55.76 mmol) in anhydrous THF (1500 mL) at 0 oC over 20 min.  The reaction 
mixture was then cooled to -35 oC and diethylchlorophosphate (10.42ml, 72.49 mmol) 
was added slowly.  After stirring this mixture at 0 oC for 30 min, the mixture was cooled 
to -78 oC (or -35 oC) and ethyl isocyanoacetate (6.70ml, 61.33 mmol) was added.  This 
was followed by addition of t-BuOK (6.88g, 61.33 mmol).  After stirring at rt for 4 h, the 
reaction mixture was quenched with a saturated solution of aq NaHCO3 (500 mL) and 
extracted with EtOAc (3x 1000 mL).  
 
The combined organic layers were dried (Na2SO4) and concentrated in vaccuo to 
give a solid residue.  This solid residue was triturated with ether (250 mL) and the 
product 3j was precipitated as an off-white solid.  The mother liquor was further purified 
by flash chromatography on silica gel (gradient elution, 40%-60% EtOAc in hexane) to 
afford additional imidazobenzodiazepine 3j with an overall yield of 72% (14.61g).  
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Ethyl-8-Chloro-6-Phenyl-4H-Imidazo-[1,5-a]-[1,4]-Benzodiazepine-3-
Carboxylate (3a). 
 
 This material was prepared under conditions analogous to the synthesis of 3j.     
3a: Mp: 180-182 oC; 1H NMR (300 MHz, CDCl3) δ 7.93 (s, 1 H), 7.68 (dd, 1H, J= 2.3, 
2.3 Hz), 7.58 (s, 1H), 7.55-7.37 (m, 6 H), 6.06 (d, 1H, J=12.3Hz), 4.70 (m, 2H), 4.15 (d, 
1H, J=14Hz), 1.46 (t, J=7.12Hz, 3 H); HRMS for C20H16ClN3O2: (M+1) 366.1007.  
Found (relative intensity, %): 366.1000 (M+1, 100); 368.0902 (M+3, 32).   
 
Ethyl-8-Bromo-6-Phenyl-4H-Imidazo-[1,5-a]-[1,4]-Benzodiazepine-3-
Carboxylate (3b). 
 
 This material was prepared under conditions analogous to the synthesis of 3j.  
3b: White solid; Mp: 175-178 oC; 1H NMR (300 MHz, CDCl3) δ 7.95 (s, 1 H), 7.82 (dd, 
1H, J= 2.2, 8.6Hz), 7.60 (d, 1H, J=2.2Hz), 7.53-7.40 (m, 6 H), 6.08 (d, 1H, J=12.3Hz), 
4.49-4.38 (m, 2H), 4.09 (d, 1H, J=12.1Hz), 1.44 (t, 3 H, J=7.1Hz); 
 EIMS m/e (relative intensity, %) 411 (M+1, 34), 410 (M+, 8), 409 (34), 365 (61), 337 
(100), 335 (100), 285 (21), 232 (17).  Anal. Calcd. for C20H16BrN3O2: C, 58.55; H, 3.93; 
N, 10.24. Found:  C, 58.30; H, 3.91; N, 9.94. 
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(R)-Ethyl-8-Bromo-4-Methyl-6-(2′-Fluorophenyl)-4H-Imidazo-[1,5-a]-
[1,4]-Benzodiazepine-3-Carboxylate (3c). 
 
 This material was prepared under conditions analogous to the synthesis of 3j.  
3c: White solid; Mp: 261-262 oC; [α]D25 -10.9 (c, 0.54, EtOAc); 1H NMR (300 MHz, 
CDCl3) δ 7.92 (s, 1 H), 7.72 (dd, 1H, J= 1.5, 8.2Hz), 7.60 (t, 1H, J=6.9Hz), 7.48 (d, 1H, 
J=8.5Hz), 7.49-7.42 (m, 2H), 7.29-7.23 (m, 1H), 7.05 (t, 1H, J=9.3Hz), 6.71 (q, 1H, 
J=7.3Hz), 4.41 (m, 2H), 1.42 (t, 3 H, J=7.1Hz), 1.29 (d, 3H, J=7.2Hz).  EIMS m/e 
(relative intensity, %) 442 (M+, 5), 443 (M+2, 5), 428 (7), 381 (58), 355 (100).  Anal. 
Calcd. for C21H17BrFN3O2: C, 57.03; H, 3.87; N, 9.50. Found:  C, 57.13; H, 3.89; N, 9.51.  
 
(R)-Ethyl-8-Bromo-4-Ethyl-6-(2′-Fluorophenyl)-4H-Imidazo-[1,5-a]-
[1,4]-Benzodiazepine-3-Carboxylate (3d). 
 
 This material was prepared under conditions analogous to the synthesis of 3j.  
3d: White solid; Mp: 253-254oC; 1H NMR (300 MHz, CDCl3): δ 7.93 (s, 1H), 7.72 (dd, 
1H, J = 8.1Hz), 7.59 (t, 1H, J = 7.5Hz), 7.48-7.42 ( m, 2H), 7.28-7.23 (m, 1H), 7.06 (t, 
1H, J= 9.3Hz), 6.51 (q, 1H, J=7.8Hz), 4.43 (m, 2 H ), 1.76-1.52 (m, 3H ), 1.43 (t, 3H, 
J=7.2 Hz), 0.96 ( t, 3H, J= 7.2Hz).  HRMS Calcd. for C22H19BrFN3O2: 456.0723; Found: 
456.0709.  
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(S)-Ethyl-8-Bromo-4-Ethyl-6-(2′-Fluorophenyl)-4H-Imidazo-[1,5-a]-
[1,4]-Benzodiazepine-3-Carboxylate (3e). 
 
 This material was prepared under conditions analogous to the synthesis of 3j.  
3e: White solid; Mp: 254-255 oC; 1H NMR (300 MHz, CDCl3): δ 7.92 (s, 1H), 7.72 (dd, 
1H, J=7.2Hz), 7.59 (t, 1H, J=6.9Hz), 7.48-7.41 (m, 2H), 7.28-7.23 (m, 1H), 7.06 (t, 1H, 
J=9.3Hz), 6.51 (m, 1H) , 4.45-4.37 (m, 2H ), 1.75-1.54 (m, 3H), 1.42 (t, 3H, J=6.9Hz), 
0.94 (t, 3H, J=7.2Hz).  HRMS Calcd. for C22H19BrFN3O2: 456.0723 (M+1); Found 
(relative intensity): 456.0703 (M+1, 100); 458.0648 (M+3, 99.8).   
 
Ethyl-8-Bromo-6-Phenyl-4H-Imidazo-[1,5-a]-Thieno-[2,3-f]-[1,4]-
Diazepine-3-Carboxylate (3f). 
 
 This material was prepared under conditions analogous to the synthesis of 3j.  
3f: White solid; Mp: 180-182 oC; 1H NMR (300 MHz, CDCl3) δ 8.33 (s, 1 H), 8.02 (s, 1 
H), 7.63-7.35 (m, 5 H), 5.31 (s, 2 H), 4.34-4.27 (q, 2 H, J=7.1Hz), 1.32 (t, 3 H, J=7.1Hz).  
HRMS for C18H14BrN3O2S: 416.0068 (M+1).  Found (relative intensity, %): 416.0049 
(M+1, 100); 418.0018 (M+3, 100).  
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Ethyl-8-Fluoro-5,6-Dihydro-5-Methyl-6-Oxo-4H-Imidazo-[1,5-a]-[1,4]-
Benzodiazepine-3-Carboxylate (3g). 
 
 This material was prepared under conditions analogous to the synthesis of 3j.  
3g: Off-white solid; Mp: 200-202 oC; 1H NMR (300 MHz, CDCl3) δ 7.88 (s, 1H), 7.81-
7.78 (m, 1H), 7.74-7.36 (m, 2H), 5.25 (br s, 1H), 4.44 (q, 2 H, J=7.3Hz), 4.38 (br s, 1H), 
3.27 (s, 3H), 1.47 (t, 3H, J=7.3Hz).  HRMS for C15H14FN3O3: (M+1) 304.1097. Found: 
304.1091.  The spectral data for 3g were identical to the published values.109,110  
 
Ethyl-8-Chloro-5,6-Dihydro-5-Methyl-6-Oxo-4H-Imidazo-[1,5-α]-[1,4]-
Benzodiazepine-3-Carboxylate (3h).1   
 
 The tBuOK (9.0g, 80mmol) was added to a solution of 1h (15g, 67mmol) in THF 
(1000mL) at 0°C.  After the solution was allowed to stir at 0°C for 20 min, the reaction 
mixture was cooled to -35°C and diethyl chlorophosphate (15 g, 87 mmol) was added 
slowly.  After stirring at 0°C for 30 min, the reaction mixture was cooled to -78°C and 
ethyl isocyanoacetate (8.3g, 73 mmol) was added and this was followed by addition of 
tBuOK (8.2 g, 73mmol).  The reaction solution was stirred at rt for 4h, after which the 
reaction was quenched with a saturated aq solution of NaHCO3 and extracted with ethyl 
acetate.  The combined organic layers were dried (Na2SO4) and concentrated under 
reduced pressure.  The residue was purified by flash chromatography on silica gel (ethyl 
acetate) and then crystallized from ethyl acetate to give white crystals 3h (19g, 89% 
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yield). 3h: mp 192-193 °C; 1H NMR (300 MHz, CDCl3) δ 8.1 (d, J = 2.4 Hz, 1H), 7.90 (s, 
1H), 7.62 (dd, J = 8.6, 2.5 Hz, 1H), 7.40 (d, J = 8.6 Hz, 1H), 5.23 (br s, 1H), 4.46 (q, J = 
7.12 Hz, 2H), 4.13 (br s, 1H), 3.27 (s, 3H), 1.47 (t, J = 7.12 Hz, 3H); C15H14ClN3O2, MS 
(EI) m/e (rel. intensity) 319 (M+, 100).  This material was used directly in a later step. 
 
(S)-Ethyl-7-Bromo-11,12,13,13a-Tetrahydro-9-Oxo-9H-Imidazo-[1,5-a]-
Pyrrolo-[2,1-d]-[1,4]-Benzodiazepine-1-Carboxylate (3i).  
 
 This material was prepared under conditions analogous to the synthesis of 3j. 3i: 
White solid; Mp: 249 oC; [α]D25 +45 (c, 1, CHCl3); 1H NMR (300 MHz, CDCl3) δ 8.23 (s, 
1H), 7.82 (s, 1H), 7.75 (d, 1H, J=7.5Hz), 7.26 (d, 1H, J=10.0Hz), 4.72 (d, 1H, J=6.0Hz), 
4.38 (q, 2H, J=7.5Hz), 3.75 (m, 1H), 3.56-3.48 (m, 2H), 2.27-2.14 (m, 3H), 1.41 (t, 3H, 
J=7.5Hz).  EIMS m/e (relative intensity, %) 390 (M+, 10), 345 (60), 316 (100), 314 (98), 
154 (24).  Anal. Calcd. for C17H16BrN3O3: C, 52.32; H, 4.13; N, 10.77. Found:  C, 52.70; 
H, 4.48; N, 10.64.  HRMS for C17H16BrN3O3: 389.0375.  Found (relative intensity, %): 
389.0373 (M+1, 100); 391.0258 (M+3, 98.8).  
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Ethyl-8-Bromo-5,6-Dihydro-5-Methyl-6-Oxo-4H-Imidazo-[1,5-a]-[1,4]-
Benzodiazepine-3-Carboxylate (3j). 
 
 This material was prepared under conditions as described earlier for large scale 
procedure for the synthesis of Imidazo-1[1,5-a]-1[1,4]-Benzodiazepine.  3j: Off-white 
solid; Mp: 192-193 oC; 1H NMR (300 MHz, CDCl3) δ 8.23 (s, 1H), 7.79 (s, 1H), 
7.77 (d, 1H, J=2.3Hz), 7.35 (d, 1H, J=6.4Hz),  5.17 (br s, 1H), 4.43 (m, 3H), 3.28 
(s, 3H), 1.45 (t, 3H, J=7.1Hz). C15H14BrN3O3, EIMS m/e (relative intensity, %) 
364 (M+, 100); 366 (M+2, 99).  
 
tert-Butyl-8-Bromo-5,6-Dihydro-5-Methyl-6-Oxo-4H-Imidazo-[1,5-a]-
[1,4]-Benzodiazepine-3-Carboxylate (3k). 
 
 This material was prepared under conditions analogous to the synthesis of 3j.  
3k: Mp: 180-183 oC, 1H NMR (300 MHz, DMSO-d6) δ 8.33 (s, 1H), 7.92 (s, 1H), 7.69 
(dd, 1H), 7.03 (dd, 1H), 4.71 (br, 1H), 4.12 (br, 1H), 3.10 (s, 3H), 1.56 (s, 9H).  
C17H18BrN3O3, EIMS m/e (relative intensity, %) 394 (M+, 100), 396 (M+2, 98). 
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5-(8-Ethynyl-6-Phenyl-4H-Benzo-[f]-Imidazo-[1,5-a]-[1,4]-Diazepine)-3-
Isopropyl-1,2,4-Oxadiazole (5, EMJ-I-026). 
 
 Isopropyl amido oxime (95 mg, 0.931 mmol) was added to a stirred suspension of 
dry powdered 4 Å molecular sieves (100 mg) in anhydrous THF (30 mL) under argon.  
After the mixture was stirred at rt for 10 min, NaH (37 mg of 60% in mineral oil, 0.931 
mmol) was added to the mixture.  After the mixture was stirred for a further 30 min, a 
solution of the forgoing ester 4 (XHeII-053, 165 mg, 0.465 mmol) in THF (30 mL) was 
added.  The mixture which resulted was heated to reflux for 8 hr.  It was cooled to rt, 
after which acetic acid (56 mg, 0.931 mmol) was added.  After the solution was allowed 
to stir for 10 min, the mixture was filtered through celite.  The filtrate was diluted with 
CH2Cl2 (75 mL) and washed with water, brine and dried (K2CO3).  Evaporation of the 
solvent under reduced pressure afforded a pale yellow solid, which was purified by flash 
column chromatography (silica gel, EtOAc/hexane, 2:3) to furnish 5 as a white solid 
(EMJ-I-026, 82 mg, 0.209 mmol, 45%). 5: mp 190°C; IR (KBr) ν 3291,3057, 2972, 1613, 
1574, 1494, 1466, 1303, 1264, 939, 832, 781, 734, 699, 666 cm-1.  1H NMR (300 MHz, 
CDCl3) δ8.07 (s, 1H), 7.81-7.79 (dd, 1H), 7.64-7.61 (m, 2H), 7.53-7.37 (m, 5H), 6.14 (d, 
1H, J=13.1Hz), 4.19 (d, 1H, J=12.8Hz),  3.20 (s, 1H), 3.24-3.15 (m, 1H), 1.44-1.41 (d, 
6H, J=6.93Hz); MS (EI) m/e (relative intensity) 393(100); Anal. Calcd. for C24H19N5O: C, 
73.27; H, 4.87; N, 17.80.  Anal. Calcd. for C24H19N5O•0.37 CH2Cl2: C, 68.89; H, 4.68; N, 
16.48.  Found: C, 68.94; H, 4.59; N, 16.32 (CHN sample was transferred to a vial for 
drying with CH2Cl2 which may explain the contaminant). 
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5-(8-Ethynyl-6-(2-Fluorophenyl)-4H-Benzo-[f]-Imidazo-[1,5-a]-[1,4]-
Diazepine-3-yl)-3-Isopropyl-1,2,4-Oxadiazole (9, YT-III-40). 
 
 Isopropyl amido oxime (0.55g, 5.4 mmol) was added to a stirred suspension of 
dry powdered 4 Å molecular sieves (250 mg) in anhydrous THF (30 mL) under argon.  
After the mixture was stirred at rt for 10 min, NaH (60% solid in mineral oil, 0.147 g, 4.0 
mmol) was added to the mixture.  After the mixture was stirred for a further 30 min, a 
solution of the forgoing ester 12 (1g, 2.68 mmol) in THF (30 mL) was added.  The 
mixture which resulted was heated to reflux for 8 hr.  It was then cooled to rt, after which 
acetic acid (0.3g, 5.36 mmol) was added.  After the solution was allowed to stir for 10 
min, the mixture was filtered through celite. The filtrate was diluted with CH2Cl2 (100 
mL) and washed with water, brine and dried (K2CO3).  Evaporation of the solvent under 
reduced pressure afforded a pale yellow solid, which was purified by flash column 
chromatography (silica gel, EtOAc/hexane, 2:3) to furnish 9 as a white solid (YT-III-40, 
0.5g, 1.2 mmol, 45%). 9: mp 160-165°C; IR (neat) ν3194, 2961,2924, 2854, 1631, 1610, 
1495, 1450, 1414, 1394, 1367, 1342, 1312, 1259, 1221, 1071, 1011, 940, 903, 862, 793, 
767, 754, 697, 671cm-1 ; 1H NMR (300MHz, CDCl3) δ 8.09 (s, 1H), 7.80 (dd, 1H, J=1.78, 
1.78Hz), 7.69 (m, 3H), 7.51 (m, 2H), 7.07 (m, 1H), 6.26 (brs, 1H), 4.40 (brs, 1H),  3.24 
(m, 2H), 1.43 (d, 6H, J=6.93Hz); MS (EI) m/e(relative intensity) 411 (M+, 43), 383 (98), 
325 (100), 299 (74), 178 (74), 57 (57); HRMS(ESI) Calcd. for C24H18FN5O (M+H)+ 
412.1644, found: 412.1628. 
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5-(8-Cyclopropyl-6-Phenyl-4H-Benzo-[f]-Imidazo-[1,5-a]-[1,4]-
Diazepine-3-yl)-3-Isopropyl-1,2,4-Oxadiazole (10, YT-III-41).  
 
 Isopropyl amido oxime (0.33g, 3.2 mmol) was added to a stirred suspension of 
powdered 4 Å molecular sieves (200 mg) in anhydrous THF (20 mL) under argon.  After 
the mixture was stirred at rt for 10 min, NaH (60% solid in mineral oil, 0.089 g, 2.4 mmol) 
was added to the mixture.  After the mixture was stirred for a further 30 min, a solution of 
the forgoing ester 8 (YT-III-231, 0.6g, 1.6 mmol) in THF (20 mL) was added.  The 
mixture which resulted was brought to reflux for 8 hr.  It was then cooled to rt, after 
which acetic acid (0.2g, 3.2 mmol) was added.  After the solution was allowed to stir for 
10 min, the mixture was filtered through celite. The filtrate was diluted with CH2Cl2 (60 
mL) and washed with water, brine and dried (K2CO3).  Evaporation of the solvent under 
reduced pressure afforded a pale yellow solid, which was purified by flash column 
chromatography (silica gel, EtOAc/hexane, 2:3) to furnish 10 as a white solid (YT-III-41, 
0.3g, 0.7 mmol, 45%). 10: mp 100-103°C; IR (neat) ν2970, 2931, 1614, 1576, 1502, 
1465, 1446, 1420, 1389, 1365, 1339, 1303, 1266, 1216, 1177, 1125, 1097, 1056, 1010, 
978, 940, 903, 819, 781, 770, 746, 699, 666 cm-1; 1H NMR (300 MHz, CDCl3) δ 8.02 (s, 
1H), 7.53 (m,7H), 7.13 (d, 1H, J=1.91Hz), 6.08 (d, 1H, J=12.6Hz), 4.05 (d, 1H, 
J=12.7Hz), 3.25 (m,1H), 1.98 (m, 1H), 1.42 (d, 6H, J=6.95Hz), 1.06 (m, 2H), 0.71 
(m,2H); MS (EI) m/e (relative intensity) 409 (M+, 42), 381 (76), 324 (100), 297 (48), 193 
(48), 115 (59), 77 (50), 55 (52).  HRMS (ESI) cacld. for C25H23N5O (M+H)+ 410.1981, 
found 410.1977;  Anal. Calcd. for C25H23N5O• 0.2EtOAc: C, 72.46; H, 5.82; N, 16.31.  
Found: C, 72.53; H, 5.92; N, 16.26. 
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8-Cyclopropyl-3-(3-Isopropyl-1,2,4-Oxadiazole-5-yl)-5-Methyl- 4H-
Benzo-[f]-Imidazo-[1,5-a]-[1,4]-Diazepine-6(5H)-one (14, YT-III-42).  
 
 Isopropyl amido oxime (0.37g, 3.6 mmol) was added to a stirred suspension of 
dry powdered 4 Å molecular sieves (200 mg) in anhydrous THF (20 mL) under argon.  
After the mixture was allowed to stir at rt 10 min, NaH (60% solid in mineral oil, 0.1 g, 
2.7 mmol) was added to the mixture.  After the mixture was allowed to stir for a further 
30 min, a solution of the forgoing ester 13 (YT-III-76, 0.6g, 1.8 mmol) in THF (20 mL) 
was added.  The mixture which resulted was brought to reflux for 8 hr.  It was then 
cooled to rt, after which acetic acid (0.2g, 3.6 mmol) was added.  After the solution was 
allowed to stir for 10 min, the mixture was filtered through celite. The filtrate was diluted 
with CH2Cl2 (60 mL) and then washed with water, brine and dried (K2CO3).  Evaporation 
of the solvent under reduced pressure afforded a pale yellow solid, which was purified by 
flash column chromatography (silica gel, EtOAc/hexane, 2:3) to furnish 14 as a white 
solid (YT-III-42, 0.3g, 0.8 mmol, 45%). 14: mp 170-175oC; 1H NMR (300 MHz, CDCl3) 
δ 7.87 (s, 1H), 7.75 (s, 1H), 7.53 (d, J=4.47Hz, 1H), 7.32 (s, 1H), 5.27 (brs, 1H), 4.50 
(brs, 1H), 3.26 (m, 4H), 2.04 (m, 1H), 1.42 (d, 6H, J=6.95Hz), 1.11 (m, 2H), 0.82 (m, 
2H); MS (EI) m/e(relative intensity) 364 (M+, 27), 335 (38), 322 (78), 277 (71), 251 (96), 
237 (55), 223 (33), 182 (25), 115 (100), 55 (28).  HRMS (ESI) calcd. for C20H21N5O2 
(M+H)+ 364.1774, found 364.1781; Anal. Calcd. for Anal. C20H21N5O2: C, 66.10; H, 5.82; 
O, 8.81. Calcd. for C20H21N5O2•0.7 EtOAc :  C, 63.27; H, 5.92; N, 17.18. Found: C, 
63.39; H, 6.08; N, 17.03 (CHN sample was transferred to a vial for drying with ethyl 
acetate which may explain the contaminant). 
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(S)-5-(8-Ethynyl-6-(2-Fluorophenyl)-4-Methyl-4H-Benzo-[f]-Imidazo-
[1,5-a]-[1,4]-Diazepine-3-yl)-3-Isopropyl-1,2,4-Oxadiazole  
(16, YT-III-44). 
 
 Isopropyl amido oxime (0.53g, 5 mmol) was added to a stirred suspension of 
powdered 4 Å molecular sieves (250 mg) in anhydrous THF (30 mL) under argon.  After 
the mixture was allowed to stir at rt for 10 min, NaH (60% solid in mineral oil, 0.14 g, 
3.9 mmol) was added to the mixture.  After the mixture was allowed to stir for a further 
30 min, a solution of the forgoing ester 15 (1g, 2.6 mmol) in THF (30 mL) was added.  
The mixture which resulted was allowed to heat to reflux for 8 hr.  It was then cooled to 
rt, after which acetic acid (0.3g, 5.2 mmol) was added.  After the solution was allowed to 
stir for 10 min, the mixture was filtered through celite.  The filtrate was diluted with 
CH2Cl2 (100 mL) and washed with water, brine and dried (K2CO3).  Evaporation of the 
solvent under reduced pressure afforded a pale yellow solid, which was purified by flash 
column chromatography (silica gel, EtOAc/hexane, 2:3) to furnish 16 as a white solid 
(YT-III-44, 0.5g, 1.2 mmol, 45%). 16: mp190-193oC; 1H NMR (300 MHz, CDCl3) δ 8.34 
(s, 1H), 7.83 (d, 1H), 7.81 (d, 1H), 7.79 (d, 1H), 7.5 (m, 1H), 7.36 (dd, 1H), 7.29 (m, 1H), 
6.89 (s, 1H),  4.59 (q, J=11.52 Hz, 1H), 4.05 (s, 1H), 3.18 (m, J=29.73 Hz, 1H), 1.56 (d, 
J=33.02 Hz, 3H) 1.2 (d, J=30.5 Hz, 6H); HRMS (ESI)  cacld. for C25H20 FN5O (M+H)+ 
426.1730, found 426.1719.   
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